0001628280-22-014372.txt : 20220513 0001628280-22-014372.hdr.sgml : 20220513 20220513170635 ACCESSION NUMBER: 0001628280-22-014372 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 22923865 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 cpix-20220331.htm 10-Q cpix-20220331
2022Q1FALSE--12-31000108729400010872942022-01-012022-03-3100010872942022-05-09xbrli:shares00010872942022-03-31iso4217:USD00010872942021-12-31iso4217:USDxbrli:shares00010872942021-01-012021-03-310001087294cpix:ClinigenHealthcareLimitedMember2022-01-012022-03-310001087294cpix:ClinigenHealthcareLimitedMember2021-01-012021-03-3100010872942020-12-3100010872942021-03-310001087294us-gaap:CommonStockMember2020-12-310001087294us-gaap:RetainedEarningsMember2020-12-310001087294us-gaap:NoncontrollingInterestMember2020-12-310001087294us-gaap:CommonStockMember2021-01-012021-03-310001087294us-gaap:RetainedEarningsMember2021-01-012021-03-310001087294us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001087294us-gaap:CommonStockMember2021-03-310001087294us-gaap:RetainedEarningsMember2021-03-310001087294us-gaap:NoncontrollingInterestMember2021-03-310001087294us-gaap:CommonStockMember2021-12-310001087294us-gaap:RetainedEarningsMember2021-12-310001087294us-gaap:NoncontrollingInterestMember2021-12-310001087294us-gaap:CommonStockMember2022-01-012022-03-310001087294us-gaap:RetainedEarningsMember2022-01-012022-03-310001087294us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001087294us-gaap:CommonStockMember2022-03-310001087294us-gaap:RetainedEarningsMember2022-03-310001087294us-gaap:NoncontrollingInterestMember2022-03-31cpix:Segment0001087294cpix:KristaloseMember2022-01-012022-03-310001087294cpix:KristaloseMember2021-01-012021-03-310001087294cpix:SancusoMember2022-01-012022-03-310001087294cpix:SancusoMember2021-01-012021-03-310001087294cpix:VIBATIVMember2022-01-012022-03-310001087294cpix:VIBATIVMember2021-01-012021-03-310001087294cpix:CaldolorMember2022-01-012022-03-310001087294cpix:CaldolorMember2021-01-012021-03-310001087294cpix:VaprisolMember2022-01-012022-03-310001087294cpix:VaprisolMember2021-01-012021-03-310001087294cpix:AcetadoteMember2022-01-012022-03-310001087294cpix:AcetadoteMember2021-01-012021-03-310001087294cpix:OmeclamoxPakMember2022-01-012022-03-310001087294cpix:OmeclamoxPakMember2021-01-012021-03-310001087294cpix:RediTrexMember2022-01-012022-03-310001087294cpix:RediTrexMember2021-01-012021-03-310001087294cpix:OtherProductsMember2022-01-012022-03-310001087294cpix:OtherProductsMember2021-01-012021-03-310001087294us-gaap:GrantMember2022-01-012022-03-310001087294us-gaap:GrantMember2021-01-012021-03-310001087294cpix:VIBATIVMember2021-12-310001087294cpix:SancusoMember2021-12-310001087294cpix:VIBATIVMember2022-03-310001087294cpix:IfetrobanClinicalMember2022-03-310001087294cpix:IfetrobanClinicalMember2021-12-310001087294us-gaap:BuildingMember2022-03-31utr:sqft0001087294srt:OfficeBuildingMember2022-03-31xbrli:pure0001087294srt:OfficeBuildingMember2021-11-150001087294srt:OfficeBuildingMembercpix:BroadwestLeaseFiveYearRenewalOptionMember2021-11-15cpix:renewalTerm0001087294us-gaap:CommonStockMember2010-05-130001087294us-gaap:CommonStockMember2016-01-3100010872942017-11-012017-11-3000010872942021-12-272021-12-270001087294us-gaap:RestrictedStockMember2022-01-012022-03-310001087294us-gaap:RestrictedStockMember2021-01-012021-03-310001087294srt:DirectorMemberus-gaap:RestrictedStockMember2022-01-012022-03-310001087294cpix:IncentiveStockOptionsMember2022-01-012022-03-310001087294cpix:IncentiveStockOptionsMember2021-01-012021-03-310001087294cpix:PinnacleBankMembercpix:FifthAmendmentMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001087294srt:MinimumMemberus-gaap:LineOfCreditMembercpix:PinnacleBankMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2020-08-142020-08-140001087294us-gaap:LineOfCreditMembersrt:MaximumMembercpix:PinnacleBankMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2020-08-142020-08-140001087294us-gaap:LondonInterbankOfferedRateLIBORMember2020-08-142020-08-140001087294us-gaap:LineOfCreditMembercpix:PinnacleBankMemberus-gaap:RevolvingCreditFacilityMember2022-03-310001087294us-gaap:LineOfCreditMembercpix:PinnacleBankMemberus-gaap:RevolvingCreditFacilityMember2022-01-012022-03-310001087294us-gaap:RevolvingCreditFacilityMember2022-03-310001087294cpix:WinHealthInvestmentSingaporeLtdMember2020-08-310001087294us-gaap:ConvertibleDebtMembercpix:WinHealthInvestmentSingaporeLtdMember2020-08-310001087294us-gaap:DomesticCountryMember2022-03-310001087294cpix:VIBATIVMember2018-11-012018-11-300001087294cpix:VIBATIVMember2022-01-012022-03-310001087294cpix:MethotrexateMember2016-11-012016-11-300001087294cpix:MethotrexateMemberus-gaap:RestrictedStockMember2016-11-012016-11-300001087294cpix:MethotrexateMember2022-01-012022-03-310001087294cpix:MethotrexateMember2020-07-310001087294cpix:MethotrexateMember2021-12-310001087294cpix:MethotrexateMember2022-03-310001087294cpix:KyowaKirinMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-030001087294cpix:KyowaKirinMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310001087294cpix:KyowaKirinMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembersrt:MaximumMember2022-01-030001087294cpix:SancusoMember2022-01-030001087294cpix:SancusoMember2022-01-032022-01-030001087294cpix:SancusoMember2022-03-310001087294cpix:ClinigenHealthcareLimitedMember2019-01-012019-12-3100010872942019-01-012019-12-3100010872942020-01-012020-12-31cpix:installment00010872942021-01-012021-12-310001087294cpix:ClinigenHealthcareLimitedMember2021-01-012021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             .
Commission file number: 001-33637 
Cumberland Pharmaceuticals Inc.
(Exact Name of Registrant as Specified In Its Charter)
Tennessee
62-1765329
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
2525 West End Avenue, Suite 950,
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
(615) 255-0068
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
ClassTrading SymbolName of exchange on which registered
Common stock, no par valueCPIXNasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      No  
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 14,766,492 shares of common stock as of May 9, 2022.




CUMBERLAND PHARMACEUTICALS INC.




PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
March 31, 2022December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents$17,266,785 $27,040,816 
Accounts receivable, net14,635,435 6,877,346 
Inventories9,878,680 8,429,882 
Prepaid and other current assets3,561,027 3,339,969 
Total current assets45,341,927 45,688,013 
Non-current inventories10,593,792 9,048,567 
Property and equipment, net409,121 442,635 
Intangible assets, net34,479,356 23,954,475 
Goodwill1,932,876 882,000 
Operating lease right-of-use assets761,177 1,024,200 
Other assets3,178,857 3,419,908 
Total assets$96,697,106 $84,459,798 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$11,447,505 $9,640,980 
Operating lease current liabilities766,488 969,677 
Other current liabilities12,343,405 8,668,303 
Total current liabilities24,557,398 19,278,960 
Revolving line of credit20,000,000 15,000,000 
Operating lease noncurrent liabilities22,712 90,016 
Other long-term liabilities11,323,593 7,488,844 
Total liabilities55,903,703 41,857,820 
Commitments and contingencies
Equity:
Shareholders’ equity:
Common stock—no par value; 100,000,000 shares authorized; 14,730,760 and 14,742,754 shares issued and outstanding as of March 31, 2022 and December 31, 2021 , respectively
48,046,764 48,452,906 
Retained earnings (deficit)(7,023,853)(5,638,600)
Total shareholders’ equity41,022,911 42,814,306 
Noncontrolling interests(229,508)(212,328)
Total equity40,793,403 42,601,978 
Total liabilities and equity$96,697,106 $84,459,798 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.
1


CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
Three months ended March 31,
20222021
Net revenues$11,175,045 $10,537,159 
Costs and expenses:
Cost of products sold2,211,885 2,417,329 
Selling and marketing4,614,429 3,787,340 
Research and development1,745,136 1,257,367 
General and administrative2,302,349 2,230,509 
Amortization1,593,245 1,168,914 
Total costs and expenses12,467,044 10,861,459 
Operating income (loss)(1,291,999)(324,300)
Interest income16,041 5,426 
Interest expense(119,575)(24,417)
Income (loss) from continuing operations before income taxes(1,395,533)(343,291)
Income tax (expense) benefit(6,900)(7,458)
Net income (loss) from continuing operations(1,402,433)(350,749)
Discontinued operations 495,410 
Net income (loss)(1,402,433)144,661 
Net (income) loss at subsidiary attributable to noncontrolling interests17,180 22,167 
Net income (loss) attributable to common shareholders$(1,385,253)$166,828 
Earnings (loss) per share attributable to common shareholders
- Continuing operations - basic$(0.09)$(0.02)
- Discontinued operations - basic 0.03 
$(0.09)$0.01 
- Continuing operations - diluted$(0.09)$(0.02)
- Discontinued operations - diluted 0.03 
$(0.09)$0.01 
Weighted-average shares outstanding
- basic14,691,623 14,974,663 
- diluted14,691,623 15,244,146 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

2


CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three months ended March 31,
20222021
Cash flows from operating activities:
Net income (loss)$(1,402,433)$144,661 
Discontinued operations 495,410 
Net income (loss) from continuing operations(1,402,433)(350,749)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization expense1,653,746 1,227,607 
Share-based compensation159,901 162,960 
Increase (decrease) in non-cash contingent consideration370,464 (280,020)
Decrease (increase) in cash surrender value of life insurance policies over premiums paid222,209 (76,300)
Decrease (increase) in noncash interest expense2,183 13,833 
Net changes in assets and liabilities affecting operating activities:
Accounts receivable(7,758,089)(171,584)
Inventories2,271,484 1,868,350 
Other current assets and other assets239,862 507,102 
Accounts payable and other current liabilities4,461,389 (1,311,123)
Other long-term liabilities(371,214)(299,937)
Net cash provided by (used in) operating activities from continuing operations(150,498)1,290,139 
Discontinued operations 495,410 
Net cash provided by (used in) operating activities(150,498)1,785,549 
Cash flows from investing activities:
Additions to property and equipment(26,986)(19,458)
Note receivable investment funding (200,000)
Cash paid for acquisitions(13,500,000) 
Additions to intangible assets(14,912)(98,883)
Net cash used in investing activities(13,541,898)(318,341)
Cash flows from financing activities:
Borrowings on line of credit20,000,000 15,000,000 
Repayments on line of credit(15,000,000)(15,000,000)
Cash payment of contingent consideration(501,505)(995,277)
Repurchase of common shares(580,130)(302,802)
Net cash provided by (used in) financing activities3,918,365 (1,298,079)
Net increase (decrease) in cash and cash equivalents(9,774,031)169,129 
Cash and cash equivalents at beginning of period$27,040,816 $24,753,796 
Cash and cash equivalents at end of period$17,266,785 $24,922,925 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.
3


CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Equity
(Unaudited)
Common stockRetained earnings (deficit)Noncontrolling interestsTotal equity
SharesAmount
Balance, December 31, 202014,988,429 $49,121,523 $(2,131,013)$(117,116)$46,873,394 
Share-based compensation187,759 162,960 — — 162,960 
Repurchase of common shares(91,724)(303,088)— — (303,088)
Net income (loss)— — 166,828 (22,167)144,661 
Balance, March 31, 202115,084,464 $48,981,395 $(1,964,185)$(139,283)$46,877,927 
Common stockRetained earnings (deficit)Noncontrolling interestsTotal equity
SharesAmount
Balance, December 31, 202114,742,754 $48,452,906 $(5,638,600)$(212,328)$42,601,978 
Share-based compensation162,155 159,901 — — 159,901 
Repurchase of common shares(174,149)(566,043)— — (566,043)
Net income (loss)— — (1,385,253)(17,180)(1,402,433)
Balance, March 31, 202214,730,760 $48,046,764 $(7,023,853)$(229,508)$40,793,403 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

4


CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(1) ORGANIZATION AND BASIS OF PRESENTATION
Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, oncology and field sales forces in the United States. We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.
Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.
Discontinued Operations
As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol® and Totect® in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.
COVID-19 Pandemic
In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.
Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines. All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.
Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, 2021 and the three months ended March 31, 2022, we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.
5


Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees’ safety and well-being, while also keeping its business operating. Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.
Recent Accounting Guidance
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU’s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.
Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company’s consolidated financial statements.
Accounting Policies:
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.
Operating Segments
The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.




6


(2) EARNINGS (LOSS) PER SHARE
The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Numerator:
Net income (loss) from continuing operations$(1,402,433)$(350,749)
Discontinued operations 495,410 
Net income (loss)(1,402,433)144,661 
Net income (loss) at subsidiary attributable to noncontrolling interest17,180 22,167 
Net income (loss) attributable to common shareholders$(1,385,253)$166,828 
Denominator:
Weighted-average shares outstanding – basic14,691,623 14,974,663 
Dilutive effect of other securities 269,483 
Weighted-average shares outstanding – diluted14,691,623 15,244,146 
As of March 31, 2022 and 2021, restricted stock awards and options to purchase 131,225 and 215,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.

7


(3) REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018.
The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Products:
Kristalose$3,945,097 $2,994,378 
Sancuso3,397,209  
Vibativ2,501,434 5,052,243 
Caldolor959,634 1,539,496 
Vaprisol(117,000)1,134,264 
Acetadote111,090 117,191 
Omeclamox-Pak22,737 (450,263)
RediTrex59,226 (32,252)
Other revenue295,618 182,102 
Total net revenues$11,175,045 $10,537,159 
The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19. They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing. In the first quarter of 2022, the amounts noted were normal adjustments by channel partners. Net revenue was impacted by product return adjustments.
With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.
Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.04 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.

8


(4) INVENTORIES
The Company works closely with third parties to manufacture and package finished goods for sale. Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company’s warehouses. The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.
The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.6 million and $1.4 million, respectively.
The Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021. Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.
As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory. At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $10.6 million and $9.0 million, respectively. The Company had $0.2 million and $0.5 million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively. The Company also has obtained $0.2 million and $0.4 million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively.
At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:
March 31, 2022December 31, 2021
Raw materials and work in process$15,004,954 $12,374,983 
Consigned inventory129,049 164,378 
Finished goods5,338,469 4,939,088 
Total inventories20,472,472 17,478,449 
less non-current inventories(10,593,792)(9,048,567)
Total inventories classified as current$9,878,680 $8,429,882 

9


(5) LEASES
Cumberland’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023.
Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland’s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2022 is 0.8 years.
On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the “Leased Premise”) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.
Lease Position
At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:
Right-of-Use AssetsMarch 31, 2022December 31, 2021
Operating lease right-of-use assets$761,177 $1,024,200 
Lease LiabilitiesMarch 31, 2022December 31, 2021
Operating lease current liabilities$766,488 $969,677 
Operating lease noncurrent liabilities22,712 90,016 
Total$789,200 $1,059,693 
Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:
Maturity of Lease Liabilities at March 31, 2022
Operating Leases
2022730,829 
202392,477 
Total lease payments823,306 
Less: Interest34,106 
Present value of lease liabilities$789,200 
Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:
Three months ended March 31,
20222021
Rent expense$285,963 $227,395 
Sublease income$161,804 $178,029 
10


(6) SHAREHOLDERS’ EQUITY AND DEBT
Share repurchases
Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased 174,149 shares and 91,724 shares of common stock for approximately $0.6 million and $0.3 million, respectively. At March 31, 2022, approximately $4.2 million of common shares was left to repurchase under this program.
Share purchases and sales
During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board. These purchases began in April 2022.
Share Sales
In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.
Restricted Share Grants and Incentive Stock Options
During the three months ended March 31, 2022 and March 31, 2021, the Company issued 65,225 shares and 35,850 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. During the three months ended March 31, 2022 and 2021, the Company also issued 166,350 and 172,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.
Debt Agreement
On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition.
On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million.
On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.
The original Pinnacle Agreement was dated July 2017. Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.
The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022. In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12 to 24 months.
11


As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility. The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.
Borrowings under the line of credit are collateralized by substantially all of our assets.
Joint Venture Agreement
In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provides for initial investment from WinHealth in the form of a $0.2 million equity contribution and an initial investment from Cumberland in the form of a $0.2 million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.
(7) INCOME TAXES
As of March 31, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.
(8) COLLABORATIVE AGREEMENTS
Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.

12


(9) ADDITIONS AND RETURN OF PRODUCT RIGHTS
Vibativ
During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5 million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.
The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2021
$6,515,627 
Cash payment of royalty during the period(501,505)
Change in fair value of contingent consideration included in operating expenses370,464 
Contingent consideration earned and accrued in operating expenses 
Balance at March 31, 2022
$6,384,586 
The contingent consideration liability of $6.4 million was accounted for as $2.3 million of other current liabilities and $4.1 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.
RediTrex
In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic’s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis.
As consideration for the license Cumberland paid a deposit of $100,000 at closing. The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products’ FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.
On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0 million milestone payment due to Nordic. During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $1.0 million milestone payment due to Nordic. This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.
Cumberland has approximately $2.6 million in net intangible assets related to RediTrex at March 31, 2022.

13


Sancuso Acquisition
On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.
Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient’s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (“CINV”). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.
Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities.
Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5 million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5 million based on the attainment of various approvals and sales performance. The Company believes that $1.5 million of the milestone payments will be earned and paid.
In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.
The acquisition was funded by cash and the Company's revolving credit facility. The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year. The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $0.3 million, inventory $5.2 million, goodwill $1.0 million, intangible assets $12.1 million, milestone payable $1.2 million and contingent liability $3.9 million.
The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly. The contingent consideration liability of $3.9 million was accounted for as $1.3 million of current liabilities and $2.6 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.


14


Ethyol and Totect
In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States. In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.
Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019. In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during 2021, as discontinued operations.
The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not incur expenses associated with these payments from Clinigen.
Three months ended March 31,
20222021
Revenues$ $495,410 
Income from discontinued operations$ $495,410 
15


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Disclosure regarding forward-looking statements
The following discussion contains certain forward-looking statements which reflect management’s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled “Risk Factors” and “Special Note Regarding Forward-Looking Statements” of our Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management’s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.

16



OVERVIEW
Our Business
Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.
Our primary target sectors are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, oncology and field sales forces in the United States. We have also established partnerships in Puerto Rico and the Middle East for our Vibativ® product and are continuing to build a network of international partners to register and provide our medicines to patients in their countries.
Our portfolio of FDA approved brands includes:
Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) oral, for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
RediTrex® (methotrexate) injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;
Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates for patients with cardiomyopathy associated with 1) Duchenne Muscular Dystrophy (“DMD”), a fatal, genetic neuromuscular disease; 2) Systemic Sclerosis (“SSc”) or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs; and 3) Aspirin-Exacerbated Respiratory Disease (“AERD”), a severe form of asthma.
Cumberland has built core competencies in the acquisition, development and commercialization of pharmaceutical products in the U.S. - and we believe we can leverage this existing infrastructure to support our continued growth both domestically and internationally. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance.
Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.




17


GROWTH STRATEGY
Cumberland’s growth strategy involves maximizing the success of our existing brands while continuing to build a portfolio of differentiated products. We currently feature eight FDA products approved for sale in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.
We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland could further develop and commercialize.
Specifically, we are seeking long-term sustainable growth by:
Supporting and expanding the use of our marketed products. We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and are expanding the labeling for both brands accordingly. We also recently further expanded the labeling for Caldolor to allow its use prior to surgery. We will continue to explore such opportunities to bring our products to new patient populations.
Selectively adding complementary brands. In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ and Sancuso are examples of this strategy.
Progressing our clinical pipeline and incubating future product opportunities at CET. We believe it is important to build a pipeline of innovative new product opportunities, as we are doing though our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET.
Leveraging our infrastructure through co-promotion partnerships. We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose and Sancuso across the U.S.
Building an international contribution to our business. We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners’ registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.
Managing our operations with financial discipline. We continually work to manage our expenses in line with our revenues to deliver cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet.

18


RECENT DEVELOPMENTS
COVID-19 Pandemic
In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. Cumberland managed through the resulting pandemic, continuing to operate our business – keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.
Throughout the pandemic, we faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were also impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products.
Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes brands that have delivered a strong performance during the pandemic.
Despite the challenges of operating during a pandemic, Cumberland has remained committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We have continued to build our portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates and acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges, while our team has remained responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission. Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.
Sancuso Acquisition
We started off the first quarter of 2022 with an exciting announcement – Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.
Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient’s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (“CINV”). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.
Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities.
Sancuso Promotion
To support Sancuso, we have established an oncology sales division, which is initially comprised of two former Kyowa Kirin employees and their five contracted inside sales individuals.
Effective April 19, 2022, we also entered into an agreement with Verity Pharmaceuticals International Limited (“Verity”) for the national co-promotion of Sancuso. Verity is a specialty pharmaceutical company that will utilize its established oncology commercial organization and customer network to co-promote Sancuso throughout the United States.
Verity will cover a majority of the U.S. market for an initial three-year term, with an option to extend for an additional two years. Verity and Cumberland will share in the incremental contribution margin resulting from Verity’s efforts.





19


New Vibativ Agreements
1.In March 2022, we announced the launch of our Vibativ product in Puerto Rico. The announcement followed an August 2021 agreement with Verity to license and commercialize our Vibativ product in that territory. Verity has a particular strength and experience in the Puerto Rican market. Vibativ can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections, including the flu and COVID-19.
2.Also in March 2022, we announced that we have entered into an agreement with Tabuk Pharmaceutical Manufacturing Company (“Tabuk”), a fully owned subsidiary of Saudi Arabia’s publicly traded Astra Industrial Group. Under the terms of the agreement, Tabuk received an exclusive license to distribute Vibativ in Saudi Arabi and Jordan, with an option to expand into other countries in the region. Cumberland has recognized an upfront payment from Tabuk. In addition, the agreement calls for milestone payments as well as an agreed transfer price on supplies of the product for that territory.
Omeclamox-Pak Supply Update
The packager for our Omeclamox-Pak product has been unable to provide us with supplies of the product, having encountered difficulties and therefore suspending operations during the pandemic. We are currently awaiting the facility’s packaging to resume, while also exploring other alternatives to restart the product’s packaging, before we build new inventory and resupply the market.
Vaprisol Supply Update
We are transitioning to a new manufacturer for our Vaprisol product. During 2021, we shipped all remaining inventory of the product and notified the FDA that supplies of the product were then not currently available. We have transferred manufacturing to a new facility, and await the submission and FDA approval for that plant before resuming shipments. That company plans to provide an interim supply of compounded product to the market while awaiting the needed facility approval.
Ifetroban Clinical Studies
We have been evaluating our ifetroban product candidate, a selective thromboxane-prostanoid receptor (“TPr”) antagonist, in a series of clinical studies. It has been dosed in nearly 1,400 subjects and was found to be safe and well tolerated in healthy volunteers and various patient populations.
Cumberland is currently sponsoring three Phase II clinical programs to evaluate ifetroban in 1) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma; 2) Systemic Sclerosis or scleroderma; a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs; and 3) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles.
After being interrupted by the pandemic, enrollment in these studies has resumed as many of our clinical study sites have reopened and begun screening patients for potential participation. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban.
We are also designing a Phase II study to evaluate the use of ifetroban to treat patients with Progressive Fibrosing Interstitial Lung Diseases. We are preparing an application to the FDA to support the new program.
In addition to our company-sponsored studies, an NIH-funded, Harvard-clinical-investigator-led trial has closed enrollment of patients with Aspirin Exacerbated Respiratory Disease. This Phase II, placebo-controlled study, complements our programs and we will announce top-line results following a completion of the data analysis.
Summary
Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates as well as the acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges amid the pandemic, while our team remains responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission throughout the remainder of the year.

20


CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 Annual Report on Form 10-K.
Accounting Estimates and Judgments
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventories, fair value of contingent consideration liabilities associated with business combinations, share-based compensation and intangible assets.
21


RESULTS OF OPERATIONS
Three months ended March 31, 2022 compared to the three months ended March 31, 2021
The following table presents the unaudited interim statements of operations for continuing operations for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021Change
Net revenues$11,175,045 $10,537,159 $637,886 
Costs and expenses:
Cost of products sold2,211,885 2,417,329 (205,444)
Selling and marketing4,614,429 3,787,340 827,089 
Research and development1,745,136 1,257,367 487,769 
General and administrative2,302,349 2,230,509 71,840 
Amortization1,593,245 1,168,914 424,331 
Total costs and expenses12,467,044 10,861,459 1,605,585 
Operating income (loss)(1,291,999)(324,300)(967,699)
Interest income16,041 5,426 10,615 
Interest expense(119,575)(24,417)(95,158)
Income (loss) from continuing operations before income taxes(1,395,533)(343,291)(1,052,242)
Income tax (expense) benefit(6,900)(7,458)558 
Net income (loss) from continuing operations$(1,402,433)$(350,749)$(1,051,684)
The following table summarizes net revenues by product for the periods presented:
Three months ended March 31,
20222021Change
Products:
Kristalose$3,945,097 $2,994,378 $950,719 
Sancuso3,397,209 — 3,397,209 
Vibativ2,501,434 5,052,243 (2,550,809)
Caldolor959,634 1,539,496 (579,862)
Vaprisol(117,000)1,134,264 (1,251,264)
Acetadote111,090 117,191 (6,101)
Omeclamox-Pak22,737 (450,263)473,000 
RediTrex59,226 (32,252)91,478 
Other revenue295,618 182,102 113,516 
Total net revenues$11,175,045 $10,537,159 $637,886 
Net revenues. Net revenues for the three months ended March 31, 2022, were $11.2 million compared to $10.5 million for the three months ended March 31, 2021. As detailed in the table above, net revenue increased for two of our marketed products: Kristalose and RediTrex during the quarter, as well as the addition of Sancuso.
Kristalose revenue increased by 31.8% during the first quarter of 2022 to $3.9 million, when compared to the prior year period. The increase was primarily the result of growth in shipments of the product to our wholesale customers.
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a slight decrease in the product's revenue when compared to the prior year period.
Vaprisol revenue was $(0.1) million for the first quarter of 2022, a decrease of $1.3 million compared to the same period last year. This decrease of net sales compared to the first quarter of 2021 is primarily due to a stock shortage as we await pending FDA approval on a new manufacturer.
22


Caldolor revenue was $1.0 million for the first quarter of 2022, a decrease of $0.6 million compared to the same period last year. The decrease was the result of lower international shipments of the product, due to order timing.
Vibativ revenue was $2.5 million for the three months ended March 31, 2022, compared to $5.1 million for the same period last year. The decrease was a result of increased purchases in 2021 due in part to a new packaging change.
Sancuso revenue was $3.4 million for the first quarter of 2022, which was $0.3 million higher than the first quarter of 2021 U.S. results reported by Kyowa Kirin, from whom Cumberland acquired the U.S. rights to Sancuso on January 3, 2022.
Omeclamox-Pak had no sales for the first quarter of 2022, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties, and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product. Net revenue for the first quarter of 2022 was positively impacted by various revenue adjustments.
Cost of products sold. Cost of products sold for the first quarter of 2022 and 2021 were $2.2 million and $2.4 million, respectively. Cost of products sold, as a percentage of net revenues, were 19.8% during the three months ended March 31, 2022, compared to 22.9% during the three months ended March 31, 2021. This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix.
Selling and marketing. Selling and marketing expense for the first quarter of 2022 increased $0.8 million compared to the prior year period. This increase is primarily attributable to an increase in marketing spending for Sancuso as well as royalty costs, direct promotional spending, meeting costs and travel expenses for all of our existing brands including our new oncology sales force.
Research and development. Research and development costs for the first quarter of 2022 and 2021 were $1.7 million and $1.3 million, respectively. A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.
General and administrative. General and administrative expense for the first quarter of 2022 was $2.3 million, which was $0.1 million higher than the first quarter of 2021. The increase was primarily attributable to increases in compensation expense.

23


The components of the statements of operations discussed above reflect the following impacts from Vibativ:
Financial Impact of Vibativ
Three months ended March 31,
20222021
Net revenue (1)
$2,651,434 $5,052,243 
Cost of products sold (2)
927,160 1,456,816 
Royalty and operating expenses681,317 402,352 
Vibativ contribution$1,042,957 $3,193,075 
(1) 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.
(2)The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.
Financial Impact of VibativSince Acquisition
Net revenue (1)
$38,772,457 
Cost of products sold (2)
13,116,416 
Royalty and operating expenses7,135,362 
Vibativ contribution$18,520,679 
(1) 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.
(2)The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.
The components of the statements of operations discussed above reflect the following impacts from Sancuso:
Financial Impact of Sancuso
Three months ended March 31,
20222021
Net revenue$3,397,209 $— 
Cost of products sold (1)
388,264 — 
Royalty and operating expenses910,100 — 
Sancuso contribution$2,098,845 $— 
(1) The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.
Amortization. Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the three months ended March 31, 2022, and three months ended March 31, 2021, totaled approximately $1.6 million and $1.2 million, respectively. The increase in amortization expense is due to the acquisition of Sancuso.
Income taxes. Income tax expense for the three months ended March 31, 2022, was comparable to the income tax expense for the three months ended March 31, 2021.
As of March 31, 2022, we had approximately $56.6 million in federal net operating loss carryforwards including approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations. We expect to continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.

24


LIQUIDITY AND CAPITAL RESOURCES
Working Capital
Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.
The following table summarizes our liquidity and working capital as of March 31, 2022 and December 31, 2021:
March 31, 2022December 31, 2021
Cash and cash equivalents$17,266,785 $27,040,816 
Working capital (current assets less current liabilities)$20,784,529 $26,409,053 
Current ratio (multiple of current assets to current liabilities)1.8 2.4 
Revolving line of credit availability$— $— 
The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2022 and March 31, 2021:
Three months ended March 31,
20222021
Net cash provided by (used in):
Operating activities$(150,498)$1,785,549 
Investing activities(13,541,898)(318,341)
Financing activities3,918,365 (1,298,079)
Net increase (decrease) in cash and cash equivalents$(9,774,031)$169,129 
The net $9.8 million decrease in cash and cash equivalents for the three months ended March 31, 2022, was primarily attributable to cash used in investing and partially offset by cash provided by financing activities. Cash used in operating activities of $0.2 million was primarily the result of accounts receivable increasing by $7.8 million mainly from Sancuso sales, positively impacted by decreases in inventory of $2.3 million and increases in accounts payable and other liabilities of $4.1 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.8 million. Cash used in investing activities was the result of the acquisition of Sancuso. Our financing activities included the increase in our line of credit of $5.0 million partially offset by the $0.6 million in cash used to repurchase shares of our common stock as well as the $0.5 million used for the payment of royalties for sales of Vibativ and Sancuso.
The net $0.2 million increase in cash and cash equivalents for the three months ended March 31, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities. Cash provided by operating activities of $1.8 million was positively impacted by decreases in inventory of $1.9 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.4 million. Cash used in investing activities was the result of additions to intangibles of $0.1 million and the payment of $0.2 million to the WHC JV. Our financing activities included the $0.3 million in cash used to repurchase shares of our common stock as well as the $1.0 million used for the payment of royalties to Theravance for sales of Vibativ.

25


Debt Agreement
On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition.
On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million.
On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.
The original Pinnacle Agreement was dated July 2017. Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.
The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022. In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12 to 24 months.
As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility. The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.
Paycheck Protection Program Loan
On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the “PPP”) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020.
Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities. Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.
In October 2020, Cumberland submitted a request for the loan’s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven.

26


OFF-BALANCE SHEET ARRANGEMENTS
During the three months ended March 31, 2022 and 2021, we did not engage in any off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments.
We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at March 31, 2022.
The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022. As of March 31, 2022, we had $20.0 million in borrowings outstanding under our revolving credit facility.
Exchange Rate Risk
While we operate primarily in the United States, we are exposed to foreign currency risk. Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2022 and 2021. Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.
Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
During the three months ended March 31, 2022, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
27


PART II – OTHER INFORMATION
Item 1. Legal Proceedings
There have been no material developments with regard to the legal proceedings previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
Item 1A. Risk Factors
In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities
We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
The following table summarizes the activity, by month, during the three months ended March 31, 2022:
 
Period
Total Number of
Shares or Units
Purchased, which were also Part of the Publicly Announced Plans or Programs
Average
Price Paid
per Share
(or Unit)
Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
        Programs
January46,642$3.96 $4,595,056 
February37,9103.42 4,465,495 
March89,597
(1)
2.81 4,213,590 
Total174,149
(1) Of this amount, 50,874 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
28


Item 6. Exhibits
No.Description
10.1*
10.2*
10.3*
10.4*
10.5*
31.1*
31.2*
32.1**
101.INS*INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.
101.SCH*INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
101.CAL*INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
101.DEF*INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
101.LAB*INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
101.PRE*INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
104COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)
*Filed herewith.
**Furnished herewith.
29


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Cumberland Pharmaceuticals Inc.
Date:May 13, 2022By:/s/ John Hamm
 John Hamm
Chief Financial Officer and Duly Authorized Officer

30
EX-10.1 2 ajkazimi-2022.htm EX-10.1 Document
image_2.jpg




March 7, 2022


Mr. AJ Kazimi
2525 West End Avenue, Suite 950
Nashville, TN 37203
Re:    Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.

Dear AJ,

Effective January 1, 2022, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.    Compensation. The Company agrees to compensate you as follows:

(a)    The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred thirty-five thousand dollars ($635,000.00), payable in arrears in equal monthly installments on the 1st day of each calendar month of 2022. For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason. Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.

(b)    You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors. The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.

(c)    You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company’s overall performance, both as determined and approved by the Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company’s Board of Directors.





(d)    You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA). Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded. You may, at the Company’s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.

(e)    Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.

2.Additional Payments. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company. Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.

3.    Employment at Will. This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.

4.    Confidentiality. All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company’s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential. Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company’s business under circumstances in which you are authorized to use or disclose such information. No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.

5.    Discoveries and Improvements. During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company’s present or planned business or products (collectively the “Developments”), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company. You agree to keep and maintain



adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times. You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments. You agree that all Developments shall constitute “Works for Hire” (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.

6.    Publication. All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.

7.    Litigation. You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company. You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.

8.    Competition. For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company’s Chief Executive Officer, is similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate). The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company’s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a “stockholder” within the meaning of that term as used in this paragraph. For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret



or confidential information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. The term “Affiliate” shall mean the Company and any entity controlling, controlled by, or under common control with the Company.

9.    Conflicting Contracts. You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.

10.    Solicitation. After you cease to be employed by the Company (or a Company affiliate):

(a)    You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.

(b)    You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.

11.    Return of Documents. Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company. This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked “Confidential.”

12.    Remedies. You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company’s remedies at law will be inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys’ fees, to enforce the provisions of this Agreement.




13.    Best Efforts and Conflicts of Interest: You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t\o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment. If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland’s Human Resources Department immediately.


image_2.jpg


14. Standards of Business Conduct and Ethics. Cumberland’s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.
15.    Debarment. You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.

16.    Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company’s principal office in the case of the Company.

17    Waiver. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

18.    Entire Agreement. This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.

19.    Governance. This Agreement shall be governed by the laws of the State of Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company’s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.

20.    Enforceability. In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.

21.    Survival. Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.






# # # #
This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.







Sincerely yours,

CUMBERLAND PHARMACEUTICALS INC.
image_1.jpg
_______________________________________         By:     Stephanie Smith, MBA, HRM
HR Manager



Accepted as to all terms and conditions
as of the 7th day of March 2022:



________________________________________
A.J. Kazimi


EX-10.2 3 leopavliv-2022.htm EX-10.2 Document





March 7, 2022


Mr. Leo Pavliv
2525 West End Avenue, Suite 950
Nashville, TN 37203
Re:    Employment of Leo Pavliv as Executive Vice President, Chief Development & Operations Officer by Cumberland Pharmaceuticals Inc.

Dear Leo,

Effective January 1, 2022, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your appointment as Executive Vice President, Chief Development & Operations Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.    Compensation. The Company agrees to compensate you as follows:

(a)    The Company agrees to pay you on a salary basis for services performed based on an annual rate of four hundred and fifty-five thousand dollars ($455,000.00), payable in arrears in equal monthly installments on the 1st day of each calendar month of 2022. For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason. Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.

(b)    You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors. The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.

(c)    You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company’s overall performance, both as determined and approved by the Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company’s Board of Directors.

(d)    You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA). Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded. You may, at the Company’s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.





(e)    Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.

2.Additional Payments. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company. Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.

3.    Employment at Will. This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.

4.    Confidentiality. All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company’s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential. Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company’s business under circumstances in which you are authorized to use or disclose such information. No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.

5.    Discoveries and Improvements. During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company’s present or planned business or products (collectively the “Developments”), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company. You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times. You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments. You agree that all Developments shall constitute “Works for Hire” (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.




6.    Publication. All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.

7.    Litigation. You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company. You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.

8.    Competition. For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company’s Chief Executive Officer, is similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate). The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company’s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a “stockholder” within the meaning of that term as used in this paragraph. For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. The term “Affiliate” shall mean the Company and any entity controlling, controlled by, or under common control with the Company.

9.    Conflicting Contracts. You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.

10.    Solicitation. After you cease to be employed by the Company (or a Company affiliate):




(a)    You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.

(b)    You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.

11.    Return of Documents. Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company. This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked “Confidential.”

12.    Remedies. You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company’s remedies at law will be inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys’ fees, to enforce the provisions of this Agreement.

13.    Best Efforts and Conflicts of Interest: You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t\o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment. If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland’s Human Resources Department immediately.





14. Standards of Business Conduct and Ethics. Cumberland’s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.
15.    Debarment. You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.

16.    Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company’s principal office in the case of the Company.

17    Waiver. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

18.    Entire Agreement. This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.

19.    Governance. This Agreement shall be governed by the laws of the State of Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company’s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.

20.    Enforceability. In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.

21.    Survival. Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.




# # # #





This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.







Sincerely yours,

CUMBERLAND PHARMACEUTICALS INC.


_______________________________________         By:     A.J. Kazimi
Chief Executive Officer



Accepted as to all terms and conditions
as of the 7th of March 2022:



________________________________________
Leo Pavliv

EX-10.3 4 johnhamm-2022.htm EX-10.3 Document
image_0.jpg




March 7, 2022


Mr. John Hamm
2525 West End Avenue, Suite 950
Nashville, TN 37203
Re:    Employment of John Hamm as Senior Director of Finance & Accounting & Chief Financial Officer Cumberland Pharmaceuticals Inc.

Dear John,

Effective January 1, 2022, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your appointment as Senior Director of Finance & Accounting & Chief Financial Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.    Compensation. The Company agrees to compensate you as follows:

(a)    The Company agrees to pay you on a salary basis for services performed based on an annual rate of one hundred and ninety-two thousand dollars ($192,000.00), payable in arrears in equal monthly installments on the 1st day of each calendar month of 2022. For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason. Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.

(b)    You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors. The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.

(c)    You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company’s overall performance, both as determined and approved by the Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company’s Board of Directors.

(d)    You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA). Such shares will be subject to the SOA and the terms set forth in




the incentive compensation plan under which they are awarded. You may, at the Company’s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.

(e)    Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.

2.Additional Payments. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company. Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.

3.    Employment at Will. This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.

4.    Confidentiality. All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company’s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential. Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company’s business under circumstances in which you are authorized to use or disclose such information. No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.

5.    Discoveries and Improvements. During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company’s present or planned business or products (collectively the “Developments”), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company. You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times. You agree to assign,



and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments. You agree that all Developments shall constitute “Works for Hire” (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.

6.    Publication. All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.

7.    Litigation. You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company. You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.

8.    Competition. For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company’s Chief Executive Officer, is similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate). The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company’s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a “stockholder” within the meaning of that term as used in this paragraph. For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. The term “Affiliate” shall



mean the Company and any entity controlling, controlled by, or under common control with the Company.

9.    Conflicting Contracts. You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.

10.    Solicitation. After you cease to be employed by the Company (or a Company affiliate):

(a)    You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.

(b)    You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.

11.    Return of Documents. Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company. This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked “Confidential.”

12.    Remedies. You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company’s remedies at law will be inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys’ fees, to enforce the provisions of this Agreement.

13.    Best Efforts and Conflicts of Interest: You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t\o the services required of you by the express and implicit terms of this Agreement, to the reasonable



satisfaction of Cumberland in its sole and complete discretion. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment. If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland’s Human Resources Department immediately.


image_0.jpg


14. Standards of Business Conduct and Ethics. Cumberland’s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.
15.    Debarment. You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.

16.    Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company’s principal office in the case of the Company.

17    Waiver. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

18.    Entire Agreement. This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.

19.    Governance. This Agreement shall be governed by the laws of the State of Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company’s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.

20.    Enforceability. In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.

21.    Survival. Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.




# # # #
This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.







Sincerely yours,

CUMBERLAND PHARMACEUTICALS INC.


_______________________________________         By:     A.J. Kazimi
Chief Executive Officer



Accepted as to all terms and conditions
as of the 7th of March 2022:



________________________________________
John Hamm

EX-10.4 5 jamesherman-2022.htm EX-10.4 Document





March 7, 2022


Mr. James Herman
2525 West End Avenue, Suite 950
Nashville, TN 37203
Re:    Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc.

Dear John,

Effective January 1, 2022, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”) In consideration of your appointment as Executive Vice President, National Accounts and Chief Compliance Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.    Compensation. The Company agrees to compensate you as follows:

(a)    The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred and ninety-two thousand dollars ($292,000.00), payable in arrears in equal monthly installments on the 1st day of each calendar month of 2022. For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason. Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.

(b)    You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors. The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.

(c)    You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company’s overall performance, both as determined and approved by the Board of Directors of the Company. Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company’s Board of Directors.

(d)    You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA). Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded. You may, at the Company’s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.





(e)    Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.

2.Additional Payments. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company. Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.

3.    Employment at Will. This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company. As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice. The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.

4.    Confidentiality. All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company’s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential. Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company’s business under circumstances in which you are authorized to use or disclose such information. No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.

5.    Discoveries and Improvements. During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company’s present or planned business or products (collectively the “Developments”), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company. You agree to disclose all Developments promptly, fully and in writing to the Company. You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be and remain the property of the Company at all times. You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments. You agree that all Developments shall constitute “Works for Hire” (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.




6.    Publication. All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company. You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company. You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.

7.    Litigation. You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company. You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.

8.    Competition. For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company’s Chief Executive Officer, is similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate). The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company’s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a “stockholder” within the meaning of that term as used in this paragraph. For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates. Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information. The term “Affiliate” shall mean the Company and any entity controlling, controlled by, or under common control with the Company.

9.    Conflicting Contracts. You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement. Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.

10.    Solicitation. After you cease to be employed by the Company (or a Company affiliate):




(a)    You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.

(b)    You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.

11.    Return of Documents. Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company. This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked “Confidential.”

12.    Remedies. You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company’s remedies at law will be inadequate, and the Company will suffer irreparable harm. Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it. You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys’ fees, to enforce the provisions of this Agreement.

13.    Best Efforts and Conflicts of Interest: You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t\o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion. Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment. If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with Cumberland, you should inform your direct supervisor and Cumberland’s Human Resources Department immediately.





14. Standards of Business Conduct and Ethics. Cumberland’s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.
15.    Debarment. You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.

16.    Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company’s principal office in the case of the Company.

17    Waiver. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

18.    Entire Agreement. This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.

19.    Governance. This Agreement shall be governed by the laws of the State of Tennessee. Any dispute arising out of this Agreement shall be resolved, at the Company’s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.

20.    Enforceability. In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.

21.    Survival. Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.





# # # #




This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.







Sincerely yours,

CUMBERLAND PHARMACEUTICALS INC.


_______________________________________         By:     A.J. Kazimi
Chief Executive Officer



Accepted as to all terms and conditions
as of the 7th of March 2022:


________________________________________
James Herman

EX-10.5 6 pinnaclebank-cpiamend7tolo.htm EX-10.5 Document


SEVENTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT

THIS SEVENTH AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this
"Amendment") is entered into as of March 31, 2022 by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation ("Borrower"), and PINNACLE BANK, a Tennessee banking corporation (the "Lender").

RECITALS:

A.Borrower and the Lender entered into that certain Revolving Credit Loan Agreement dated as of July 31, 2017, as amended by that certain First Amendment to Revolving Credit Loan Agreement dated August 14, 2018, as amended by that ce1iain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018, as amended by that certain Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement dated May 10, 2019, as amended by that certain Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement dated October 7, 2020, as amended by that certain Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement dated as of October 28, 2021, and as amended by that certain Fifth Amendment to Revolving Credit Note and Sixth Amendment to Revolving Credit Loan Agreement dated as of December 31, 2021 (the "Loan Agreement"). Capitalized terms not otherwise defined therein have the same meaning as set fo1ih in the Loan Agreement.

B.Borrower and the Lender desire to amend the Loan Agreement as provided herein.

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

1.Section 6.7 of the Loan Agreement is hereby amended and restated as follows:

6.7 Maximum Funded Debt Ratio. Permit the Funded Debt Ratio of Borrower as calculated for Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quaiier basis to exceed 2.50 to 1.00.

2.In connection with item 1 above, any and all provisions or definitions related to the
"Funded Debt to Tangible Capital Ratio" set forth in the Loan Agreement ai·e hereby deleted.


follows:
3.
3.The definition of "EBITDA" contained in Section 9.1 is hereby amended and restated as

"EBITDA" means (a) Net Income Attributable to Borrower's Shareholders, plus (b) to the extent deducted in determining Net Income Attributable to Borrower's Shareholders, and without duplication, the sum of (i) Interest Expense, (ii) income tax expense, (iii) depreciation expense, (iv) amortization expense, (v) Non-Cash Compensation Expense, (vi) cost of products sold associated with the Vibativ Acquisition provided that (x) the inventory was acquired on the acquisition date, and (y) the aggregate amount of such cost of products sold shall not exceed 30% of EBITDA in any measurement period, (vii) the one-time write down of Vibativ inventory recognized in the quarter ending December 31, 2021 in the amount of $1,100,000, and, as reasonably agreed to by Lender, any additional one-time non-cash adjustments as reported by the Borrower on the Borrower's quarterly "Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) ...", and (viii) cost of products sold associated

105639-301010




with the Sancuso Acquisition provided that (x) the work in process and finished goods inventory was acquired on the acquisition date, and (y) the aggregate amount of such cost of products sold shall not exceed 30% of EBITDA in any measurement period. For purposes of calculating EBITDA, EBITDA shall only include EBITDA arising from a permitted Acquisition if Lender is provided with a quality of earnings report related to any such Acquisition reasonably acceptable to Lender. Notwithstanding the foregoing, EBITDA shall include the following amounts for the specified periods related to the Sancuso Acquisition:

Period
Amount
3 months ending 6/30/2021
$2,001,365
3 months ending 9/30/2021
$2,001,365
3 months ending 12/31/2021
$2,001,365


1.The following is hereby added as a new definition under Section 9.1 of the Loan Agreement:

"Sancuso Acquisition" means Borrower's purchase of certain assets related to the manufacture, marketing and sale of the proprietary oncology-supportive care medicine, Sancuso, from Kyowa Kirin, Inc.

2.The Loan Agreement are not amended in any other respect.

3.Borrower reaffirms the terms and provisions of the Loan Documents and agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.

[signatures commence on following page]





ENTERED INTO as of the date first written above.

BORROWER:

CUMBERLAND PHARMACEUTICALS INC.

By: --


image_0a.jpgDigitally signed by AJ. Kazimi
image_1a.jpgDN: cn=A.J. Kazimi, o=Cumberland Pharmaceuticals Inc., ou=CPI, email=tmajor@cumberlandpharma.
A.. Kazimi, Chief.    'eootv.e=iicer

LENDER:

PINNACLE BANK

image_2a.jpg






[Signature Page to Seventh Amendment to Revolving Credit Loan Agreement]

EX-31.1 7 a2022q1-exhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, A.J. Kazimi, certify that:
1
I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 13, 2022By:/s/ A.J. Kazimi
A.J. Kazimi
Chief Executive Officer


EX-31.2 8 a2022q1-exhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, John Hamm, certify that:
1
I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
May 13, 2022By:/s/ John Hamm
John Hamm
Chief Financial Officer


EX-32.1 9 a2022q1-exhibit321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 of Cumberland Pharmaceuticals Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that:
1
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ A. J. Kazimi
A.J. Kazimi
Chief Executive Officer
May 13, 2022
/s/ John Hamm
John Hamm
Chief Financial Officer
May 13, 2022
 


EX-101.SCH 10 cpix-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statement of Equity link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Organization and Basis of Presentation Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Inventories (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Inventories (Schedule of Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 2115105 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Leases - Lease Position (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Leases - Rent Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Shareholders' Equity and Debt link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 2127109 - Disclosure - Additions and Returns of Product Rights link:presentationLink link:calculationLink link:definitionLink 2328305 - Disclosure - Additions and Returns of Product Rights (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 cpix-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 cpix-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 cpix-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Repurchase outstanding common shares Stock Repurchase Program, Authorized Amount Ifetroban Clinical Ifetroban Clinical [Member] Ifetroban Clinical Operating lease noncurrent liabilities Operating Lease, Liability, Noncurrent Convertible note Debt Instrument, Face Amount Convertible Debt Convertible Debt [Member] Interest expense Interest Expense Net income (loss) attributable to common shareholders Net income (loss) attributable to common shareholders Net Income (Loss) Attributable to Parent Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Range [Domain] Statistical Measurement [Domain] Decrease (increase) in cash surrender value of life insurance policies over premiums paid Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy Retained earnings (deficit) Retained Earnings (Accumulated Deficit) Term of contract Lessee, Operating Lease, Term of Contract Line of credit, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Operating Segments Segment Reporting, Policy [Policy Text Block] Acetadote Acetadote [Member] Acetadote Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition [Line Items] Security Exchange Name Security Exchange Name Numerator: Numerator [Abstract] Numerator. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Cash payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Entity Registrant Name Entity Registrant Name Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Inventory Disclosure [Abstract] Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Additional borrowing capacity Line Of Credit Facility, Additional Borrowing Capacity Line Of Credit Facility, Additional Borrowing Capacity Entity File Number Entity File Number Income tax (expense) benefit Income Tax Expense (Benefit) Total equity Balance, Beginning of Period Balance, End of Period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Products: Products [Abstract] Products. Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Inventories Total inventories classified as current Inventory, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization Amortization of Intangible Assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Repurchase of common shares Repurchase of shares, value Stock Repurchased During Period, Value Statement of Financial Position [Abstract] Common shares left to repurchase Stock Repurchase Program, Remaining Authorized Repurchase Amount Tiered royalty payment, threshold Tiered Royalty Payments, Threshold Tiered Royalty Payments, Threshold Noncurrent portion of the contingent consideration liability Business Combination, Contingent Consideration, Liability, Noncurrent Present value of remaining lease payments, percent Operating Lease, Weighted Average Discount Rate, Percent Inventory Schedule of Inventory, Current [Table Text Block] Common stock available for purchase through restricted stock awards and options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Vibativ VIBATIV [Member] VIBATIV Financial consideration received in exchange for product license rights, installment payments Proceeds from Sale of Intangible Assets, Installment Payment Proceeds from Sale of Intangible Assets, Installment Payment Office Space Building [Member] Denominator: Denominator [Abstract] Denominator. Fifth Amendment Fifth Amendment [Member] Fifth Amendment Business Acquisition [Axis] Business Acquisition [Axis] Clinigen Clinigen Healthcare Limited [Member] Clinigen Healthcare Limited Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Equity Component [Domain] Equity Component [Domain] Relationship to Entity [Domain] Title of Individual [Domain] Share-based compensation (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Selling and marketing Selling and Marketing Expense 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Repurchase of shares (in shares) Repurchase of shares (in shares) Stock Repurchased During Period, Shares Equity Award [Domain] Award Type [Domain] Local Phone Number Local Phone Number Financial consideration, payment period Financial Consideration, Payment Period Financial Consideration, Payment Period Schedule of Business Acquisitions by Acquisition, Contingent Consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Statement [Line Items] Statement [Line Items] Revolving line of credit Long-term Line of Credit, Noncurrent Unvested restricted shares (in shares) Stock Issued During Period, Shares, Acquisitions Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Restricted stock granted in period, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Note receivable investment funding Payments to Acquire Investments Share-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Tiered royalty, percent Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent Federal Domestic Tax Authority [Member] Retained earnings Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Total Lease, Liability Lease, Liability Square feet of office space Area of Real Estate Property Broadwest Lease, Five Year Renewal Option Broadwest Lease, Five Year Renewal Option [Member] Broadwest Lease, Five Year Renewal Option Other revenue Other Products [Member] Other Products Income (loss) from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Vaprisol Vaprisol [Member] Vaprisol Segment Reporting [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Shareholders' Equity (Textual) [Abstract] Shareholders Equity (Textual) [Abstract] Shareholders Equity. Inventory, Current [Table] Inventory, Current [Table] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Use of Estimates Use of Estimates, Policy [Policy Text Block] Reconciliation of numerator and denominator Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Title of 12(b) Security Title of 12(b) Security Total assets Assets Incentive Stock Options Incentive Stock Options [Member] Incentive Stock Options Director Director [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of operating segments Number of Operating Segments Current portion of the contingent consideration liability Business Combination, Contingent Consideration, Liability, Current Earnings (loss) per share attributable to common shareholders - basic (in dollars per share) Earnings Per Share, Basic Rent expense Operating Lease, Expense Title of Individual [Axis] Title of Individual [Axis] Repayments on line of credit Repayments of Notes Payable Document Type Document Type Sublease income Sublease Income Omeclamox-Pak Omeclamox-Pak [Member] Omeclamox-Pak Product and Service [Domain] Product and Service [Domain] Noncontrolling interests Noncontrolling Interest [Member] Research and development Research and Development Expense Interest rate spread Debt Instrument, Interest Rate, Stated Percentage Renewal term Lessee, Operating Lease, Renewal Term Net (income) loss at subsidiary attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Additional liability Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Loss Contingency Accrual [Roll Forward] Loss Contingency Accrual [Roll Forward] Net intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Lease Contractual Term [Domain] Lease Contractual Term [Domain] - basic (in shares) Weighted-average shares outstanding – basic (in shares) Weighted Average Number of Shares Outstanding, Basic Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share) Earnings Per Share, Diluted Dilutive effect of other securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment RediTrex RediTrex [Member] RediTrex Initial investment in joint ventures Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Number of renewal terms Lessee, Operating Lease, Number Of Renewal Terms Lessee, Operating Lease, Number Of Renewal Terms Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Income Tax Disclosure [Abstract] Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Entity Small Business Entity Small Business Percentage of tiered royalty payments (up to) Tiered Royalty Payments, Percentage Tiered Royalty Payments, Percentage Maturity of Lease Liabilities at March 31, 2022 Lessee, Operating Lease, Liability, Payment, Due [Abstract] Restricted stock awards, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Total liabilities and equity Liabilities and Equity Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Future minimum sublease income under noncancelable operating subleases Lessor, Operating Lease, Payments to be Received Financial consideration, number of installments Financial Consideration, Number of Installments Financial Consideration, Number of Installments Accounts payable Accounts Payable, Current Depreciation and amortization expense Depreciation, Depletion and Amortization Cash payment of royalty during the period Payments for Royalties Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Pinnacle Bank Pinnacle Bank [Member] Pinnacle Bank Common stock, par value (in dollars per share) Common Stock, No Par Value Upfront payment Collaborative Arrangement, Rights and Obligations, Upfront Payment Collaborative Arrangement, Rights and Obligations, Upfront Payment LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Inventories Increase (Decrease) in Inventories Income Tax Contingency [Table] Income Tax Contingency [Table] Common stock, shares outstanding (in shares) Balance, Beginning of Period (in shares) Balance, End of Period (in shares) Common Stock, Shares, Outstanding EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Other long-term liabilities Other Long Term Obligations, Excluding Current Portion Other Long Term Obligations, Excluding Current Portion Entity Interactive Data Current Entity Interactive Data Current Net Revenues Revenues [Abstract] Kristalose Kristalose [Member] Kristalose Cost of products sold Cost of Goods and Services Sold Minimum Minimum [Member] Document Period End Date Document Period End Date ORGANIZATION AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additions to intangible assets Payments to Acquire Intangible Assets Change in fair value of contingent consideration included in operating expenses Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Lease Contractual Term [Axis] Lease Contractual Term [Axis] Entity Central Index Key Entity Central Index Key Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Inventory [Domain] Inventory [Domain] Inventory Inventory, Net, Items Net of Reserve Alternative [Abstract] Lease Position Assets and Liabilities, Lessee [Table Text Block] Assets and Liabilities, Lessee Income Tax Authority [Domain] Income Tax Authority [Domain] Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Property and equipment, net Property, Plant and Equipment, Net Vested common stock, value Stock Issued During Period, Value, Acquisitions Current liabilities: Liabilities, Current [Abstract] WinHealth WinHealth Investment (Singapore) Ltd [Member] WinHealth Investment (Singapore) Ltd General and administrative General and Administrative Expense Lender Name [Axis] Lender Name [Axis] Trading Symbol Trading Symbol Earnings (loss) per share attributable to common shareholders Earnings Per Share [Abstract] Line of Credit Line of Credit [Member] INVENTORIES Inventory Disclosure [Text Block] Schedule of Rent Expense and Sublease Income Schedule of Rent Expense and Sublease Income [Table Text Block] Schedule of Rent Expense and Sublease Income [Table Text Block] Total inventories Inventory, Gross Other current assets and other assets Increase (Decrease) in Other Operating Assets Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility [Table] Line of Credit Facility [Table] Finished goods Inventory, Finished Goods, Gross Present value of lease liabilities Operating Lease, Liability Leased area Lessee, Operating Lease, Leased Area Lessee, Operating Lease, Leased Area Summary of net revenue Revenue from External Customers by Products and Services [Table Text Block] Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Document Transition Report Document Transition Report Common stock—no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Costs and expenses: Costs and Expenses [Abstract] Commitments and contingencies Commitments and Contingencies Liability recorded Business Combination, Consideration Transferred, Liabilities Incurred LEASES Lessee, Operating Leases [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year ADDITIONS AND RETURN OF PRODUCT RIGHTS Business Combination Disclosure [Text Block] Sancuso Sancuso [Member] Sancuso Restricted Stock Restricted Stock [Member] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Decrease (increase) in noncash interest expense Amortization of Debt Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Obsolescence and discontinuance losses Inventory Valuation Reserves Cover [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Increase (decrease) in non-cash contingent consideration Excess Tax Benefit from Share-based Compensation, Operating Activities Total costs and expenses Costs and Expenses Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Current assets: Assets, Current [Abstract] Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Leases [Abstract] Income Tax Authority [Axis] Income Tax Authority [Axis] LIBOR London Interbank Offered Rate (LIBOR) [Member] Income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Entity Address, Postal Zip Code Entity Address, Postal Zip Code Non-current inventories less non-current inventories Inventory, Noncurrent - diluted (in shares) Weighted-average shares outstanding – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Kyowa Kirin Kyowa Kirin [Member] Kyowa Kirin Net revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax INCOME TAXES Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Contingent consideration earned and accrued in operating expenses Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Variable rate Debt Instrument, Basis Spread on Variable Rate Methotrexate Methotrexate [Member] Methotrexate [Member] SHAREHOLDERS' EQUITY AND DEBT Stockholders' Equity Note Disclosure [Text Block] Schedule of Dissolution Payments Disposal Groups, Including Discontinued Operations [Table Text Block] Document Quarterly Report Document Quarterly Report Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Common stock Common Stock [Member] Interest income Investment Income, Interest Entity Address, Address Line One Entity Address, Address Line One Variable Rate [Axis] Variable Rate [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Net changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] REVENUES Segment Reporting Disclosure [Text Block] Operating income (loss) Operating Income (Loss) Sales milestone payments, expected Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Sales milestone payments, maximum Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum Entity Shell Company Entity Shell Company Operating lease current liabilities Operating Lease, Liability, Current COLLABORATIVE AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Total current liabilities Liabilities, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Cash paid for acquisitions Payment to acquire business upon closing Payments to Acquire Businesses, Gross Share-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Inventory [Axis] Inventory [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other Payments to Acquire Businesses Other Payments to Acquire Businesses Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Equity and Debt [Abstract] Equity and Debt [Abstract] Wet Laboratory and Office Space Office Building [Member] Current Fiscal Year End Date Current Fiscal Year End Date Net cash provided by (used in) operating activities from continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Accounts payable and other current liabilities IncreaseDecreaseInCurrentOperatingLiabilities Statement [Table] Statement [Table] Prepaid and other current assets Other Assets, Current Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Business Combinations [Abstract] Maximum Maximum [Member] Range [Axis] Statistical Measurement [Axis] Total liabilities Liabilities Raw materials and work in process Inventory, Raw Materials, Net of Reserves Discontinued operations income Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Goodwill Goodwill Intangible assets, net Finite-Lived Intangible Assets, Net Schedule of Maturity of Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity Attributable to Parent Net operating loss carryforwards Operating Loss Carryforwards Common stock, shares issued (in shares) Common Stock, Shares, Issued Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total Net income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Caldolor Caldolor [Member] Caldolor City Area Code City Area Code Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Grant Grant [Member] Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Entity Address, City or Town Entity Address, City or Town Financial consideration received in exchange for product license rights Proceeds from Sale of Intangible Assets Consigned inventory Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross Borrowings on line of credit Proceeds from (Repayments of) Lines of Credit Inventory [Line Items] Inventory [Line Items] Repurchase of common shares Payments for Repurchase of Common Stock Shelf Registration, sale of corporate securities (up to) StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] EX-101.PRE 14 cpix-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 image_0.jpg begin 644 image_0.jpg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end GRAPHIC 16 image_0a.jpg begin 644 image_0a.jpg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end GRAPHIC 17 image_1.jpg begin 644 image_1.jpg MB5!.1PT*&@H -24A$4@ :0 "Z" ( !NA:X] !N#4E$051X7NR] M^;\41;+^?_^2>^]\9KOWSLQK9MS&A7%4W!5<4$ $9-]!$$% 0$$1$=E14<$- M%5>41=P7$%E$05%0E%5P89'M<+;N,CMOT>%N7QG(AVLP1U"B!1$MM+$=E=_R'-MB( M5@)!%=HM'ZU.B0X71ZH@2FRAW1J'-[(T%K%+G,:+5@N\&N$:1CH&?2VQ92^9 M5 &5N&1TW*;'V[HTE@O19HZ@1@DD6FIC.2J[XT2R"P=18@OMUCB\D:6QB%WB M-%ZT6N#5"-\FD"JC$):/C-CW>UJ6Q7(@V<2'916([.G@H5 M1**E-MI3H*7'B++T*AA$"2RT&^$52*,BJ'$"20D:AR40KCF4QDN,.*AQ@I+1 M$0TL?1%CH=UQ(ME%83DZ>RI4$(F6VFA/@98>(\K2JV 0);#0;H17((V*H,8) M)"5H')9 N.90&B\QXJ#&"4I&1S2P]$6,A7:'YYI=T,?".4J"&B60Q&NTM=Q8 M/;'L#B>0:)% 2_/1Z@B\COE1/:35>TD5Q!(K>\F(IG)X!=*H"&J"@G)1CC!++4>+5.&,,TE&B=42, MQDN,HU?C-18AK;[Q6"TJNQ<1I@SHZ(*@QA)8=HG3I!+K#WR(D#FT2.#5"-<< M4A"CT9\14A")#F$CO4XDNY_Q:IPQ!NDHT3HB1N,EQM&K\1J+D%;?>*P6E=V+ M"%,&='1!4&,)++O$:5*)]0<^1,@<6B3P:H1K#BF(T>C/""F(1(>PD5XGDMW/ M>#7.&(-TE&@=$:/Q$N/HU7B-14BK;SQ6B\KN180I SJZ(*BQ!)9=XC2IQ/H# M'R)D#BT2>#7"-8<4Q&CT9X041*)#V$BO%,DN%5809[<$$BTEO!IEE%B.$J_& M&6.0CA*M([1(H*7Y6&)EEW@%EF,JNS/&(!V]ODJ0"AVK<>CHQX+R]B1_^WY! MBP1>C7#-(061&D=04 01/H#T*G8W5B)]))9 N 90CA(MM=&>@E2:HT]9>E)R MD+2.J<02Z1CT324^:L3TRBN01FF7Q&@<2AQ$^Q\[O+V21FDO.R>2W<^(2$>; MLO2DY"!I'5.))=(QZ)M*?-2(Z957((W2+HG1.)0XB/8_=GA[)8W27G9.)+N? M$9&.-F7I2++%E#Z(<)5I*:%&"UA7@U2NC M17ZD7T@ED!K+'L1R5/8@(F0.KT892R:_J<:BHPNTE-"B$-J?T*($K2,L36RR M"Z(<+8)Z$3*'%@FT- XKB+([@H*&4$]2B2VL()8]B'*4:&D^J<06*HB%=B-2 M":3&LI>,-YHT2GLJ5!")I1'>385J4:*EA%<@C=)NH?0.K2,LS8EDEQ=$V1U! M04.H)ZG$%E80RQY$.4JT-)]48@L5Q$*[$:D$4F/92\8;31JE/14JB,32".^F M0K4HT5+"*Y!&:;=0>H?6$9;F1+++"Z+LCJ"@(=235&(+*XAE#Z(<)5J:3RJQ MA0IBH=V(5 *IL>PEXXTFC=*>"A5$8FF$=U.A6I1H*>$52*.T6RB]0^L(2W.< M)SM+'&E/A3>(UUB$5'I+[+4[HT0*8HAQ%.$#:,\(O+XB9 XI*()VRT>K!5Z- MUUC$+HG1.&+$3A,DE:,22[24\ JD4=HE2N-%^Q"61B>[DE$-2+0TGU3BGU+J M+7&,W6LL@E?OC!(I4 0U(DR8LCA*M(Z(T91,R<&5HT1+;;2G0$OSL<3*+HG1 M.&+$3A.D9,>2B6E1:;QH'\+2G$AVIMUK+()7[XP2*5 $-2),F+(X2K2.B-&4 M3,G!E:-$2VVTIT!+\['$RBZ)T3ABQ$X3I&3'DHEI46F\:!_"TIQ(=J;=:RR" M5^^,$BE0!#4B3)BR.$JTCHC1E$S)P96C1$MMM*= 2_.QQ,HNB=$X8L1.$Z1D MQY*):5%IO&@?PM*4DNQ4K""68Q%C"78O2FR15A^/Z$L.+1+$:!R6V&MW1@LI MCB'&480/H#T-M)N-]@RA_0DM,M!N!8Z671*C<91%G-;N" H43F\YZH\)I?&B M?0A+4\YDIW4%I-);8LL>1#E*M+2H.!4Z;@&I])8XQNZ,%E*L\&J\1H73!-&> M!MK-QG)4=H=PS:%%!MHMCE1!+'&,W6N4=@NE=P0%"A'R:&"U?B+9_8R6%A6G M0L$L?8G=%"BA5>C=>H<)H@VM- N]E8CLKN$*XYM,A N\61*H@ECK%[ MC=)NH?2.H$ A0AX-K-9/)+N?T=*BXE3HN 6DTEOB&+LS6DBQPJOQ&A5.$T1[ M&F@W&\M1V1W"-8<6&6BW.%(%L<0Q=J]1VBV4WA$4*$3(HX'5^L_)SOHLTN[% MB25>C=<8;W?TN\?B98V ;I)@9;:I'5,JW279X]*%#V():CLPQ'(/V>$$1E*\C*%"(D $L1Z]=&2U<$"^IQ#^EUSN4 MHT1+"\3Z8T)I)%H:AS>(UZA0&B^66(3)$:-QI!+_5*!W:%T!I=R@2(7N48@8 M1Q'>0XPX1N/%N+% M$HLP)5+V@!8GDIVI\6(Y*KO#$@3MY25M*VGU#LO1:_<:B]C+0LG!2W:T*'O MDE$]\6*)19@2*7M BQ/)SM1XL1R5W6$)@O;RDK:5M'J'Y>BU>XU%[&6AY. E M.UJ4/6#)J)YXL<0B3(F4/:"%3G9E;U@%+ NZC7PLL;)+O!JOL:EQC5JMZX^+ MHGP=6E> =DC0N@*T@T$JL22_M5AT%!^6.&B7! 42*59H:8%8?UQ R6(+2RS" ME$C) 96C1$N)HYWLO':O,<:>BI@@7H$T1I+*T37D)9584;*C)%40*2Z"=BMP M#-I3H8)XL<1!NR0HD$BQ0DL+Q/KC DH62[W7^.M!=D^AI<2)9)>'5R"-D:1R M= UY2256E.PH215$BHN@W0H<@_94J"!>+''0+@D*)%*LT-("L?ZX@)+%4N\U M_GJ0W5-H*7$BV>7A%4AC)*D<74->4HD5)3M*4@61XB)HMP+'H#T5*H@72QRT M2X("B10KM+1 K#\NH&2QU'N-OQYD]Q1:2@22G40I"\7Z8T)I4A$31#3E0:L% M04U04"Y<0UXLL667! 46TM%"^Q!:9*#="AQ3V;W&M%A!TMH=3F"A'01:6B#6 M'Q-*X]"Z BR]URB1 H66YI-*;*&"2+24:/)D)_'JO<8BI-(KL22H$6'\:(<0 MVK]QQ 0/"BRDH_3U&BVD6*&E!6+]<0%>L31&(D*62'FC-0;9D[)T)AA-"A1: MFD\J<;DXD>Q,C0CC1SN$T/Z-(R9X4& A':6OUV@AQ0HM+1#KCPOPBJ4Q$A&R M1,H;K3'(GI2E,\%H4J#0TGQ2B:(U!]J0LG0E&DP*%EN:32EPN2DEV^H,$$2:' M%H70_@4$]75U=34U-55550>>.*)/7OVP%)?7P\]/JVMK55!O.BX MA!:E0<C7 -(QVEK]=H(<4*+2T0I[4W':Y%"^V0H'5$C*9D4@57 M8HE7(UQS2('"J_$:I3T&KZ,T2KLDD.S4IXS2.+2.T*(0VC\]2&I(H4.'UJU;KUZ].I/)9+-9?(I_2VY4.5IHM_2DBB;%,?JC0UEZ9051 M=H=P#:.=?6B? K1#@M81,9JC@^J)1$L;AS>R-$I[#%Y':91VR?&9["HJ*I8M M6W;--=>,&S=N]^[=K[WV6H\>/;[]]EO.=%SBE=:H_=65U?WZM7KZ:>?Q@(6R0XKV9(;58X6VBT]J:))<8S^ MZ%"67EE!E-TA7,-H9Q_:IP#MD*!U1(SFZ*!Z(M'2QN&-+(W2'H/741JE7?*K M2W82*X@([P$")#B4Q'*T[$$L1\ON< *)%H6P'$7('#$:AQ)+ MO!JO4=HME-Y+*G')Z&07@_37GQ4@Q4&]);;L7E"[??'%%ZU;MUZ^?'D-@03W M^>>?]^[=^]"A0YE,IHYP>A7<$13$X(*4A6,>/"@H&1E9!E=VB?#V8(F5W2%< M_:35>U%!@EB.(F2.&$TJO-&D4=IC4+Z.H$#A%0>#'(?)#H*5*U=V[-@1*8^3 M'4"MU[Y]^_W[]R,5\F)6ZKT$!3&X(&7AF 5) @EJ,(F2-&DPIO-&F4]AB4KR,H4'C%P2#'9[*;/W_^]==?_]577U57 M5V/%BM7KGCU[+KGDDA]^^ $6)#L8I=Y+4!"#"U(6CGGPH*!D9&097-DEPMN# M)59VAW#UDU;O104)8CF*D#EB-*GP1I-&:8]!^3J" H57' QRM).=%TLWA])NX15+ M8XP]%2J(Q*OQ&A66QMF# F7W(L+DL#3*[A"N.6#GV?'PX<.\(.#! R.6"VX@ M:;>"5BQ[62@YN'.T\(JE4=IC4+Z.H""&8)!?5[(K&1D-R6[4J%$]>_8\=.@0 MDAT_;H)QB5IORY8M7.NI&[(Z7-%N:RFA10F60+CZ*5D"0W;-Z&-0H@45:O4,T]>]$R9MP M'"8[C+_^_?O/GCU[__[]_,4)#$K\T;9MVVW;MO'H/)'LBI,JH!)++(WPCA4H M4HE+!N,$@V?KUJV]>O4Z[;33FC=O/FS8L 4+%F"AX++>B61WE"EY$WX5R4X2 MXRC">\0HXE#6O?322P@0C2;0XL2+$$J MN]?8&%Q B18)8C1>+$=GCQ>.G7JU,F3)V/1@)0W M9,B0S9LW9PCY&)-S%+W(LTLLC;('*;NCL\<+FAK5 8?6%:649%C)\=.W9<<,$%"QK3I\\77WS!2UUD M.HPK[5\2WDV01FE/A17$LL<+FIJR=. X3'88?(,'#\:B ^.2+ZG@CW7KUK5K MUP[)CA^[DWJ)CDO$:"1>L32FM7N-BAB-PXDE)6B\:!\B1E,:*K)$2].#P?/ M P^<>>:9!PX/5#?[=Z]F^_89L7#FXW!NPG2*.VI ML()8]GA!4U.6#OR<[,H2* ;5D)=4XH9$+RT8H*-'C^[6K1O6LWR%#L/T[;?? MOO'&&WEF+I+L)%9/G-U"Z5/A#>(U*F(T7BQ'9Y>JIIQX\>)!O;0'.:RCT4-:U;=MV[MRYU03?HO6BVR,L3= H[1*O M1ADEEF,0YQB#=O:12MR0L@..7T6RT[JBQ/AB#=N^??L??_RQHJ*"$QQ&Y,B1 M(WFM49CLG&/0*.T62N^P!,(UAU<@C=)NH?1>++$(DR,HD$BQ0DOST6J!EI8) MW4P"!@]&3K-FS?C.OM-C)8M!A7R'3P<,&("ZKY:^VWJ# M!(W2;J'T#DL@7'-X!=(H[19*[\42BS Y@@*)%"NT-!^M%FAIF=#-)&"??SXF3@PDI^?E I8.:]>N;=.FS>K5JS'2_GTK.XD6)6A=-#J0CQBQ"%DB MQV&RPP#%^J)[]^Y???45WS[;MV\?"KW%BQ?SB&2\08)&:;=0>HADKT:($K8M&!_(1(Q8A2Z11R/QC%M9XW2-!8A*#>$CB[Q"N01FFW4'HOEEB$R:$T MCJ! (4)ZT&I!C,8A0N;P:I11@B&$A>K\^?/E:H!'$<^=BQ8M&CQX,*H\U'K" M+P^K=8E7XS5*N\2K449)OO^P5 MNR E@T&Y>_?NCAT[WG???1B1&*SOO?=>Y\Z=,1Q56PX=PD9["K2T<90E.(":XT#DM@V1U.8"'%QV>R0X(;-FP8JCFL-3!&9\R8,6G2 M).O9NH8TC6I/@98VCK)$3A5$BH-Z2YS6'L1R5'8O(DR.&(T$M=L]]]QSV667 MJ?M:3O#MM]\V;]Y\\>+%J.R<42JEV+)+O )IE/8@RE&BI8TC)KC2."R!97<,--WS__??(=^W:M7ODD4?27E+QHCT%6MHXRA(Y51 I M#NHM<5I[$,M1V;V(,#EB-(XZ^BVZM6O7GG_^^9]]]IG7$8/MZJNOQH2:M5^2 M&+1+O )IE/8@RE&BI8TC)KC2."R!97L)+MT*$#ID],G/STDKPS"TO[]NTG3IQ8&_<3G1+9D)>@0.'T,8Y::F,Y M*GO)6 $MN\,))%J4T"3)SB*MOC3XL8 ??_P1!=TSSSSSP0PJTM$Q8K2B[1'A[B!$KC4/K"$MCV;U88F67"&^_6'^G3Q\DN[3/?'K1G@(M+1-6*\HN$=X> M8L1*X] ZPM)8=B^66-DEPMLOUA^G)TNOS$%!MVS9LG///??SSS]'E<=)36J> M>^ZYD2-'JMG4":1186F$$38K5Z/&9['B KERYLE.G M3L.OHH8>.'#ERHK)C8L1*X] ZPM)8=B^66-DEPMLOUA^GARL[S)T'#Q[L MTJ7+I$F3Z LX/]^I??GK$B!'JT1,GD$:%I7%V2V"AW?)))998CI%V MAQ,T*5:C.ME9.B^IQ#^EU)$$38K5:*.279.2 MJB=2R8^> "2X@0,'8H#NW;OWT*%#,HC42[L7)8Y!AR@33=I*V8,' UH"RRY1 M&H?6%: =?'C%&S=N;-&BQ=JU:[&2E1,G5W9#APY5-RA$FWZD.$9_] EV3PJD M1MD=PO48<'PF.U[&8O!-F3*E7;MV>_;L0;*37_>1^H8TP2/1("IU=B2[YY]_?M2H459E9R'%,?JC M3[![4B URNX0KL> XS#9\45E#,T#!PYTZ=+EJJNN^NBCCY#L8AZ#\J+$,>@0 M9:))6RE[\&! 2V#9)4KCT+H"M(,/KQA+U^>>>P[Y;L>.'7(9BW$U9\Z<,6/& MG*CL++M#N!X#/-^-E6AY'*F"6&)EEQ378" BV1T^?!CKCG[]^HT8,6+DR)%8 M>A1Y#,H%]*+5$>@0<7B#**,DWSL6*XBR2X2W7ZP_)BR-LCN"@H8XC9=4CEXQ M!M6^??LP=S[\\,,83C7)V]B1[,:-&W?''7=87[&PD&*I5W8O(HR?5&*)=)0$ M!8U!M-^$>)*=EJ0G5< 8L:6QC+R&7;)DR<"! Q,SI*_06&)+7O) M> -ZC8W!"JCL$N'M%^N/"4O#_^7#(>0Y\MSRT=)\M%H0HW%XQ1A16*C>>>>= MF$'YQ<49^E4*V-NU:S=ERA3Y=;$89/ &HU$+$<9/*K%$.GI]+8%EERB-0^N: MAN,SV?%SQ3?>>".&X)8M6]JV;;MFS1KUS*?$^7JQQ):]9+P!O<;&8 54=HGP M]HOUQX2E::#KJM7T [Y"GD,Y2K0T'ZT6Q&@<7C'_MLYGGWW6K5NWQQY[K):^ M2L'%W=577SUW[ESYM8H89/ &HU$+$<9/*K%$.GI]+8%EERB-0^N:!D^RDVAY M'*F"Q(B5)@@RW>[=NSMW[KQ^_7J,T:Y=NPX=.C1#/[[#*+VW(:\QQAXO4'CU M7F.A7>+5>(U%[)(8C2,HKJ??[>672#NQ1#L(O!JO45)XQ-U(<"A!(=QGU'1] M^_;%/(HQ5DELWKSYVFNO_?SSS]4RUL+JK65/16&0(IM6*"X!*XBS2Y3&H74% MI-);XB:Y05&6(!;>X-+"@_+##S_LW;OWCAT[#AX\.'_^_#Y]^O!*%O.P>@)> M(N-XC3'V>$%C4,$E7HW7*.TQ>!VEL8C=BQ-+M$C@U7B-DEIZ9WHU_3 8DA0_ M*)>A5V^RL4C5[\@2AP\??N&%%[IW[[YZ]6HDOD.'#BU?OAS_W;MW;Y'K)!+7 MVY+1$05:2F+^QML1@JO1*OKQ(*GQ!E%VAQ.43-J J?26^#A,=AAS.)9WWGGG MZ-&CJ^C=V2M6K&C>O#G_CB(/>N>HD'&\QAA[O* QJ. 2K\9KE/88O([26,3N MQ8DE6B3P:KQ&"5]E-^;.G3MWMFS9.'R< M[QS>X%YC)%Y'%[ LJ. 2K\9K+&(/4K*C)&T0KUX:Z^F"H!L/.-S??__]FC5K M'GC@@_;$PK-?OWY#APX=/GSXK;?>.G?N7&0$=U57!G=P MS&IBY>.,->%USS36//OHH+Y"UCP_7VY+1$8O".P%K[5-..>6\\\Z[ MY))+WGSS34YV;DO5)@<;$GTID;0!4^DML4YV,>2'RF$)A&L Y2C14L)]RD>4 MER?X8\Z<.;UZ]=J[=R\/0GW_^^=577[UERQ8>K.Y,X,.LX^:3ZT0!ED9X M-Q4Q+7H%TEC$'B2MHU?O-4I[*I#FD'UPQ#'#[=FS!SD.95>+%BW./__\T:-' MO_322^O7K\>$YUJIHW=S0KQNW3J4>WPE*^;2&X*@LD.B_.BCCZZ__GI,J[QB M<#W1#@+1WQ+1$8O".?K99Y_]XQ__^.*++TZ8, $[!,F:3P'\RW._;H.0OWFN4]E0TT".6!PX<6+!@0:=.G:Z[[CJ345,BUZ! M-!:Q!TGKZ-5[C=*>"ASH]]]_'PM5+%>1X[9OW\Z%//_T%U]6X^F-R=!WJ.MH MV:K5NWHA6,J#ONN(/O@JJM'V[=OC=$!VYK7\Z7=OX^4M=3+THW*KI_BF? M[76T@%4""PRM_?OWWWOOO1A1\^;-PXCBF57VRD+T/8#EJ.S%J:>7 &'N_\M? M_O+ZZZ_S)>Q)DR:A(/CVVV^S=)-:;7*P(2>PT X)6E<2.F@(Y^AYJ#@7M52L M@%Z[UQB)\\+1PNR-(8B,-FC0(,SJM73Q3HX_C&SDP?'CQU?2SQN+-G.(V#E* MUGB-"J61:&F!6']L8SFFM9<7U8I$2VT@1J+!T?_PPP]Q D^;-HT?) M%C)T+1@3YX477OC>>^_Q4TT8O/GJU:NKZ$7SLMIMB CH!!;:(4'K2D('#>$Y$X7299==-F/&# RV+#V5X@2R MZ9);MX)$VAV\LKGEEENF3Y]>0:^5!UVZ=)DZ=2J* [XM(_7!@$Y@H1T2M*XD M=- 0SO'X278X8!AS*-P&#Q[,ZQ<R+9E68O+ZH5B9;: MU-.SOEC MFC18M6J5;R>;>IDAT:17OOV[=NJ5:L! P;P&O;7F>RX#L!JYJ&' M'NK5JQ=*/-X_2'QGGWTVUOO\:+1T*1ZP(6)SM$."UI6$#AK".19+=LHN<1HO MEEC9&^A(>?Q_Q?10^1%Q&@<(F0.+4J#CD5HD8]4X@:C(8=6"[0T'ZT6 M:*D-#A]*N=FS9T^:- FCB!>P/(ITT 0=(@X9 0U]_?77R'3SYLU#DL5* BE# MCE@I;C!:Y/&9H1MK=713N)ZN(P=GXDB[@Y?YRYWS+EBU3IDQY M]]UW\9$JRH(TT+?$/O[XXPX=.GSYY9?2[N"&OOGFFZY=NV)T\D.DM?FWYT1( M/R)>GE[9'<(U'3I0@M85H!T2M*Z M'J'(E M2RJ@1'BG0$; L%F]>G7[]NWY7>TOO_PRW^W5/D7!P,/LRZF')WN>@-/.OL7M M#92:$19M]>C18]JT:6ZFQW^?>.()-=\[1XG\U"MH:E0''%I7E&.6[!KH&/!. MW[Y]^QUWW-&O7S]D.DQ!/-')14$0CC9\^'!^'86T.W@X(L>-&C4*)7UM<@?C M1+)CTNH=RE&BI38E.^)$7;MV+8J4I4N7RC&C DJ$=PIDA(J*BOONNV_HT*'X M8\:,&?W[]T=UB;^U3U$::-#RUQEW[-C!4SX7 :XA[4/D^I&O\=H;J Y WQ!\ M\N3)6,GNVK6KFA@_?GSW[MWY-G2AHT1^ZA4T-:H##JTKRK%,=MC%^_?O?_CA MA]NV;?O""R]@$5I%]X:R]&WM.N/9'R^(MGOW;APYU.K24?8Y2Y>0<@!.;-FY&MM$]1,O3:%?S[SCOO7'GE ME8L7+\9_^<:::TC[$*(C>1JOO8'J4'XJ"_/!V6>?O6#!@AJZ)_OZZZ__ZU__ MXKLKA8X2^:E7T-2H#CBTKB@E)CLOVK\ KM=JZ0TSM?0F88P8+%WY*ZNUR552 M+K5BEK&N+L,?;[[Y9KMV[7;NW%ECO,&B/OF^)/(=JLB5*U?6)6] <>@&""E0 MQ&B\6(Z6W1$46#A'BQB]5R"-"DOC[$%!T(X#.G?N7)Z]U-05@PL8I('>E92E M:\&???89:DF^Z<_O:G_PP0>M)85%EI[YP+\8_\B8-]]\,Y8FV[9M\R8[X:>Q M-,[(%P0QU+&2'3APX)PYT3X[WGGG??IIY]:R4X:8[ [=NQ=_HVAZ\LDG!P\>C-6H$^MF#)R^ MFEX>A>)NTZ9-)2<[+U*)R%.G3N7?VZNFV]8=.G18NW:MO)+38#3J-2HLC=?N MC!92K-#2.(YJLN,K!5BN/O300]===]V6+5LP*QZB7W2-#R+A X;QAX(."P&L M83'R7(6H DKCZM6K.W;LN&O7KDIZMX\(Z4$Z6F*E"6(YBI !E*-$2^.(">(5 M2*/"TCA[$,O167 "8^+LW;MW'2&T48BF O"Z!(/MQQ]_[-FSY[QY\U 9\8ID MQ8H5&'Z??_ZY$^MF#)R^FF[*[=^_GV??0H%PTCB-%ZG$)KS]]MMGG''&1Q]] MQ)=TL+1:N'#AB61GHEM.T+H"<#B1W3 '=N_>G1,-#FUCDETMW4M%' QW5'85 M].)9_.L-*(UPP:H!$W+,Q4'IV&#T4&F"6(XB9 #E*-'2.&*"> 72J+ TSA[$ MA:JBYQ *!<))XS1>I!*MH'[$8OF^^^[C>X-#A@QYX($'5$7L]?4: M%9;&:W=&"RE6:&D%VR4,K2O93ZY*DKT9<)LQ8P8*222F:GJ< MH):^A#MKUBPDC@KZ80V^NB)]+5Q#O 9W:%U1O+W%*7;CC3>BI)"7L#/T=,NT M:=-:MV[][;??HO]WW'''P($#58N% >OIR>TJ^D$UAI?S:H<7.A;!B2VT@\ K M"#J6F.STQ[:@CEXNDJ'K=!,F3!@U:M2>/7OX6K+P_@451.+5U-*]CH\__OCB MBR_^X8L:8<2VD."W>(#@OSC[[ M;.1EF8^P?W#J??KII__\YS_150RP,6/&7'_]]59OG:6>OC$"7W[[?!4]J8=T M;YUK(E@>6A>--X[76&AW-'FRXR&"P[]BQ8JV;=OB-*ZF9XN\XU(%D7@U&2H; MAPT;-G7J5,X47!R)D'[X@*&8O__^^V5P+[+%2'2(@B!>>QW='6[7KMU%%UV$ M+,QS,BPB3!F0+3;XNOI3@<:A=26A@Z9!QZ)H.&^QQS#GR?NADF 0"^F5I:?5 M5JYN7:=,F;)UZU8D M/GE/1B*"Y:%UT7CC>(V%=D>3)SNN4+!31HX<^>"##]8FC_S$!)%X-0B.Q0O6 ML!CNE?1")U[]B9!^:NE*\_KUZWOV[!E\%E2V&(D.41#$:^?%0J=.G3#9WG;; M;7SYQCJ!2T:VV.#KZD\%&H?6E80.F@8=BZ)MW+CQTDLO?>.--ZQY+AC$0GIE MZ?%/I(E;;KF%7V#'2Q9>7N!39!:L"OF_7)4[=-P"I#@MWB X%[!/,(J0H9RQ MGKXQB3,%V6K$B!'8!,SW6!7%+&.Q1=]__STRX_CQXZ^XX@J^[&XM.T2P/+0N M&F\DA2YAJC]"4NC[ [AZHP4?S8LQ5$V24B M9 I*#B*]<$3X]ZL.'CR(C,";P(6#=LM'!BF"=B/'G3MW=NS8\>FGG[:2G20F MH!=>RF&]_,HKKS0(1TZ"@!_WXR^BJEK)0C3K0:L-O'J,9W1UU*A1<@C5TU=Q M,=I1=IQUUEDH%.Z]]]Y++KE$^/GADO"##S[HV[861S:G[ TRNX0KGYX-=2E2Q<,0M-K JT>73C_]]-MOOUTM8ZL) MOLR]>?/FR9,G8[XO,LTSG"57KUZ]8L4*_(&9[/GGGX?CD"%#D#%QQ)'UY#Y1 M[LX>+U HO4/K"$O3Y,DN0S> ,!;???==[UBT'&/8O7LW!M^B18MD.1T3D'N% MH_[,,\_T[MV;*[LBL['V)RR-LCN$JQ_T ?/DI$F3A@\?WJ)%"[ZU9P51=HD( MF8*2@T@O]'G5JE5__O.?SSCCC)4K5U;0UZ%XN:?=\I%!BJ#=R!&M8 G))[;^ MN("8@%YP+"9.G(C1HBXL9),?;^)786-$9?*_<%T$&:<0K3;PZM')?_SC'RB^ MY*CF?M;0EW!1"R]=NG3"A D#!@PH,O(9SI(5]&A7+=V2YNMW6-4.'CQXRY8M M?"OMA-8U(O' MJ9Y]]MGKK[\>^[TB_]DZB?8G>&V% ;%UZ];++KML_?KU6;K>K)T3M#^A12&" MCAA#6"AALL7<<,455W"R"UY/*<1IO&BU@7;+1ZL3<"+A'/B?__F?4TXYY?++ M+U^[=FT%O3?8VHI@0(5V(T>,*XP$K-I03FJ'!*GWXA74$URI8;3TZ=/GA1=> M4->%ZQ(PHMQE.W6#PL+;:$/2+H]S'@.E>O7KQ[_:QTOU;B+6] MSFZA](Z@H$%HBOW@3KY+'EI:5/SJJZ_>?KFWV]\\X[7$46UE92[\4KX/V/D59%7_B_YIIK<%;S(L#I)1B-.//CG\GP MVMT(Q[_8>T?HM2B??_XYEI"+%R_&.@;%(Y;,6%-_^>67_ H3WL,N$_'WB,X] M]UR5R#AGU1*C1X^>/7OV;;?=QK<-1?O^7GE!5[=MVX92!F$#*$>)EMI8CKP2 M!S@)D7KXKF7&_DD7A_Q4H:7YU">/4_3OWQ^+,DXTV4;\KH(T.[=>N&\?"O?_WKJJNN M0D76HT.Y76W:-_?*R^U=$L-T\"55UZ)2;J&%LA\N+U!G#$M,H@W MCA)(G.9H)#MDNDA G#QQ)5S[!APX8,&>+FDY(#[MRY$P,4PU0% MD6@?0HM\:!]"BQ)X%&(#%RQ8@,%]\.#!?[O*KI9^2\]165HYK>I )0)"+S;MBP@3/=KSK9>3_3'_@(BK'9]]QS#S_!V&#HG3&&*GJL M@7\T#_]R@E#GDH4+(HT8.JCVD8ZK\M^_(A'MY]"B @KK,F?7)J*>GF;"R)L^ M?3K?C:VERT-:%T)W-!^MCD"'L(/4T]4EKJW<'UFCSI*6(N2W_ M24$/7DC9M MVH0AP>\K1I[UMJ@<)5X!)SMLR)0I4_BQD@Q]@S5C7-&OHJ\)#1PX,&WKG"!X M;L#PGCAQ8HL6+5"7??755S7TT#)7EYSFN$N\>WFFAQT+>9P.J &1\3%9PG[V MV6(T6+DBQ9&>12HRCCH(9]QHT;AUE+IB.$U!0]*7D%PI59OU 5U!,3WW7<4)= ,& M(F0*=!2!EJ846VA/@986(,6\TW"^(3MT[-AQ_?KUA?>LO([2[A7@2"'!(?L@ M@RQ>O+B&%K!%3F8(EBU;Q@]^2KMN@Y "SM?@N^^^P[KU\LLO7[-F#2HFJ9%X M@Z"K^_;M6[IT::]>O?KUZX?*#DOO*GK"N9J^,B13,+:B??OV%UYXX98M6]3F M>(-[X?'<0"4>\C(6UVB=K])J*>$B2[1(H*7Y:+6!TQ^-9(=,AWS' T5_G![L MUO???Y]WJSQ(3B!ZI_%J<& PJLX]]]P//_S0"6*00;SPB<'5 6\^I[,&8[^Q M "X//_SPS3??S.\TK3.N]19!A$R!CB+0TI1B"^TIT-("I)AW&O;5UJU;.W3H M,&O6+)SV-<9E7&F4=J^@EKX.,7?N7"P2>?5:)-,UT"KA^^^_O_CBBU%D2;MN M@Y "KK;0Q+///GO**:>L6K4*,SHOAKQX@V /\ 73W;MW8RUUVFFGW7CCC97T MIHS:Y&?"G1A_(R%BV/-5-A'&']P+[XJ?9V]:E/0C^/:(EA(NLD2+!%J:CU8; M.'V3)SOLZ(4+%PX:-*C"^/)_6A!GS)@QM]QR"S*4G*F<0/1.X]5DZ.87 B+% M.$$,,HB7>OJR5R;Y4?I:6I/RLD+'(AJ2\W;RY,E#APZM)*18-V @0J9 1Q%H M:4JQA?84:&D!3LFG&<\H5?126"S-L$:+/(%%2(\ 89%TNG3I@@1:1[4YG]CU M1KZKH?LS(T:,>/KIIZ5=MT%(09;>5XRV+KC@@COOO!.#'"GCL/BFE\(;!,.8 M?S87OBCQSCKK+.0RG"S(O[R E677WX9LS>/8R['N*KBO[F\:A"7 MVWY*'IVO3_(71MCV[=M7KUZ-A8\=DZ.'-*5.FC!T[EO,OB]VVR'3#AY*IHO3H@<%O579I<0=%?Y &%Z249!=$>M71'?3KKKN.OT$A/])N-O5T M)O#5!V20GCU[8K?R#F6!#%L$%U :,W1Y%3,ARG[DY0S-@1@9Z#97^'RQ@\\< MV&'$&07EBR^^.'[\>*2S\\X[[Z233OK#'_[PV]_^]H]__./?_O:WRXG!@P>_ M]-)+F.B0YOC7IW@L\K^,W"<9.FG!33?=A!.&QZ[HZ2^::GIM7Y'QY-U,9Y1( M@:61*+V7&+%7P"5&AM9B;D?5IRELZ^B'TM]XXPV!VE,4NIYY%''AD^?#@?W#I*>1@PZ,G.G3OYOSR> M9:_X@&(X86KVJ=/'UD)(OC))Y]\VVVWH>E; M;[UUX,"!D$',5P;1.G9.NW;MKKKJ*G4M+P:QMW+4TP_X8L/Y;:#.KIU]B#!^ MM$."UA6ER9-=EKZ9,''B1,PPZN!I-YLL35;X%^, DS:_89B'"PMDV"*X@-)8 M3?>S<.Q[]^[]VFNO(7(UW6#"R$!SWWWWW9=??OG^^^]CD8N\AO%QR267_.__ M_N\99YS1OGU[#*-GGWUV\>+%'WSP 29_;"F/T4KZ3;P:NNJ;'B,'2 M@W]/%C/PQHT;D=TPI7?JU F#!K7;99==AI2-NA*G$(9O)OE)XUI*7CQC MP=]__SV6.1BU\E11>#?3&2528&DD2N\E1EPHP"F'!(%9Y.RSS\8._^JKKSC3 MI3IM>"; .;][]VXD36+[=====V-5:FN""RU9X&8$#@2D'Y3G/6VJ'2[TC M0[7YQQ]_?/755^_=NQ=_8[[LW[\_%J%@-3)@P M 7L TRJVHL@A=APAL-9IV[:M'$OH28<.'?B;2XB,L@X:I"'^3@N, P8,F#MW M+O)=X?7-(&)OY> J 3%QAJ::HAJ,@!+MD*!U1?$D.POG$S1*LO3CL!AMV/6H M@/CDQ\BV"A,74,(9DP>><\XY6&+@O_???[];N[DS"G]@U8^/.('6TZJJDIZCQDBZXHHK M3CGEE.NOO_ZMM]XZ3+_XR5N4OZT>.'*=H#K_86S.++Q;A%\34D\7/?E88&HY MZ:23L/9=1@G*09NO[PX8KI^XE??/$%4@;6 M")P4.!$4=Y3PVV]]]X;/WX\AA=*>N0@C)M''GD$\S &!P^X M:OL) "]\ F,;#]*/XUUSS36H#K TV[=O7RT]ZX^8&/?(K'OOWV6YPDR'$8FF^__3:\^ &%&KKX@GZZS52= M<49NA0L63L><99PC9XJZY#7Z*@[CQ!(MBJ:>+EU5T,N^40YT[MP9NP@69 0< M%)[,K'$2PS///(,!T[)E2QP%GIEX?VI=/EFZ\(+S=OKTZ9CV>OEEU_FJ05[==&B16>==18^JLK_89TL74A!FD.6 M?."!!U \BPH8OM!QS",,3%/FC1)!JRE]ZIU[-@Q2_-Q%5WO1E$))886*@]^ M.^R@08/0G-K)XMAZMM$K^"FY7X<9 MM^)/^=&D[C-:9%!I%8 F=O\F17DZSU M>$?SS^)4YM]DE(AVAK>7+ MEY]^^NF8#W#Z89&.=1S_=A?78MHM#MY2E(JGGGHJLAY?J^*86IH/IP8L13%+ M85[))F\*43+OYM][[[W_^M>_,!5A('WSS3>8SP8.'(@,SL>QBFX%H*3B-S#* MGO!!P8(7 X8?#,!Z,R;9P?'--]]$HP\]])#,XV@1K;=ITX8[SQM50Z^90-\P MHV_;M@V^8\>.O?766\N8[#!+8:JNS'_TQ&F\QK3((!)+X.Q-GNRX/*FEXHY? M'H>BILB8$^WD@'C[]NU88Z+@XCDV2Z2J[' 4$%@E3IDR!"42!,F3$!>0[7( MKP"HH??>8&@BB532JR8XUU33.R1$!\/4T:L*,'LC/>$TYBFZAKXCS:G_"'T] MGDL_3+]8SV[>O/D@?1,6]BU;MF!BGS=O7BT57Y7TEI&C!HU M"JF'[Q)DDT>1I,R[^3B(=]YY)ZI4-%I)/]>)C,-S&T\MZ $6!TC \I3 /L! MFXQ^8B6+TP35'S\Z(V+[P6'%:$$%AR&-UIT=#6$2A1$"SG=96ME@<8UA@VER MS9HU&(=SY\Y%\E5951Q;SS9Z!3_128HM'3=N7)\^?6+VE7!-APPBL03.WN3) MSH%]@5.H7[]^.-GX8E,=7>>2TY&DCLC0PP-@U M))4%]X'/@?ONN^^..^[@3,1A@^=&(7#'"!LP8,""!0OJZ9'7>@&?/+S5//JA M1*,5]$U8_'?;MFU(?TA,5;2"?O755Y'I^&V [,5Q\,C&JVB-:\,Z*A/WC6R8\<. M#&ZDAG???;>6X$VNH_[//GDDS_\\,-W MWGD'ZSB4V/+HZ[8)/IWX4/(<4$-SZF'ZHAA:7+)D"9(.-@1I!?%1*XT9,^9K M>G\R3V"5HK:J3QZ6Y#]6KER)_?#BBR]RNN$^.#'CW>%H'Z_9"E@GKAPH5(KY=>>BFF80P ''<^3;)4[W.0 M.AJN/$/ !>D;%0 6L*A#<60__?13;#M/KH?IY9J=.G7B!PSXLB,VOWOW[IA. M<#9A/^,C= ^'VYK;++S;GJ5[+%CX\[)=?N3%!4F+#I00%)3R(]DE@V.&-1T. M)P8?#WW^UPEDSWAD\+_(<3CA,1KX%/7JG=%"BJ5>&C$$,5+Y=JIPS2'%#480 M=))K*#G36J AI DL*["-G MPDF!5\OKKKZ,;&,TX8W'N\?A6^PH"+'BG3Y]N M]9;W,(8@5N[()BASUJ]?_^"##[9OWYY/(4Y)G(EP$J*RP!(,U2). '[S#Y]C M+J#L-GR19Y%-KKON.BR%SCCCC*>??II3=I8*4F2B"1LP GFD*HHR ) H7?) M)9=@]^) XZ#C^/+;55%FHLK+;8.!VUZ)%&!?80RCS%RW;IUUU+1_TR-;/ZK) MKI*^.?C00P]A_W[SS3=UR9U0)Y ]<]D0&JQ!,"/AF''AX-4[HX442[TTXOP\ M[;33N$80KCFDN,$(@@YC1OV*WET\#2 /XJRN,5Y'SA46SC><2)AC,!;QWXC/3ZPP\_0 7KA&\LTL=70-ZY)%',+AY#8[,\O>__QU5!I]L?.!0J?WU MKW_%IE$:__F\K4H>-LP2J"EP2N/XHI+ZTY_^A&R+\H33>H8N]5JG#<>OI L. M_,@NSEC$0<]1-]UXXXU\$X!#U=+73I%Y,0/AT_'CQV,G'Q!?-^2BB96<(Q - M+FF3'5R0K9#WL3>P Y'O.$\Y035=-T2BP7[#8*M+[MU/FS;MRBNO1/Y%K]!) MI/[FS9L/'3J4O^G%&YNE^8EWXY-//HG2[/[[[^<"'$<0RAX]>F")BB%11;>8 MOOCB"XP-5/'8(@3$WY@&./MCIR'EX8AC:L?)N'SY)M]]^&^45ZL?[[KL/-<[_ M_N__XLS'V@W3PRVWW(+D"!<4F)"AP]8%4XP$# EDVRE3IF =C52.G88S[;'' M'D/KZ#8VA%,#)Y0J6MFA/^^]]QZ&$Q:86->[FHN372VM@E&*HC-\R]X:G V^ M?0(^^^PS] 0)%T&P:2@GC^0_05)/7S- #S&?+5NV+$.%)'IRZJFG8N_QXAI' MX:CC#^PNU!) M8&?^\Y__1 >0\;$S^8A@;R,;LJPFN4F%@#BY4)4C+8J-\..V5R(%"(Y>8?5= MX?NA*$;[-SVR]10O[]0?VUB.SH*!A8.!O5Q#RR@WO\E]5$E/EF$TX&!C-/,, M5F44&@T1W9-BJ9=&C'6,PD/TVC*OP(*OI-0D5^MP'O)IIG4%\ F)B7KX\.&< MSI#FD..01#!OJU]T;Q#=KB/0Z,LOOXSE4I:6JQFZDN4T&5K9H5+HV[=O+95R MV*4(CLF&3\(C]#0U:CTLG%%HU"=LV;+EK+/.@JR"'ECAJJ>.OI_ :1?=0S;D MGSJ2.1WY$:43DB"VHH:N-.&,0MF"4^X/?_C#?_[G?_[7?_W7_R/P7YRT6(5A M[>8R"URP".K=NS=2QN]___OSSCL/T5 F8Y=B&Y'+,!*PKL=R#$LP%))(!VW; MMD7Z7KAP(4:(E1DE: BK"A1W:!WI !4T6M^?O/ 2=1E:1"[FO& =09Z),\G7 M8'BW;-NV#6D%\];(D2/YRX*5R5UOZ5A-E]O&CAV+#4$60VI#58MC=)A^DS!# MTP\Z,V[<.*1+A$+6PUSUF]_\YK>__2VF#%D M!SUF;)SS6[=NK2 :\I,=P,*<+\!A[R&SG'SRR:CRJF@!BQ,,F0B;S.>/ZQ4^ M0M'TCW_\XZVWWJI/;N#4T&,Q>_;L08) ID"^X/*P+O_Y%12D.'N1IQ"!OW^. M7B%KXS@B':!=I#_TEO/L87H^G,\6/DLKJ50Y1* RPGH0JZTA!,Y;5*#( C-G MSIP]>S9_/SJ;7'S,V*^3D=0DB^C5JUZ(.0M^P_L4LA3V)X.XWL"MIY9@[ M5 )._34T55L;]LZQQCT,X^M ]A:8Y9LCM"RRLLP5"X\93.LZ5TQ)F DQ.5 MR!%ZY*TN>>I5QXI#1FXPCBA:09KEV[L&^1>G Z<6*MRW__>S7=%$+IT:9-&YR'+I7 "S747_[R%W28 MRS'^R+581<\_\XV+/__YS__]W__]6P+I#\O2"GK8D#>9DV]%\@MJG)?YY.&D M7TD++LZ5G)I9R1F!,SN?TC7)=Y!E3RQXL%71=2XT@6D&ZW>D&Y11V"B40A]\ M\ %?+?DY@QH7(CC3<2>1ME#$(7.A$H<%LSCV)PHQ+-(Y; MI@1,:>Y^';?(5-+/C>-X(8=B4&%,A<0VD$0U$@! M)@F,$)PU#](/]]12J6N5BLXQ!NWL0_L0EJ91R>>W@H\W /)CO5D&7W4DF_I_G99Y_)\<3]J4MN$?#?[M]Z M.JY5=$D(G1PQ8@36':@7>.SF0@O8RX7"6@:;N6+%BBJJ<'$.].S9<\R8,:_0 M:ZR*;&]M\J0%UF7(62BIY JB/OG. $Y@Q#Q,]PVPSKKSSCNQXN,GJ'OTZ+&- MJJVJ_*]#5=$*=_WZ]<@".-G0$Q1T.#]1AJ#=W>T'9XFG/AGS[K_H(28VOLIYF%XA M557T4K4X#F&TLP_M0UB:1MV@L()*E,;AABPF_-Z]>R/?86#Q8:ZAA08&P9MO MOMFV;=N//OJHUGCAA!>IE&)EES@-3DBXN//_XX$B[&-R;,JOQK ME!9H?=&B13?>>..6+5OX1.(Q5TVE!]9*J-%0@$"#M<9CCSTV;-@P?O\/-LH% MD5WETZR*GMCHW+GS7__Z5_Y6+_+XJZ^^RCE+ZF/P-N0U2GN3PD>PGK(>M@N+ MOH<>>@A9#[L+VXOCB$R!W(>*#UD>BVBL3%$H]>_?OTN7+LAQ.&JHN; 8::Q.D(*BIIPQ>2=<]4?BC5]===]WSSS^/_QZF'S.J3:9_G@9X*#+\*?(C MYC-D;3=6=6.$\[*HIVJTEA)Q#=7%?+9NV+"A5:M66/CS ]O21;=Q%)'=D#TY MELDNFURLQ:R(<8;) 5,B)\$:*N-Q]N)$Y0=3I:]N(Q^IE&)EES@-.G#ZZ:=O MW;HU(V;C(_3>UVW;MB%9?/SQQYSI>$'!2:&.%C6^ZYYUY__75WCLEB(1)O0UZCM#1?E.?C MQX_'/%1%93(G,AZ'SI?_BTH"&9GKP6JJFG5CA/.RJ$]^"BI#CT9BJW?MVH4E M%VH1E"E= MI*]N(Q^IE&)EES@-A@6J&!YA[E,,&MB1@) O3CGEE/GSYU?2(ZS58G'-F0M= MO?#""S$6!PT:M&3)$JO;/!5STN3?W$0V.9)\0>V^^^Y#93=ERA0>7M9L+(%R M[]Z]R-&H!W%R8N:OH+NH1^A".]96B/_WO_\=0Q-E';_@@*]Y%4EVW'2&:D_. MN9C,?\[HOA,[!F]#7J.T-RE\%+ M"QS,%-D(*@ABL[-\PXRZ!,>^FEEP8.'-BB10O,D3B:%W?..U+PP@LOG'KJJ5A$((M==MEE?"D'4RL_/\G# MJ)JNPEQSS370#!DRY+777E/)CL\9SG2U-%=_]=57[=JU>^JIIWAAR*D$RR7, MQHL7+ZZF5;"5,259NKX)Y5;ZQ@*R[3OOO//==]\A+-;";[WU%OJ,DH3?9<9Y MF7,6;W@A?'9EDR]XU=!72FOIBJH[^;5/"-=;_8&/TL1IP=[@L[1/GSX8>YRP MJNA+"?PZ&49HWN6X%JT[!+W*>_MNN2]6QF:7VN3UR^N M6+%BQ(@1R#C(.Q@SJU:MPEJ2NY%)KD)@(8+E-K_UVAUQ/G;U5.6YAGASZL77 MYC@4=Z">-A]Y%C/]U5?__./<<^;,X0>>.0E6%=R!+=PX=I->!6,M8:;0(BMUXQ>&\^^Z[^9Y:)G\9 MB[(.66S;MFTXWO_\YS\/T9M7L-+!,.*K[U7T#5#4H5===156/1B%+[[XHLH+ M-DC\.)83R\A6\*# 0CIZ?8."GPHT7K1/-'P@D!'^]*<_8:YU MZ4SK"M ]2+ $0;O$*Y!&R;???HLTAU4M)C,,T=Z]>S_YY)-+ER[=O'GS 7HE M'Y8CO#RO)'A.Y>DL#]0*^AWN#S_\$,MVC.K++[]\P( !+[_\ M,H)SA*Q1A4B\ FF4=@NE=U@"X9KCUY7LL/OV[-F#J@2'#5D#HY#OT-4:U8TT M6@3%+M,!?FVD2G;?TSL7GWGFF7W[]J$6.^.,,_AB#<8-BB8,,AQ^+LU>>>65 MUJU;8UB@O,(0J4V>EN!YLC)Y>!T5UJ.//GKII9>B?,/?7%Q4)R^&PC*V?__^ MK@,N5S)NCU#0I^*M!XT3[1 MU-+R'V4OY@,> %S+:%T!N@<)EB!HEW@%TBBIH8L5.-88I9A]L31!:L,BMWGS MYA=<<$'GSIU_][O?(4/A5/KFFV\XP?&T6BW>Y)JEVR"8R)':D#JQ['WBB2

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image_1a.jpg begin 644 image_1a.jpg MB5!.1PT*&@H -24A$4@ '( !B" ( #:1"Q !@$E$051X7NW5 ML6V$4!0%45)$1TC0@ ,G-$$M! 240"?;!0B:( <;R=GSKAA# M]B5 %B_H/Y@585:$61%F19@585:$61%F19@585:$61%F19@585:$61%F19@5 M85:$61%F19@585:$61%F19@585:$61%F19@585:$61%F19@585:$61%F19@5 M85:$61%F19@585:$61%F19@585;$[:S'<;1M^Y&JIFFV;8M1?KF==1B&+&%= MU\4BS]S+NJYK411Q*AEE6>[['J,\?SKNHY3R9[/UQ6GDE%5U<7C_^-2UO..YV GRAPHIC 19 image_2.jpg begin 644 image_2.jpg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image_2a.jpg begin 644 image_2a.jpg MB5!.1PT*&@H -24A$4@ [0 "H" ( !?636$ R#DE$051X7NV9 MZ[KK*JY$]_N_=,[IL%*S4@(A+DX<6^.'/R*5"A#&<_7N_QY)DMR2__[[#\\D M21QP60J:3I+D6N0E3Y*;@C_S^<<^B7//?QW*9;EA!Y+D5N0-3Y*;DG_LDU'D MWX@W 5N609(D5R5O>)+<%/Y+GW_LDR#\;T3-71=L-B]+DMR!O.1)=]M^DMR- MO.%)E;%FVGR3)A)32Q(&]^N&;PCOFI_'\9E9DB1I MD72 /MBW.HEP69M'[:#*8Z>*$D2A[Q[ MR3;P*>?/>AD<]Z&'?WD>-]'UJ!Y-=B^QX"6IOC.71S9[]/9A?N@L29(XY-U+ M]N#\U2Q!&U^')\5814D;VRYN9G):/ORV\W1W>T-XLQ@?UX&C_9,DB9#7+]E M^917/^CXUDM\"SPI#U27-*AVK!I,SL/Z 4W4O605?,=;G_*N8 [^$\*#O;-<'MNN;./)X0,:/2;4Q@OM7*,.OTYU^V^* M?6"NXZ9(DJ1+7K]D"?FS426B&05_/&![Q"R7I]6T5CSY.GCSRUB>/J(?*N%) M@[77@'>*C1^W_:/]DR2)D#W(1H$A/'F<#%'M6_;SM/!MXF<7 MG&E07[ E]WPWYKHW1)GBZ%F2).F2UR^9A+_@_G<\HAD"ANSY[Z_*OEEN0JMC MK7CR7>S+CPC+!-;\NR?DX&"591PLOPS8['$;?W6Z?YI)DAQ-WL!D$OZ4.^!; MWU4.8?^$'#31'6@UK15/OLO9>\E1A6?0I"A9S#[W0;JGZ67@+-U.DN0K MY"5,QL"W._@%YX^^YJ9HS=Z*)UV8>,]QB*B*F[24-G)MI(?;MW^T M?Y(D0^0-3,88_7:7CSX^_8M@=NN&E,23($[KLK(([-GA^G3=BE)J\;P) MW 3;D%UP8X_P3Y)DB+R$R0 3W^Z)DA;XRV3=6O$DB-.ZDG($R<>8. 5[-7"@ MOILMY)2&K@Z:IHD=H,^MAB=)\F'R'B91^ NNN39S557@(%:[_&]+MW4XQ.2W MP-7@XRL_(P=J-8C8U%5!#\LSV+HAV!P_DR3Y(GD)DQ#3W^N-G_O67R;$;2H) MTNV>GTT^0/>,A-:E*!$;%R"S2ANY,&@C&J**-:SS]BF2)!DE+V$28NX/@_WN M3^-8(96LX/00G7NB3WQ8.%ED(8?L7WQW&N>),D<>0^3 M/BM_$LK?U[E:QEF#DTJ&:/5PUR$F*^ ]#QY$]5Z@W#=Q9FG%KPIWS&G+-$?[ M)TDR0=[#I ,^W)J(L5A>P)\-ZP-_FTKBH'M^&_UL2;O;G^-5U)Y\!=V,.N5K3 M."9EBFHJ&<)O([*.)CF4H?ZWQ(C;%-.2^577@]O8ZLD*XKG1.?D)^,2K=ZWZ M[E6?*+<#EEF!U5?C90HG52(<9X$?E!3P-:UX%3]K&5,G=T->OE%0/NWPH/*J MB9-*]I*M_BY#MZDE0[R:+?@3M>+7@QM5=KU]XV*[W3]9@8^CC)T#8H$C>QB- M+<2SJ^1!&4NM5;+F7YGK7!7;%%=5QZT(8PWYR1I'8#5"U<%2CR;)H_?J1/CO MA2;"8 TMD_4ID@):K0G"SR:'$G_5'1E.N25XM">*U%X,V?+>O;,M(F^*9#?2 M\#+FH)Q%]2>>XF,'T/"@)>:!'Q>-C"5HGT)KQNI/GVKM?T\D6X)(<80+;54U M4@:2]=WP4^) ?R=)H?H^#>&\=J,X#KNF2!YT9"VRVU\$S>_VWSFF4NZ;(&4U MCO/UP&9YUQOW+K:8*!D%?>,!-Q8I^],6QG\B:'UX#($\;=S*X""1\[-]M6+8 M\F_%'^\G\IZIT%JK!J\*M*QC7L_R/8"<#=LE_PG5]D!_RR4GU;# HY4E2^#ORHK]HEHD@^3 M1Y+46;^NQ8$_$Q/ 1!-/_&PR2J23$4UR!+A*_A%$LHX&J:JFK*&:NA[H%>]Z MU]ZMX2[G'T+VSAVP$:::;?6S%;?9JJT%LJ&JY+?(XTS>*!=^RVU?]T%YU6'1 M/&G1;:E_+LD1<,^=MOM'@W@U6WC-4!%$RB^&[+?5F0G@+(,+P\WDS4H<*1E( MH>C])Y"?2=(B7Y3DC?*MV?(%J7Z;XD3*(YID.[O>D&0(O.U.\R/9KJ8\6QHG M=3'0BO+[!Y1LA-_V5L_][&-$4-4@7LU>$MER MJS.C6%M5'$-K(HZ7MZ'3D+9%NRKDE9@".X$MR- M;F?BP&K=F:O$!_Y6(%5<6"VW V C/TVU%56@\0N3*8I+[S_VCNI0A$X,E^ V5N"B_'J]]NN%_=N#7G0P@HD MXAARJEIE-7:Z2X*=RL;+ $@DKN<45\DS.2=Y-DGS&S%-<9@SD<6T\+/)(O'V MQI7)-)%+T14\>IHR"^:RH+PEN!C8KSQ7@(,TL_7D@?RLBLO8!BTM_VO#S>%! M]Z>D)%@&5L^35BF"Y(3DV23_V'5I43YA@A*_-BA+%HFT]_6^_#OTY BXP]4^ MQX_ USA3%.(370#L%+M>WS@;(B(_\;0#*4>6-8D@K2M/'@A<:%,\L$\>,%:) M69)SDB=T=^R-7;RW\BV(P_IN;5>0K#!TB'%E,@VS%0QYP#+65W\F0:3#W'8@)4E2R#*#LZCVMAJLXB@C9X=E:.)W\!?/6=XL.L.#ZK,Z$(VXL2R9 &TLG<23@TDR M2KXW]X4_'!L_(L5GU(U7\IYY ^OT9IZR9X_)$G'&405#(M=-N-\<>"J/J))DBWZ0[ M8C\BN[XIQYAL)U^I^R(?%_Q471BQ&B(X>U>0 M',%0V_$"#%4E+=#,:C]'6]U2MOP!3^0KCZ Z>_4G8U>+2$&RT'#*EDQ@RQ'A M8-*">T6=^Q=)DNWDBW5'\$&1 3\GF"X/EN!3&-0G6YCN]G1API37'B^_I15G MNA?'28'N2K9@S67Q=B_5)44B5> /$)Q&3.P@:2%'\#J3?\$D.8A\O6X'?VC* M0"+3P&?(BE?RGE%VK3,99:+G$R5)%>>U'[IKCMA)@:+IRJ:!U'&B*@N@/@@R*E$D*9E MHY+/DR_VF9RBN-5?*4U MKS(TX\-,*@,\F7^5AQ&<0I:TN#:8=(-WAEO-S<'/)/DP^=K="/DB;_SZR.=, MTPU&E7%]LAV_^>4MLAH;2>*TNEHH\5:6Z9ITP4HSD%]LA?_9$M6 M*'%DM28)X#00$9L2')-"*RY8'^L)3>3G)RE+C4S-BT1)I+!*==YUV\L@S4%; MLC/)U\E7\"[(%[G\!*H>9,('^FY57)D<3?4(_IW]BQ)!BG\F0]A^(LY9'U_F MI!A>B0QD7'[*X+M@P7@ZE+T 1%07 %52#EL.WHJ__E*',59UDGR#?!'O G]T M^#.T_C$Z^KOV^G(>8IY$\,\7!V1EK7'2!C"^:&\',4[IB-(WL3T(I[;C_Y1?(%O1W;OU#%9,AM5!G7 M)\?AG 5.OYHM.*G$TKI6W3X72F'5!&.VJ@:9EY_&#V++1%ASW*THN2I>R[1J M6_$+PUM&5Y/DY.1K>@OD>X2?Z]^I\K$;_>05<;=DSCPY#N<@<$S\Y*P-)@[\ MYG>;B7$UQ4'^:<4.4G4*#377)BB>,T\.I7H6.":@"M)H(C&@AZU^2J3:6]3:L9J>U2?.+Z(6!>_/DYS<1J,>_* OQR M)W4->(.E%1?>;')A\JV]./QADL\6XM/@PS?D%A?#/%Z2'$WU..QK8#4(5E.W M!=W@YJ#)96 U'&2]8)6+;#<$[+P^B[AINH%4Q0L95-ER^-O4Q2@;O/PVDPN3 M[^[UX2\4OEE;/EM_7_JP&\3=D@GSY&A:QX$SY8&OU,05D$^.Q%.>J?'$WU!&W$ MX3)G:C=2W13+J@(!'2X#E'"0]2V@U\0+)U6E:[B+U[XG)T+AD DF+27Q0H8= M+'\3- 2_2]G1]?:5W)9\E>\"?[RV?,+X0Q\TG%#&2Y*/84\$AR5Q/UA-G8KR M^F&U/,93?K8T<<2GFI)XE:I#H:1:V1:H&BTM]096 M91LI*['SVI\.**^65,V[<-5H;019\\04LL(AAZ)'U5!MP2]D\VO ^[W2OI+D M_\D7^LKP!VOO)PP?^B'#(?W<%,G1V..8.ZE1_2[*I/STX_;GT6 -TB(;:0%E M5=R*1W!L5V##,N9G'*QM8IW3A< O9'_-_0Y8_#6VDR0M\K6^+/P5DR_:.G.& M@")J9(/HFSY MX97_]$:2)$*^WU<&'^N]WV58#7ERE>8,$_[)QY!SX9/]B?/":C5Q JJ=Y XC MZ% U :UXA%*[XF"!F_6TD2J0T>I"A5!?,W0VY)J\.M4EQ1< M*F\6(!Z$JX8*"Y&JHNG*3LX%MI D$?(MOSCXEFW\HLU]Y>-Z^$_,LL+&&;>8 M_!!EOW.[7JD=XF,3K8"7D-L,+<]GB\F9*>>";6(\O?'%\BZ\ MPN-F6:>Z3@ZRV,&:,-5@'-]\%':;,$25/$>MI@L?L:JBB2C/ U;[0VM.DEWD M2W]-\%';_G43YPA#XL*FC MG6&]5!7GN%4+.*Q;/=9.'SM:,7F\^VBN1V1>./NRD\"+_(D%)\EV\KV_+ =] MCHOMJ.>0'E,,504IGM:Y%1\%#NM69X9/!ZU;W/*Z@P,6J8DS43I@ESK:&?:1 MN$3F@/^Z(4PFK+@$)G.K6EE#I(K](_IOP=L);BU)+DF^^M?DH&\Q/I=#GD/B M!^E'"Z>13:W,>U#GST:U8\^W8W[+QS4-"SO"?".VC1,K;Y64>-S'H>H_S>C" M($:A16M$-R&/(?$ MC_>74'.'@;DVSKO1ZFR4?>&)G2[N=XN)Y2#;[4A7Y1FD55+.R,;GP"R+AG#P M?5YK_Q-C7'XBR%5!Q%;3+D%]<<8LFOXVO/$3+B])/D_]&N F#Z$NR?N_S-@S9&52]-*;:30(3[[*+Q(_#P;W$!>Y]!J M9:<83U@Y[/*$@V^"Z:#$@ 5E@&"0JF&$>,GT%!\ JSKG\I+D*S1O0KDG0-,O M@K+DDY2#X.Y%5O+U]23).?$N!JYTY/ZP.*)/#@+]WWL*?%CY8S\07+7)&2",'93PO6SP,\JS]!B2PB_D? 4WQ@.I_J D;7 Q,4EO&H M3Q [W1!86]6!XS;+1#15XE,($$>JYJ8X NP72TJ2I(IW/89N$8LC^N0(T/SM MIP"WN.WK78CJ"UO6SU/[/B+SQ0XHY,&TVZE 9VRC>(\_GN[$GR6WBW!?C.2.OV4LR'G.?6,S%1E&[? M]4:K(-C%5RBS@Q)1D8L4SIF,@EE&)RHEP(EH)<%*S?4(3B$,B0MS$^VBS/N5 MJ9/D1_%N"VY4Y%*Q6/22 JQA(K*(YFZ4/AS1$W;67)LA,W>-B39ZGA/LD7+K-.N/VC+57%D+DVW M@3A8)?OZ,++:KZPA27X.[YZ4*XV+[3AR>[&<0V9\"SZT4+H MAZJ$8N)/;2>RD47VNIT'WA$W;7L#"W#;:WLJI'5HYNB6;7E!=0K'@MGFB3)5_ NZM!]CH@CFH*O81]?>1_0A^W=8.+JYJ6V)=;X295_8G0S*>"-'>)X*Z1Y^JJZ'+!>F7&E<; =6.N*(IM#5L)6OO -H M C]W <^A5L^M9&XNAFM;#E4-!^.T]-4I+@9VQ]L\8LMHYE[;\R ;G-XI._#/ MCS$W75DGHPJ7H@\6\A0\4%T#*8S#$XW6CB+^$ZM-DL2[,^52M6@)U.6=B-+/ M)I;2KFYCISG.6< LTW.AO.7 <8R+?G%J9J_;.9&F?6;+AYI_!>D;-CBQ4S@ M51R/[.(#8*>1+;,R7E7@$LWUP(P3M2M\>+HDN0S>S>'['$0M:G3%?C81T*YN M8^<0?TUO!1-I(@:7MTS*+F0O*)%X'*E:-SP_V!WVR..]R"R:_F5X4XM[1)<6 M?1;!U)^97;;L( L+5FT!,^*Y'3'_V-:2Y))XEP??#GO'< \MHK1TQ4XJL73[ MN4BQ'3*?*"FL[\4O+W%^(FZ#$5IZ7D9+L>6K-I/?D\4&L@.>7^&3 M"P@VK0B8$L0SR)"8F9@K#ML>-$62W KO%M%GQ),]&M^=%KZL%4]:H&,']0WF M0?^5Q8S.):"P6LXI$52#<:J%BWOY";"ULDW J8T-Q5V]HZP&$X?2KN/ZUCHI M"V01<97@1"W\I2)K-:VX3Q&W2MBPI;D V!IO%N.-L+GF?A;I&'ZJ+@;[3)ML M9'$[07B6ZES5GG"0XQ;6^$H?.*R8"&RUUSE);HYWE_Y]$L)7CO5^B2.K!I,6 M3B>W .>N/Z^D*VZ!N>8<_')D->&F?/P2MO65OPOOJW3^N%V+^07@CB%"^6&L MX7DX;E7.KDN0GYRJQ@68 U6$*;7\G ,./%@Q3))$\*X3KESPUK&^6U)51@H3 M@'8=VC=,H0FB+""B]&&?"?Q:9WDHK&9;=,7%EE'%[U,V)4\9[ )N>VV_B/1J M>\?.PZ'[DC9RD%-<@HB-"^S0%?NPSXH5.ZSX)$G2PKM7N('QZ\71]D^RVP M%T9%U^*(#=H&VK'6F!>U"FL<69QBPL\XJ))!DB3;\:Y6N7M#-Y!+NE56V2U) M&-O (RCFSBR\C)8FR(I)J6J5^\Y^UC*D+S)^7@QLC=LB02F9AFTU]VO8%EUC M7U\!#2Q/^?FN_8>?+;"AKPS":QLRE*JAVB1)1O$N6+F'0W>82[I5HHR4). S M?<,4FG@G*.NRLI=2VRIW4@]:OZ,!D$7$#W,I@E6_0MF./'F/G-K"97I8-H+M M7&9?7\&VL0RBWP$;* M\]>W\W7^O6&$*MXI D<9])D S@XMF7HE27( WDV;N)"C):P/EH")DLOPWK9C MFU#\6[-@ 2U!G!4KI]!)@8CF06TO8TV[<-5H[?<.=#%Y+U@=+'N.S%+AJJ/ :8,M'[[WX M.[-L/(5I'UK"6WDU6"6H9(VOM/Q-\'*X#-P0?X-.:HA=/M\%O;K&=GX.O_DE M6$UMA-=00) '29)\&._B_=W7WOUD943/3)0\S(R:OCIERY_9N]-D+ //%:8W MA1(I+/&((9>WQ.S3TOC H0S8\*?!IN0I<+ J&,*9Z%?H=BPYFE;SGU?S'Y(Z M"*P$DWYLZB1)+-[UPT4=18U<)JIHJC]4=%T^N6O,8N?B-=CL*.PV2G4-0VN+ MB(L&:#H&EZ_XG IL"JCB14DY@B'\N4X.M^MW=_'KH/E\!!S)HTF2>Z(W_^]K M/8Y8Q9DH?Y]YK/:G*9OEY]%@+IFN%9]FSE"J9("?/A%Q1!.AE,-DW? ,8!?= MO?SKX/*N=_E\B[)L?B:?I_H6X6>>2Y+2Y),F=^?+]YX]1$@$?[H\U#6>$27F@ZEFF M/>V2IGU0:_&ST\"V.!\QQ<>86SQO?+1\KNHD\,8UEWP0O$4X$3R3)+DM7_X$ MY-^&4?@[_C'DSP;_W,CP6["1A'O2&E\ V8[=*9ZMGS)&^;7YZ#ZEK=STTV+7//JL!D5P M*IX;?4,53T3 @^"3!Q9).&MBG([LP MK7;)V ]>C\<-^- FM;6$2H]$YTZ2)$F2)$G"Z#^MKLB'-JFM?:&Z@]'IDR?H M3+:H2VD1/^^,[88\97!;G!>FVC?1W 1LW'9#GC*X*KR[:A_*,S@HXXN!36&G M_K,Z:/W\";!R?OH#&2=5/M0@.LHW5'<\95+_R0,9?Q1'Y:K!O6P /6G!_>CHUCCZ J%JS^_)2E\M,B63N0 ML?UY-^SV;21)DB3(YSX?__Z"O=!TTJ,T[<+=PP8UT0"MV-49-MSEN4Y9 ]:# M"/_$\Z>1G79WQ)JN^#Q@FS^TYB1)DEOQZ:]S_CV8IK2.GU<"^QK:&OZ1,5IH M@8,,%FTW@O64)?' /GE@@WB>"JQ6EMH"&E]V-GB#29(DR0G)#_1O@#^H%_ZS MBJT-;7!C0WCV?XW>Y+P7K,VAR")/Z&$N@P^#)94%R/(8429)DB3)%O*/RF^ M?P%<^-\!7]\@_5OK7[?/#];)W9.-5(&,]>+#(&)31X E83VR $Y179(D29*L MDG]7?@/^!\%5_S5PAMUA#=]=Q@?QXG M29(DR5[RK\L/@'\0X'E)\"^>"^\Q6>$F%R%)DB3Y+OD'YC>XR;\:LCF-\8>ZPQ^0KX ;]^CL667Q58X/7:,B% MV7) 6TR2SY.G=07X^C&J&T3MGJCH '@NFOD/5OZ5+: 3#*)V6]')")6.HXY/ M5)2KS(FN.H!:_P_I&Q&'.)/D6>5K7 M02_B$Q6-L-%J%)Z4EO 6Q',C=B)? %1W #KE$Q4-LM"2)X M;L1.Y"#BKGX=G6]YQHU6#D'_B.:>^,?$V:K@))Q_A1;JZ\S*_4(RK@O.#"^^ MNGX15#4G9\OBUQV.YN3+^Q;9D4N!>PA4$6:7SPIE7CP_LY[165@?+%EAXW0; MK7R"_A'-#0F>44233$#M'^[M=.'YH:YX&PS*3LOZLL^__=,N[+MD4RX%WT.@ MH@!J,66R"UW*$Q5M8FZ6N:H)9**"BF*HRZQ/A(A_1'-/X@<4E"5#H/\3[9VK M^A6H*]X&6>8K+\GY-W[RY7V+[,BEP#UD5!1 +:9,-O+)Q4S,0DL;KAU"IWFB MHACJ,NL3(>(?T=R0O^,)-">N3(:@0QCK[43)#Q%L"\M\Y24Y^<;/O+;ODDVY M%'C1<2$1B2.U!15]@\\LAC8],!%7#16. O.5Z;@6J&@3$?^(YIZ,=B:N3.+@ M%(;:.U'R6U!7O#VRS%=>DI-O_.3+^R+9D4O!;SE>^M'WOFKR+OD.GUD,9AF= MB M':X.P\\I(>'Q+](L"\L2D'5+U1GL$JJ_H,J-C,ZT9!,4!%1U5!I)6N94UI4;1!9O- !)D&K MB)+\/%F!Q8SJ#%I J'20N!4K16R#)*S;LD!0*:'2=[IB$531FG=4;=""%ZI[ M4=5P$%!176#ADGN2+;@4\EJ_O^W]LQ8EE79J13CR]C*5Q:LC$J]VJJ& M2KW:+G$?J^2($_^S>%%-446EY-&HBL1; D&4_)/1,D(T5/07!-6L!)GWZC\B MFMN2';D4\I;SJ\_Q%E9I(Y:6!G$_!8&&GE1+_HP()S5$=R('KITHCR#.H]/- ME3L:)_78X5]H98.%50%2W6P1\+@J. B9"*@N0*N67+U4R?+8:OXJWV%-1*:) M)V2@ DY!H"%3-43<9U3F*UL:JM94P95APIC4Z!628,N7:BO(NU?9^P,Z/51&I]33"K"8(,FC(GVTUULQ%!5>:D M-L*S6%3MXI0XGIRJ"D2CN2==0:&K(1O5<(JSU> <0:NNH!!QM5+?PT=,@V](XJ0)5 MJ\9) 5_@9V].-N525%]T7(!J%MALO*HE((.*@+-5@5!5VL@BF&7"EFLGRKM4 M;8,S5@61VA4!4M4L\#5^]O$4:"A0]>@MS\\6(II=\%P651M\V;O9FZP59[9H M_&R!/"I*)[4%]F]-X6<%7^QG"RU!*UZ LR_S$9,N6F\<-/U.5].R:L6!$_<+ M'R.KTL03)U5 N94Y*> +_.S-R:9^@Y-B?!FR+4&58 EY5Y1."D0T&\%T M553]@@75IU"ME;C0U?@"9%L"X"B=U"ZZ4S@I(6C5RCJ0<0BMCZ$N#;2,",H> MX;F 4\LIGVZ5GRWX&F0C.+62 K[&2279E$O1>M%Q!WQ!-5A-=>':EH.?%:PX M6#B*G2@.UTZ4=VDYTYR5+ 0:7=@L%P(5A?U]#7DT-4)<3,8J=E(@HMD.3VI1 M]1,5]6B52QQ0Z:3&20EDHV(GM0N>HCI+*UZEZ]/*^DAM=8#G-*\9_GE.$'=@ M981NN0BJ=/5^MD >*N-4A%:YQ!E?@VQ+<&>R(U>C^I;S';""5IQ3U6P+K@(J M&C<7<;QP",PR9[Y8WJ7JS),Z68ESJIJMPB6"2F/^HQI?6=BE=%(%JFYJ#H*G M%E1:VTA55N7/URWI:LBFHG%2 MFHV$EMQ)FE%:]"-A6]D^JR4AL'LTQ/%'<( MRAQHJC]4](ZO=%(,>:BR%0]"QDT'7^.DDFS*I7!>=%P#*Z@&"ZV2*A"SWD88 M/\M :5'I&BNVM*A)ARXM9V?>5IQ3U:S0$E>#W103D4$CJ.Z)GQ4*4(%7-^DP7#D$+G)PH[A"4 M1: Y_U#1DY4L@,PJ6_$@D7)HJC(GE613+H7_HN,FL&:B1/ UD50U:Q$Q5?\% MUUGQ7*D-XIA79[<1ABKJ@D= XV2IM)(%$0U#KO7"5KR*(W92!0@&PA;5WPZ#D\>@(_RT#) M8@YR?(5I0RX:F%<).P1EH]#\%>=@ M5A/O.#(G%2%2#DU5YJ22;,JEZ+[HN R,BHBN9E'@9X6J&$&)3S-M.%T8I^M/ M2WA#=2^ZFJ[@X:Z*JBM9$-%4(?OYM\)1.JD"!(YFA5'GUGI:\2I6$ZGM:B"H M:OPLXRB=U'9DKKE)V<&";$L 1,.%'*\2T52)3]$B[A!7/IYBYZ?@V#JI1WA) MCLQ)6:PF4NX+_.S-R:9__OHI_J(CHRKJ"1_M<.%7- E_3BA>JM0A*O(JC=%(%"!S-"J/.K<4@;E,6 MJXG4_DW0D/D"SE8%P)$YJ2/@Z28F[19V!M?/SS)05L5^ M=HA1*]8'2U;HSO*^'$_Y"&QV4>!G056#GS;%5&LY;E.,+W-2P-&48#45I.7< MHK48Q%L"8+.1JD=[:D V=4U74' T9%#);H>GFYO4+R3CIN91.S($&1$4G%27 MKGF7(0<6.WJ;M1&AY8FX316Z@D=/P]FJH-#*!@M; F1;@CN3';D4D1>=KD-' M^>@9DLVJ0!,U?#&R+4&0(1\6=TN",H=(.4W243X"2_(%G.T*)$BJIHRSB NV M4.+5+/ %?O;16+E-V6R0T7)'CU1$$XPS70T$NS2:>.)G]X*YIF?LUI+]'R4N M6:ULU%JT+,RZR9 #BT$K90LYPE1+)%7-/LR\FG[B"S@+6@*.^RG@:ZK9EOAN M9 LNA7W1JXS*6F)?T,K*V I:^&+.5@5!(B:L 2HR#(E;1,KCLT#IZ*U&(E6J MM8PS!9 LEP GBU0U6XAD(P*KX515$&&HO*LD,P\M&W36W(M1357FI!ZQ*?:R M,F.PEF4MM.:%Z@Q:,,*ZSZ@#ZUMH36^62*J:+;#&RJI9D8FF!9?80LV]Z&I8 MP*CN?F0++D7PY1[2"$&93[7VW5@1L=5K^HEH?+0XC!K5F"BQ!!TBFH=94D%% M#5FA)>B6LZ KJP8EQ4&&ZNJ%-E455#4/(W-2D@VB%FV344T+K3%5FG[2U8B@ MJBFHKH;6O(AH]K(R'2VV8Z*Z=U3]CJH)E8Z@7E-N:A$PT8)W5/U$136TIEVE MNK;28=1!]-425=0T_QF9II^(YIYD%WX>?:\-6O#$B4>(Z%N"5KP 9U]6&)6U MT(( :A%@NIP++:I^TDWY1$I:6:JK"#1'M&0<;\%Z0:7OJ/J)BHBNX+^VYF^" M,&K10^MK: TQH=3$.Q%!%=6]4-T+U;U0W6[F)J(%*BI]H;HG*FJCE2.UC+K4 MT!J#%KRCZAI:\T1%+Y!]E_]1U2/%SQ9_C),D27Z+_P.H^W@GB\O#60 !)14Y$KD)@ !@@$! end XML 21 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
3 Months Ended
Mar. 31, 2022
May 09, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-33637  
Entity Registrant Name Cumberland Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code TN  
Entity Tax Identification Number 62-1765329  
Entity Address, Address Line One 2525 West End Avenue  
Entity Address, Address Line Two Suite 950  
Entity Address, City or Town Nashville  
Entity Address, State or Province TN  
Entity Address, Postal Zip Code 37203  
City Area Code 615  
Local Phone Number 255-0068  
Title of 12(b) Security Common stock, no par value  
Trading Symbol CPIX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   14,766,492
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Central Index Key 0001087294  
Current Fiscal Year End Date --12-31  

XML 22 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 17,266,785 $ 27,040,816
Accounts receivable, net 14,635,435 6,877,346
Inventories 9,878,680 8,429,882
Prepaid and other current assets 3,561,027 3,339,969
Total current assets 45,341,927 45,688,013
Non-current inventories 10,593,792 9,048,567
Property and equipment, net 409,121 442,635
Intangible assets, net 34,479,356 23,954,475
Goodwill 1,932,876 882,000
Operating lease right-of-use assets 761,177 1,024,200
Other assets 3,178,857 3,419,908
Total assets 96,697,106 84,459,798
Current liabilities:    
Accounts payable 11,447,505 9,640,980
Operating lease current liabilities 766,488 969,677
Other current liabilities 12,343,405 8,668,303
Total current liabilities 24,557,398 19,278,960
Revolving line of credit 20,000,000 15,000,000
Operating lease noncurrent liabilities 22,712 90,016
Other long-term liabilities 11,323,593 7,488,844
Total liabilities 55,903,703 41,857,820
Commitments and contingencies
Shareholders’ equity:    
Common stock—no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 48,046,764 48,452,906
Retained earnings (deficit) (7,023,853) (5,638,600)
Total shareholders’ equity 41,022,911 42,814,306
Noncontrolling interests (229,508) (212,328)
Total equity 40,793,403 42,601,978
Total liabilities and equity $ 96,697,106 $ 84,459,798
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 14,730,760 14,742,754
Common stock, shares outstanding (in shares) 14,730,760 14,742,754
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net revenues $ 11,175,045 $ 10,537,159
Costs and expenses:    
Cost of products sold 2,211,885 2,417,329
Selling and marketing 4,614,429 3,787,340
Research and development 1,745,136 1,257,367
General and administrative 2,302,349 2,230,509
Amortization 1,593,245 1,168,914
Total costs and expenses 12,467,044 10,861,459
Operating income (loss) (1,291,999) (324,300)
Interest income 16,041 5,426
Interest expense (119,575) (24,417)
Income (loss) from continuing operations before income taxes (1,395,533) (343,291)
Income tax (expense) benefit (6,900) (7,458)
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total (1,402,433) (350,749)
Discontinued operations 0 495,410
Net income (loss) (1,402,433) 144,661
Net (income) loss at subsidiary attributable to noncontrolling interests 17,180 22,167
Net income (loss) attributable to common shareholders $ (1,385,253) $ 166,828
Earnings (loss) per share attributable to common shareholders    
Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share) $ (0.09) $ (0.02)
Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share) 0 0.03
Earnings (loss) per share attributable to common shareholders - basic (in dollars per share) (0.09) 0.01
Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share) (0.09) (0.02)
Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share) 0 0.03
Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share) $ (0.09) $ 0.01
Weighted-average shares outstanding    
- basic (in shares) 14,691,623 14,974,663
- diluted (in shares) 14,691,623 15,244,146
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income (loss) $ (1,402,433) $ 144,661
Discontinued operations 0 495,410
Net income (loss) from continuing operations (1,402,433) (350,749)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization expense 1,653,746 1,227,607
Share-based compensation 159,901 162,960
Increase (decrease) in non-cash contingent consideration 370,464 (280,020)
Decrease (increase) in cash surrender value of life insurance policies over premiums paid 222,209 (76,300)
Decrease (increase) in noncash interest expense 2,183 13,833
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (7,758,089) (171,584)
Inventories 2,271,484 1,868,350
Other current assets and other assets 239,862 507,102
Accounts payable and other current liabilities 4,461,389 (1,311,123)
Other long-term liabilities (371,214) (299,937)
Net cash provided by (used in) operating activities from continuing operations (150,498) 1,290,139
Discontinued operations 0 495,410
Net cash provided by (used in) operating activities (150,498) 1,785,549
Cash flows from investing activities:    
Additions to property and equipment (26,986) (19,458)
Note receivable investment funding 0 (200,000)
Cash paid for acquisitions (13,500,000) 0
Additions to intangible assets (14,912) (98,883)
Net cash used in investing activities (13,541,898) (318,341)
Cash flows from financing activities:    
Borrowings on line of credit 20,000,000 15,000,000
Repayments on line of credit (15,000,000) (15,000,000)
Cash payment of contingent consideration (501,505) (995,277)
Repurchase of common shares (580,130) (302,802)
Net cash provided by (used in) financing activities 3,918,365 (1,298,079)
Net increase (decrease) in cash and cash equivalents (9,774,031) 169,129
Cash and cash equivalents at beginning of period 27,040,816 24,753,796
Cash and cash equivalents at end of period $ 17,266,785 $ 24,922,925
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statement of Equity - USD ($)
Total
Common stock
Retained earnings
Noncontrolling interests
Balance, Beginning of Period (in shares) at Dec. 31, 2020   14,988,429    
Balance, Beginning of Period at Dec. 31, 2020 $ 46,873,394 $ 49,121,523 $ (2,131,013) $ (117,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Share-based compensation (in shares)   187,759    
Share-based compensation 162,960 $ 162,960    
Repurchase of shares (in shares)   (91,724)    
Repurchase of common shares (303,088) $ (303,088)    
Net income (loss) 144,661   166,828 (22,167)
Balance, End of Period (in shares) at Mar. 31, 2021   15,084,464    
Balance, End of Period at Mar. 31, 2021 $ 46,877,927 $ 48,981,395 (1,964,185) (139,283)
Balance, Beginning of Period (in shares) at Dec. 31, 2021 14,742,754 14,742,754    
Balance, Beginning of Period at Dec. 31, 2021 $ 42,601,978 $ 48,452,906 (5,638,600) (212,328)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Share-based compensation (in shares)   162,155    
Share-based compensation 159,901 $ 159,901    
Repurchase of shares (in shares)   (174,149)    
Repurchase of common shares (566,043) $ (566,043)    
Net income (loss) $ (1,402,433)   (1,385,253) (17,180)
Balance, End of Period (in shares) at Mar. 31, 2022 14,730,760 14,730,760    
Balance, End of Period at Mar. 31, 2022 $ 40,793,403 $ 48,046,764 $ (7,023,853) $ (229,508)
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Basis of Presentation
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND BASIS OF PRESENTATION ORGANIZATION AND BASIS OF PRESENTATION
Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, oncology and field sales forces in the United States. We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.
Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.
Discontinued Operations
As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol® and Totect® in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.
COVID-19 Pandemic
In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.
Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines. All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.
Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, 2021 and the three months ended March 31, 2022, we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.
Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees’ safety and well-being, while also keeping its business operating. Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.
Recent Accounting Guidance
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU’s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.
Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company’s consolidated financial statements.
Accounting Policies:
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.
Operating Segments
The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings (Loss) Per Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS (LOSS) PER SHARE
The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Numerator:
Net income (loss) from continuing operations$(1,402,433)$(350,749)
Discontinued operations— 495,410 
Net income (loss)(1,402,433)144,661 
Net income (loss) at subsidiary attributable to noncontrolling interest17,180 22,167 
Net income (loss) attributable to common shareholders$(1,385,253)$166,828 
Denominator:
Weighted-average shares outstanding – basic14,691,623 14,974,663 
Dilutive effect of other securities— 269,483 
Weighted-average shares outstanding – diluted14,691,623 15,244,146 
As of March 31, 2022 and 2021, restricted stock awards and options to purchase 131,225 and 215,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Revenues
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018.
The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Products:
Kristalose$3,945,097 $2,994,378 
Sancuso3,397,209 — 
Vibativ2,501,434 5,052,243 
Caldolor959,634 1,539,496 
Vaprisol(117,000)1,134,264 
Acetadote111,090 117,191 
Omeclamox-Pak22,737 (450,263)
RediTrex59,226 (32,252)
Other revenue295,618 182,102 
Total net revenues$11,175,045 $10,537,159 
The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19. They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing. In the first quarter of 2022, the amounts noted were normal adjustments by channel partners. Net revenue was impacted by product return adjustments.
With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.
Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.04 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
The Company works closely with third parties to manufacture and package finished goods for sale. Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company’s warehouses. The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.
The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.6 million and $1.4 million, respectively.
The Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021. Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.
As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory. At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $10.6 million and $9.0 million, respectively. The Company had $0.2 million and $0.5 million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively. The Company also has obtained $0.2 million and $0.4 million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively.
At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:
March 31, 2022December 31, 2021
Raw materials and work in process$15,004,954 $12,374,983 
Consigned inventory129,049 164,378 
Finished goods5,338,469 4,939,088 
Total inventories20,472,472 17,478,449 
less non-current inventories(10,593,792)(9,048,567)
Total inventories classified as current$9,878,680 $8,429,882 
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
LEASES LEASES
Cumberland’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023.
Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland’s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2022 is 0.8 years.
On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the “Leased Premise”) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.
Lease Position
At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:
Right-of-Use AssetsMarch 31, 2022December 31, 2021
Operating lease right-of-use assets$761,177 $1,024,200 
Lease LiabilitiesMarch 31, 2022December 31, 2021
Operating lease current liabilities$766,488 $969,677 
Operating lease noncurrent liabilities22,712 90,016 
Total$789,200 $1,059,693 
Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:
Maturity of Lease Liabilities at March 31, 2022
Operating Leases
2022730,829 
202392,477 
Total lease payments823,306 
Less: Interest34,106 
Present value of lease liabilities$789,200 
Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:
Three months ended March 31,
20222021
Rent expense$285,963 $227,395 
Sublease income$161,804 $178,029 
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity and Debt
3 Months Ended
Mar. 31, 2022
Equity and Debt [Abstract]  
SHAREHOLDERS' EQUITY AND DEBT SHAREHOLDERS’ EQUITY AND DEBT
Share repurchases
Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased 174,149 shares and 91,724 shares of common stock for approximately $0.6 million and $0.3 million, respectively. At March 31, 2022, approximately $4.2 million of common shares was left to repurchase under this program.
Share purchases and sales
During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board. These purchases began in April 2022.
Share Sales
In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.
Restricted Share Grants and Incentive Stock Options
During the three months ended March 31, 2022 and March 31, 2021, the Company issued 65,225 shares and 35,850 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. During the three months ended March 31, 2022 and 2021, the Company also issued 166,350 and 172,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.
Debt Agreement
On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition.
On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million.
On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.
The original Pinnacle Agreement was dated July 2017. Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.
The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022. In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12 to 24 months.
As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility. The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.
Borrowings under the line of credit are collateralized by substantially all of our assets.
Joint Venture Agreement
In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provides for initial investment from WinHealth in the form of a $0.2 million equity contribution and an initial investment from Cumberland in the form of a $0.2 million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESAs of March 31, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Agreements
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATIVE AGREEMENTS COLLABORATIVE AGREEMENTSCumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights
3 Months Ended
Mar. 31, 2022
Business Combinations [Abstract]  
ADDITIONS AND RETURN OF PRODUCT RIGHTS ADDITIONS AND RETURN OF PRODUCT RIGHTS
Vibativ
During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5 million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.
The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2021
$6,515,627 
Cash payment of royalty during the period(501,505)
Change in fair value of contingent consideration included in operating expenses370,464 
Contingent consideration earned and accrued in operating expenses— 
Balance at March 31, 2022
$6,384,586 
The contingent consideration liability of $6.4 million was accounted for as $2.3 million of other current liabilities and $4.1 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.
RediTrex
In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic’s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis.
As consideration for the license Cumberland paid a deposit of $100,000 at closing. The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products’ FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.
On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0 million milestone payment due to Nordic. During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $1.0 million milestone payment due to Nordic. This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.
Cumberland has approximately $2.6 million in net intangible assets related to RediTrex at March 31, 2022.
Sancuso Acquisition
On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.
Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient’s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (“CINV”). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.
Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities.
Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5 million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5 million based on the attainment of various approvals and sales performance. The Company believes that $1.5 million of the milestone payments will be earned and paid.
In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement.
The acquisition was funded by cash and the Company's revolving credit facility. The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year. The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $0.3 million, inventory $5.2 million, goodwill $1.0 million, intangible assets $12.1 million, milestone payable $1.2 million and contingent liability $3.9 million.
The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly. The contingent consideration liability of $3.9 million was accounted for as $1.3 million of current liabilities and $2.6 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.
Ethyol and Totect
In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States. In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.
Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019. In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during 2021, as discontinued operations.
The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not incur expenses associated with these payments from Clinigen.
Three months ended March 31,
20222021
Revenues$— $495,410 
Income from discontinued operations$— $495,410 
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Guidance
Recent Accounting Guidance
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU’s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.
Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company’s consolidated financial statements.
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.
Operating Segments Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings (Loss) Per Share (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Reconciliation of numerator and denominator The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Numerator:
Net income (loss) from continuing operations$(1,402,433)$(350,749)
Discontinued operations— 495,410 
Net income (loss)(1,402,433)144,661 
Net income (loss) at subsidiary attributable to noncontrolling interest17,180 22,167 
Net income (loss) attributable to common shareholders$(1,385,253)$166,828 
Denominator:
Weighted-average shares outstanding – basic14,691,623 14,974,663 
Dilutive effect of other securities— 269,483 
Weighted-average shares outstanding – diluted14,691,623 15,244,146 
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Revenues (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Summary of net revenue The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:
Three months ended March 31,
20222021
Products:
Kristalose$3,945,097 $2,994,378 
Sancuso3,397,209 — 
Vibativ2,501,434 5,052,243 
Caldolor959,634 1,539,496 
Vaprisol(117,000)1,134,264 
Acetadote111,090 117,191 
Omeclamox-Pak22,737 (450,263)
RediTrex59,226 (32,252)
Other revenue295,618 182,102 
Total net revenues$11,175,045 $10,537,159 
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Inventory At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:
March 31, 2022December 31, 2021
Raw materials and work in process$15,004,954 $12,374,983 
Consigned inventory129,049 164,378 
Finished goods5,338,469 4,939,088 
Total inventories20,472,472 17,478,449 
less non-current inventories(10,593,792)(9,048,567)
Total inventories classified as current$9,878,680 $8,429,882 
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Lease Position
At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:
Right-of-Use AssetsMarch 31, 2022December 31, 2021
Operating lease right-of-use assets$761,177 $1,024,200 
Lease LiabilitiesMarch 31, 2022December 31, 2021
Operating lease current liabilities$766,488 $969,677 
Operating lease noncurrent liabilities22,712 90,016 
Total$789,200 $1,059,693 
Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:
Schedule of Maturity of Lease Liabilities
Maturity of Lease Liabilities at March 31, 2022
Operating Leases
2022730,829 
202392,477 
Total lease payments823,306 
Less: Interest34,106 
Present value of lease liabilities$789,200 
Schedule of Rent Expense and Sublease Income Rent expense and sublease income were as follows:
Three months ended March 31,
20222021
Rent expense$285,963 $227,395 
Sublease income$161,804 $178,029 
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights (Tables)
3 Months Ended
Mar. 31, 2022
Business Combinations [Abstract]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2021
$6,515,627 
Cash payment of royalty during the period(501,505)
Change in fair value of contingent consideration included in operating expenses370,464 
Contingent consideration earned and accrued in operating expenses— 
Balance at March 31, 2022
$6,384,586 
Schedule of Dissolution Payments
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not incur expenses associated with these payments from Clinigen.
Three months ended March 31,
20222021
Revenues$— $495,410 
Income from discontinued operations$— $495,410 
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Basis of Presentation Organization (Details)
3 Months Ended
Mar. 31, 2022
Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 1
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings (Loss) Per Share (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator:    
Net income (loss) from continuing operations $ (1,402,433) $ (350,749)
Discontinued operations 0 495,410
Net income (loss) (1,402,433) 144,661
Net (income) loss at subsidiary attributable to noncontrolling interests 17,180 22,167
Net income (loss) attributable to common shareholders $ (1,385,253) $ 166,828
Denominator:    
Weighted-average shares outstanding – basic (in shares) 14,691,623 14,974,663
Dilutive effect of other securities (in shares) 0 269,483
Weighted-average shares outstanding – diluted (in shares) 14,691,623 15,244,146
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings (Loss) Per Share (Details Textual) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Common stock available for purchase through restricted stock awards and options (in shares) 131,225 215,600
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Revenues (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Products:    
Revenues $ 11,175,045 $ 10,537,159
Kristalose    
Products:    
Revenues 3,945,097 2,994,378
Sancuso    
Products:    
Revenues 3,397,209 0
Vibativ    
Products:    
Revenues 2,501,434 5,052,243
Caldolor    
Products:    
Revenues 959,634 1,539,496
Vaprisol    
Products:    
Revenues (117,000) 1,134,264
Acetadote    
Products:    
Revenues 111,090 117,191
Omeclamox-Pak    
Products:    
Revenues 22,737 (450,263)
RediTrex    
Products:    
Revenues 59,226 (32,252)
Other revenue    
Products:    
Revenues 295,618 182,102
Grant    
Products:    
Revenues $ 40,000.00 $ 100,000
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Narrative) (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Inventory [Line Items]    
Obsolescence and discontinuance losses $ 600,000 $ 1,400,000
Non-current inventories 10,593,792 9,048,567
Inventory, Finished Goods, Net of Reserves 5,338,469 4,939,088
Ifetroban Clinical    
Inventory [Line Items]    
Non-current inventories 200,000 400,000
Vibativ    
Inventory [Line Items]    
Non-current inventories   15,600,000
Finished goods $ 200,000 500,000
Sancuso    
Inventory [Line Items]    
Non-current inventories   $ 3,000,000
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Schedule of Inventories) (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Inventory    
Raw materials and work in process $ 15,004,954 $ 12,374,983
Consigned inventory 129,049 164,378
Finished goods 5,338,469 4,939,088
Total inventories 20,472,472 17,478,449
less non-current inventories (10,593,792) (9,048,567)
Total inventories classified as current $ 9,878,680 $ 8,429,882
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Narrative (Details)
$ in Millions
Mar. 31, 2022
USD ($)
ft²
Nov. 15, 2021
ft²
renewalTerm
Lessee, Lease, Description [Line Items]    
Present value of remaining lease payments, percent 7.42%  
Weighted average remaining lease term 9 months 18 days  
Future minimum sublease income under noncancelable operating subleases | $ $ 0.1  
Office Space    
Lessee, Lease, Description [Line Items]    
Square feet of office space 25,500  
Wet Laboratory and Office Space    
Lessee, Lease, Description [Line Items]    
Square feet of office space 14,200  
Leased area   16,631
Term of contract   157 months
Wet Laboratory and Office Space | Broadwest Lease, Five Year Renewal Option    
Lessee, Lease, Description [Line Items]    
Number of renewal terms | renewalTerm   2
Renewal term   5 years
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Lease Position (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Leases [Abstract]    
Operating lease right-of-use assets $ 761,177 $ 1,024,200
Operating lease current liabilities 766,488 969,677
Operating lease noncurrent liabilities 22,712 90,016
Total $ 789,200 $ 1,059,693
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)
Mar. 31, 2022
USD ($)
Maturity of Lease Liabilities at March 31, 2022  
2022 $ 730,829
2023 92,477
Total lease payments 823,306
Less: Interest 34,106
Present value of lease liabilities $ 789,200
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Rent Expense (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Leases [Abstract]    
Rent expense $ 285,963 $ 227,395
Sublease income $ 161,804 $ 178,029
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity and Debt - Shareholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended
Dec. 27, 2021
Nov. 30, 2017
Mar. 31, 2022
Mar. 31, 2021
Jan. 31, 2016
May 13, 2010
Shareholders' Equity (Textual) [Abstract]            
Repurchase of shares, value     $ (566,043) $ (303,088)    
Shelf Registration, sale of corporate securities (up to) $ 19,000,000 $ 100,000,000        
Restricted Stock            
Shareholders' Equity (Textual) [Abstract]            
Restricted stock granted in period, shares     65,225 35,850    
Incentive Stock Options            
Shareholders' Equity (Textual) [Abstract]            
Restricted stock granted in period, shares     166,350 172,350    
Director | Restricted Stock            
Shareholders' Equity (Textual) [Abstract]            
Restricted stock awards, vesting period     1 year      
Common stock            
Shareholders' Equity (Textual) [Abstract]            
Repurchase outstanding common shares         $ 10,000,000 $ 10,000,000
Repurchase of shares (in shares)     174,149 91,724    
Repurchase of shares, value     $ (566,043) $ (303,088)    
Common shares left to repurchase     $ 4,200,000      
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity and Debt - Debt (Details) - USD ($)
3 Months Ended
Aug. 14, 2020
Mar. 31, 2022
Dec. 31, 2021
Aug. 31, 2020
Line of Credit Facility [Line Items]        
Revolving line of credit   $ 20,000,000 $ 15,000,000  
WinHealth        
Line of Credit Facility [Line Items]        
Initial investment in joint ventures       $ 200,000
Convertible Debt | WinHealth        
Line of Credit Facility [Line Items]        
Convertible note       $ 200,000
LIBOR        
Line of Credit Facility [Line Items]        
Variable rate 0.90%      
Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Revolving line of credit   $ 20,000,000    
Pinnacle Bank | Line of Credit | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Interest rate spread   3.65%    
Line of credit, unused capacity, commitment fee percentage   0.25%    
Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR        
Line of Credit Facility [Line Items]        
Variable rate 1.75%      
Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR        
Line of Credit Facility [Line Items]        
Variable rate 2.75%      
Pinnacle Bank | Fifth Amendment | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Additional borrowing capacity     15,000,000  
Current borrowing capacity     $ 20,000,000  
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Textual)
Mar. 31, 2022
USD ($)
Income Tax Contingency [Line Items]  
Net operating loss carryforwards $ 44,100,000
Federal  
Income Tax Contingency [Line Items]  
Net operating loss carryforwards $ 56,600,000
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 03, 2022
USD ($)
Nov. 30, 2018
USD ($)
Nov. 30, 2016
USD ($)
shares
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
installment
Dec. 31, 2020
USD ($)
installment
Dec. 31, 2019
USD ($)
Jul. 31, 2020
USD ($)
Business Acquisition [Line Items]                  
Payment to acquire business upon closing       $ 13,500,000 $ 0        
Goodwill       1,932,876   $ 882,000      
Financial consideration, payment period               2 years  
Financial consideration, number of installments | installment           4 4    
Financial consideration received in exchange for product license rights, installment payments             $ 3,000,000    
Clinigen                  
Business Acquisition [Line Items]                  
Financial consideration received in exchange for product license rights               $ 5,000,000  
Discontinued operations income           $ 2,000,000      
Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Business Acquisition [Line Items]                  
Upfront payment $ 13,500,000                
Sales milestone payments, maximum $ 3,500,000                
Sales milestone payments, expected       1,500,000          
Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum                  
Business Acquisition [Line Items]                  
Tiered royalty, percent 10.00%                
Vibativ                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing   $ 20,000,000              
Other Payments to Acquire Businesses   $ 5,000,000              
Percentage of tiered royalty payments (up to)   20.00%              
Tiered royalty payment, threshold   $ 2,500,000              
Additional liability       6,384,586   6,515,627      
Current portion of the contingent consideration liability       2,300,000          
Noncurrent portion of the contingent consideration liability       4,100,000          
Methotrexate                  
Business Acquisition [Line Items]                  
Payment to acquire business upon closing     $ 100,000            
Additional liability           $ 1,000,000     $ 1,000,000
Liability recorded     $ 900,000            
Vested common stock, value       900,000          
Net intangible assets       2,600,000          
Methotrexate | Restricted Stock                  
Business Acquisition [Line Items]                  
Unvested restricted shares (in shares) | shares     180,000            
Sancuso                  
Business Acquisition [Line Items]                  
Other Payments to Acquire Businesses $ 1,200,000                
Additional liability 3,900,000     3,900,000          
Current portion of the contingent consideration liability       1,300,000          
Noncurrent portion of the contingent consideration liability       $ 2,600,000          
Prepaid expenses 300,000                
Inventory 5,200,000                
Goodwill 1,000,000                
Intangible assets $ 12,100,000                
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights - Change in Consideration (Details) - Vibativ
3 Months Ended
Mar. 31, 2022
USD ($)
Loss Contingency Accrual [Roll Forward]  
Beginning balance $ 6,515,627
Cash payment of royalty during the period (501,505)
Change in fair value of contingent consideration included in operating expenses 370,464
Contingent consideration earned and accrued in operating expenses 0
Ending balance $ 6,384,586
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Business Acquisition [Line Items]    
Revenues $ 11,175,045 $ 10,537,159
Clinigen    
Business Acquisition [Line Items]    
Revenues 0 495,410
Income from discontinued operations $ 0 $ 495,410
XML 58 cpix-20220331_htm.xml IDEA: XBRL DOCUMENT 0001087294 2022-01-01 2022-03-31 0001087294 2022-05-09 0001087294 2022-03-31 0001087294 2021-12-31 0001087294 2021-01-01 2021-03-31 0001087294 cpix:ClinigenHealthcareLimitedMember 2022-01-01 2022-03-31 0001087294 cpix:ClinigenHealthcareLimitedMember 2021-01-01 2021-03-31 0001087294 2020-12-31 0001087294 2021-03-31 0001087294 us-gaap:CommonStockMember 2020-12-31 0001087294 us-gaap:RetainedEarningsMember 2020-12-31 0001087294 us-gaap:NoncontrollingInterestMember 2020-12-31 0001087294 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001087294 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001087294 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001087294 us-gaap:CommonStockMember 2021-03-31 0001087294 us-gaap:RetainedEarningsMember 2021-03-31 0001087294 us-gaap:NoncontrollingInterestMember 2021-03-31 0001087294 us-gaap:CommonStockMember 2021-12-31 0001087294 us-gaap:RetainedEarningsMember 2021-12-31 0001087294 us-gaap:NoncontrollingInterestMember 2021-12-31 0001087294 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001087294 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001087294 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001087294 us-gaap:CommonStockMember 2022-03-31 0001087294 us-gaap:RetainedEarningsMember 2022-03-31 0001087294 us-gaap:NoncontrollingInterestMember 2022-03-31 0001087294 cpix:KristaloseMember 2022-01-01 2022-03-31 0001087294 cpix:KristaloseMember 2021-01-01 2021-03-31 0001087294 cpix:SancusoMember 2022-01-01 2022-03-31 0001087294 cpix:SancusoMember 2021-01-01 2021-03-31 0001087294 cpix:VIBATIVMember 2022-01-01 2022-03-31 0001087294 cpix:VIBATIVMember 2021-01-01 2021-03-31 0001087294 cpix:CaldolorMember 2022-01-01 2022-03-31 0001087294 cpix:CaldolorMember 2021-01-01 2021-03-31 0001087294 cpix:VaprisolMember 2022-01-01 2022-03-31 0001087294 cpix:VaprisolMember 2021-01-01 2021-03-31 0001087294 cpix:AcetadoteMember 2022-01-01 2022-03-31 0001087294 cpix:AcetadoteMember 2021-01-01 2021-03-31 0001087294 cpix:OmeclamoxPakMember 2022-01-01 2022-03-31 0001087294 cpix:OmeclamoxPakMember 2021-01-01 2021-03-31 0001087294 cpix:RediTrexMember 2022-01-01 2022-03-31 0001087294 cpix:RediTrexMember 2021-01-01 2021-03-31 0001087294 cpix:OtherProductsMember 2022-01-01 2022-03-31 0001087294 cpix:OtherProductsMember 2021-01-01 2021-03-31 0001087294 us-gaap:GrantMember 2022-01-01 2022-03-31 0001087294 us-gaap:GrantMember 2021-01-01 2021-03-31 0001087294 cpix:VIBATIVMember 2021-12-31 0001087294 cpix:SancusoMember 2021-12-31 0001087294 cpix:VIBATIVMember 2022-03-31 0001087294 cpix:IfetrobanClinicalMember 2022-03-31 0001087294 cpix:IfetrobanClinicalMember 2021-12-31 0001087294 us-gaap:BuildingMember 2022-03-31 0001087294 srt:OfficeBuildingMember 2022-03-31 0001087294 srt:OfficeBuildingMember 2021-11-15 0001087294 cpix:BroadwestLeaseFiveYearRenewalOptionMember srt:OfficeBuildingMember 2021-11-15 0001087294 us-gaap:CommonStockMember 2010-05-13 0001087294 us-gaap:CommonStockMember 2016-01-31 0001087294 2017-11-01 2017-11-30 0001087294 2021-12-27 2021-12-27 0001087294 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001087294 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001087294 srt:DirectorMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001087294 cpix:IncentiveStockOptionsMember 2022-01-01 2022-03-31 0001087294 cpix:IncentiveStockOptionsMember 2021-01-01 2021-03-31 0001087294 us-gaap:RevolvingCreditFacilityMember cpix:FifthAmendmentMember cpix:PinnacleBankMember 2021-12-31 0001087294 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-14 2020-08-14 0001087294 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-14 2020-08-14 0001087294 us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-14 2020-08-14 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2022-03-31 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2022-01-01 2022-03-31 0001087294 us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001087294 cpix:WinHealthInvestmentSingaporeLtdMember 2020-08-31 0001087294 cpix:WinHealthInvestmentSingaporeLtdMember us-gaap:ConvertibleDebtMember 2020-08-31 0001087294 us-gaap:DomesticCountryMember 2022-03-31 0001087294 cpix:VIBATIVMember 2018-11-01 2018-11-30 0001087294 cpix:VIBATIVMember 2022-01-01 2022-03-31 0001087294 cpix:MethotrexateMember 2016-11-01 2016-11-30 0001087294 us-gaap:RestrictedStockMember cpix:MethotrexateMember 2016-11-01 2016-11-30 0001087294 cpix:MethotrexateMember 2022-01-01 2022-03-31 0001087294 cpix:MethotrexateMember 2020-07-31 0001087294 cpix:MethotrexateMember 2021-12-31 0001087294 cpix:MethotrexateMember 2022-03-31 0001087294 cpix:KyowaKirinMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-03 0001087294 cpix:KyowaKirinMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0001087294 cpix:KyowaKirinMember srt:MaximumMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-03 0001087294 cpix:SancusoMember 2022-01-03 0001087294 cpix:SancusoMember 2022-01-03 2022-01-03 0001087294 cpix:SancusoMember 2022-03-31 0001087294 cpix:ClinigenHealthcareLimitedMember 2019-01-01 2019-12-31 0001087294 2019-01-01 2019-12-31 0001087294 2020-01-01 2020-12-31 0001087294 2021-01-01 2021-12-31 0001087294 cpix:ClinigenHealthcareLimitedMember 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares cpix:Segment utr:sqft pure cpix:renewalTerm cpix:installment 2022 Q1 false --12-31 0001087294 10-Q true 2022-03-31 false 001-33637 Cumberland Pharmaceuticals Inc. TN 62-1765329 2525 West End Avenue Suite 950 Nashville TN 37203 615 255-0068 Common stock, no par value CPIX NASDAQ Yes Yes Non-accelerated Filer true false false 14766492 17266785 27040816 14635435 6877346 9878680 8429882 3561027 3339969 45341927 45688013 10593792 9048567 409121 442635 34479356 23954475 1932876 882000 761177 1024200 1024200 3178857 3419908 96697106 84459798 11447505 9640980 766488 969677 969677 12343405 8668303 24557398 19278960 20000000 15000000 22712 90016 90016 11323593 7488844 55903703 41857820 0 0 100000000 100000000 14730760 14730760 14742754 14742754 48046764 48452906 -7023853 -5638600 41022911 42814306 -229508 -212328 40793403 42601978 96697106 84459798 11175045 10537159 2211885 2417329 4614429 3787340 1745136 1257367 2302349 2230509 1593245 1168914 12467044 10861459 -1291999 -324300 16041 5426 119575 24417 -1395533 -343291 6900 7458 -1402433 -350749 0 495410 -1402433 144661 -17180 -22167 -1385253 166828 -0.09 -0.02 0 0.03 -0.09 0.01 -0.09 -0.02 0 0.03 -0.09 0.01 14691623 14974663 14691623 15244146 -1402433 144661 0 495410 -1402433 -350749 1653746 1227607 159901 162960 -370464 280020 -222209 76300 2183 13833 7758089 171584 -2271484 -1868350 -239862 -507102 4461389 -1311123 -371214 -299937 -150498 1290139 0 495410 -150498 1785549 26986 19458 0 200000 13500000 0 14912 98883 -13541898 -318341 20000000 15000000 15000000 15000000 501505 995277 580130 302802 3918365 -1298079 -9774031 169129 27040816 24753796 17266785 24922925 14988429 49121523 -2131013 -117116 46873394 187759 162960 162960 91724 303088 303088 166828 -22167 144661 15084464 48981395 -1964185 -139283 46877927 14742754 48452906 -5638600 -212328 42601978 162155 159901 159901 174149 566043 566043 -1385253 -17180 -1402433 14730760 48046764 -7023853 -229508 40793403 ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, oncology and field sales forces in the United States. We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines. All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, 2021 and the three months ended March 31, 2022, we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees’ safety and well-being, while also keeping its business operating. Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU’s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers. <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU’s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company’s consolidated financial statements.</span></div> <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div> Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers. 1 EARNINGS (LOSS) PER SHARE<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and 2021, restricted stock awards and options to purchase 131,225 and 215,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div> The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table> -1402433 -350749 0 495410 -1402433 144661 -17180 -22167 -1385253 166828 14691623 14974663 0 269483 14691623 15244146 131225 215600 REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19. They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing. In the first quarter of 2022, the amounts noted were normal adjustments by channel partners. Net revenue was impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.04 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3945097 2994378 3397209 0 2501434 5052243 959634 1539496 -117000 1134264 111090 117191 22737 -450263 59226 -32252 295618 182102 11175045 10537159 40000.00 100000 INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company’s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.6 million and $1.4 million, respectively. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition. For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory. At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $10.6 million and $9.0 million, respectively. The Company had $0.2 million and $0.5 million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively. The Company also has obtained $0.2 million and $0.4 million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,004,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,593,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,878,680 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 600000 1400000 15600000 3000000 10600000 9000000 200000 500000 200000 400000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,004,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,593,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,878,680 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 15004954 12374983 12374983 129049 164378 164378 5338469 4939088 4939088 20472472 17478449 10593792 9048567 9878680 8429882 LEASES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland’s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2022 is 0.8 years.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the “Leased Premise”) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761,177 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,829 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,106 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25500 14200 0.0742 P0Y9M18D 16631 P157M 2 P5Y <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761,177 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,488 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div> 761177 1024200 1024200 766488 969677 969677 22712 90016 90016 789200 1059693 100000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,829 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,106 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 730829 92477 823306 34106 789200 Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 285963 227395 161804 178029 SHAREHOLDERS’ EQUITY AND DEBT<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased 174,149 shares and 91,724 shares of common stock for approximately $0.6 million and $0.3 million, respectively. At March 31, 2022, approximately $4.2 million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board. These purchases began in April 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million. The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and March 31, 2021, the Company issued 65,225 shares and 35,850 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. During the three months ended March 31, 2022 and 2021, the Company also issued 166,350 and 172,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017. Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022. In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12 to 24 months. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility. The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets. The agreement provides for initial investment from WinHealth in the form of a $0.2 million equity contribution and an initial investment from Cumberland in the form of a $0.2 million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc. 10000000 10000000 174149 91724 600000 300000 4200000 100000000 19000000 65225 35850 P1Y 166350 172350 15000000 20000000 0.0175 0.0275 0.009 0.0365 0.0025 20000000 15000000 200000 200000 INCOME TAXESAs of March 31, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations. 56600000 44100000 COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span> ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5 million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,384,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $6.4 million was accounted for as $2.3 million of other current liabilities and $4.1 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic’s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing. The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products’ FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0 million milestone payment due to Nordic. During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $1.0 million milestone payment due to Nordic. This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.6 million in net intangible assets related to RediTrex at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient’s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (“CINV”). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5 million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5 million based on the attainment of various approvals and sales performance. The Company believes that $1.5 million of the milestone payments will be earned and paid.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs. As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility. The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year. The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $0.3 million, inventory $5.2 million, goodwill $1.0 million, intangible assets $12.1 million, milestone payable $1.2 million and contingent liability $3.9 million.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly. The contingent consideration liability of $3.9 million was accounted for as $1.3 million of current liabilities and $2.6 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States. In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5 million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20000000 5000000 0.20 2500000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,464 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,384,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table> 6515627 501505 370464 0 6384586 6400000 2300000 4100000 100000 900000 180000 180000 900000 1000000 1000000 2600000 13500000 3500000 1500000 0.10 300000 5200000 1000000 12100000 1200000 3900000 3900000 1300000 2600000 5000000 P2Y 4 3000000 4 2000000 <div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 495410 0 495410 EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 94 199 1 false 36 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.cumberlandpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statement of Equity Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity Condensed Consolidated Statement of Equity Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Basis of Presentation Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 2104102 - Disclosure - Earnings (Loss) Per Share Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 8 false false R9.htm 2108103 - Disclosure - Revenues Sheet http://www.cumberlandpharma.com/role/Revenues Revenues Notes 9 false false R10.htm 2111104 - Disclosure - Inventories Sheet http://www.cumberlandpharma.com/role/Inventories Inventories Notes 10 false false R11.htm 2115105 - Disclosure - Leases Sheet http://www.cumberlandpharma.com/role/Leases Leases Notes 11 false false R12.htm 2121106 - Disclosure - Shareholders' Equity and Debt Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt Shareholders' Equity and Debt Notes 12 false false R13.htm 2124107 - Disclosure - Income Taxes Sheet http://www.cumberlandpharma.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2126108 - Disclosure - Collaborative Agreements Sheet http://www.cumberlandpharma.com/role/CollaborativeAgreements Collaborative Agreements Notes 14 false false R15.htm 2127109 - Disclosure - Additions and Returns of Product Rights Sheet http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights Additions and Returns of Product Rights Notes 15 false false R16.htm 2202201 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies Organization and Basis of Presentation (Policies) Policies 16 false false R17.htm 2305301 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.cumberlandpharma.com/role/EarningsLossPerShare 17 false false R18.htm 2309302 - Disclosure - Revenues (Tables) Sheet http://www.cumberlandpharma.com/role/RevenuesTables Revenues (Tables) Tables http://www.cumberlandpharma.com/role/Revenues 18 false false R19.htm 2312303 - Disclosure - Inventories (Tables) Sheet http://www.cumberlandpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.cumberlandpharma.com/role/Inventories 19 false false R20.htm 2316304 - Disclosure - Leases (Tables) Sheet http://www.cumberlandpharma.com/role/LeasesTables Leases (Tables) Tables http://www.cumberlandpharma.com/role/Leases 20 false false R21.htm 2328305 - Disclosure - Additions and Returns of Product Rights (Tables) Sheet http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables Additions and Returns of Product Rights (Tables) Tables http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights 21 false false R22.htm 2403401 - Disclosure - Organization and Basis of Presentation Organization (Details) Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails Organization and Basis of Presentation Organization (Details) Details 22 false false R23.htm 2406402 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) Details http://www.cumberlandpharma.com/role/EarningsLossPerShareTables 23 false false R24.htm 2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual Earnings (Loss) Per Share (Details Textual) Details http://www.cumberlandpharma.com/role/EarningsLossPerShareTables 24 false false R25.htm 2410404 - Disclosure - Revenues (Details) Sheet http://www.cumberlandpharma.com/role/RevenuesDetails Revenues (Details) Details http://www.cumberlandpharma.com/role/RevenuesTables 25 false false R26.htm 2413405 - Disclosure - Inventories (Narrative) (Details) Sheet http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails Inventories (Narrative) (Details) Details http://www.cumberlandpharma.com/role/InventoriesTables 26 false false R27.htm 2414406 - Disclosure - Inventories (Schedule of Inventories) (Details) Sheet http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails Inventories (Schedule of Inventories) (Details) Details http://www.cumberlandpharma.com/role/InventoriesTables 27 false false R28.htm 2417407 - Disclosure - Leases - Narrative (Details) Sheet http://www.cumberlandpharma.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 28 false false R29.htm 2418408 - Disclosure - Leases - Lease Position (Details) Sheet http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails Leases - Lease Position (Details) Details 29 false false R30.htm 2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) Sheet http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) Details http://www.cumberlandpharma.com/role/LeasesTables 30 false false R31.htm 2420410 - Disclosure - Leases - Rent Expense (Details) Sheet http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails Leases - Rent Expense (Details) Details 31 false false R32.htm 2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details) Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails Shareholders' Equity and Debt - Shareholders' Equity (Details) Details 32 false false R33.htm 2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details) Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails Shareholders' Equity and Debt - Debt (Details) Details http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt 33 false false R34.htm 2425413 - Disclosure - Income Taxes (Details Textual) Sheet http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.cumberlandpharma.com/role/IncomeTaxes 34 false false R35.htm 2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details) Sheet http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails Additions and Returns of Product Rights - Narrative (Details) Details 35 false false R36.htm 2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details) Sheet http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails Additions and Returns of Product Rights - Change in Consideration (Details) Details 36 false false R37.htm 2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details) Sheet http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails Additions and Returns of Product Rights - Dissolution Payments (Details) Details 37 false false All Reports Book All Reports cpix-20220331.htm a2022q1-exhibit311.htm a2022q1-exhibit312.htm a2022q1-exhibit321.htm ajkazimi-2022.htm cpix-20220331.xsd cpix-20220331_cal.xml cpix-20220331_def.xml cpix-20220331_lab.xml cpix-20220331_pre.xml jamesherman-2022.htm johnhamm-2022.htm leopavliv-2022.htm pinnaclebank-cpiamend7tolo.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cpix-20220331.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 94, "dts": { "calculationLink": { "local": [ "cpix-20220331_cal.xml" ] }, "definitionLink": { "local": [ "cpix-20220331_def.xml" ] }, "inline": { "local": [ "cpix-20220331.htm" ] }, "labelLink": { "local": [ "cpix-20220331_lab.xml" ] }, "presentationLink": { "local": [ "cpix-20220331_pre.xml" ] }, "schema": { "local": [ "cpix-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 318, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 5, "total": 5 }, "keyCustom": 20, "keyStandard": 179, "memberCustom": 18, "memberStandard": 16, "nsprefix": "cpix", "nsuri": "http://www.cumberlandpharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cumberlandpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Inventories", "role": "http://www.cumberlandpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115105 - Disclosure - Leases", "role": "http://www.cumberlandpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Shareholders' Equity and Debt", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt", "shortName": "Shareholders' Equity and Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Income Taxes", "role": "http://www.cumberlandpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Collaborative Agreements", "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements", "shortName": "Collaborative Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127109 - Disclosure - Additions and Returns of Product Rights", "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights", "shortName": "Additions and Returns of Product Rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies", "shortName": "Organization and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Revenues (Tables)", "role": "http://www.cumberlandpharma.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Inventories (Tables)", "role": "http://www.cumberlandpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - Leases (Tables)", "role": "http://www.cumberlandpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328305 - Disclosure - Additions and Returns of Product Rights (Tables)", "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables", "shortName": "Additions and Returns of Product Rights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails", "shortName": "Organization and Basis of Presentation Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Earnings (Loss) Per Share (Details)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails", "shortName": "Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual", "shortName": "Earnings (Loss) Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Revenues (Details)", "role": "http://www.cumberlandpharma.com/role/RevenuesDetails", "shortName": "Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ie877302447534894b2d5513d38b31fbb_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Inventories (Narrative) (Details)", "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "shortName": "Inventories (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)", "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories (Schedule of Inventories) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Leases - Narrative (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Leases - Lease Position (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails", "shortName": "Leases - Lease Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cpix:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "lang": "en-US", "name": "cpix:LeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails", "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Leases - Rent Expense (Details)", "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails", "shortName": "Leases - Rent Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails", "shortName": "Shareholders' Equity and Debt - Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "i61780641954246b1a1327370732b7ffa_D20211227-20211227", "decimals": "-6", "lang": "en-US", "name": "cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermLineOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails", "shortName": "Shareholders' Equity and Debt - Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "i42ffe35d0bb445bca3edfba518ae51db_I20200831", "decimals": "-5", "lang": "en-US", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Income Taxes (Details Textual)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual", "shortName": "Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)", "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "shortName": "Additions and Returns of Product Rights - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231", "decimals": null, "lang": "en-US", "name": "cpix:FinancialConsiderationPaymentPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "i0daea624eb8d4452969618186921bc8f_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)", "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:PaymentsForRoyalties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)", "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ifb20159ba2734e579f3392f2e79daeab_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "shortName": "Condensed Consolidated Statement of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "ifb20159ba2734e579f3392f2e79daeab_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Basis of Presentation", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Revenues", "role": "http://www.cumberlandpharma.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cpix-20220331.htm", "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "cpix_AcetadoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acetadote", "label": "Acetadote [Member]", "terseLabel": "Acetadote" } } }, "localname": "AcetadoteMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets and Liabilities, Lessee", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Lease Position" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cpix_BroadwestLeaseFiveYearRenewalOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broadwest Lease, Five Year Renewal Option", "label": "Broadwest Lease, Five Year Renewal Option [Member]", "terseLabel": "Broadwest Lease, Five Year Renewal Option" } } }, "localname": "BroadwestLeaseFiveYearRenewalOptionMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses", "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses", "terseLabel": "Contingent consideration earned and accrued in operating expenses" } } }, "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CaldolorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Caldolor", "label": "Caldolor [Member]", "terseLabel": "Caldolor" } } }, "localname": "CaldolorMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_ClinigenHealthcareLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinigen Healthcare Limited", "label": "Clinigen Healthcare Limited [Member]", "terseLabel": "Clinigen" } } }, "localname": "ClinigenHealthcareLimitedMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected", "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected", "terseLabel": "Sales milestone payments, expected" } } }, "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum", "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum", "terseLabel": "Sales milestone payments, maximum" } } }, "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent", "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent", "terseLabel": "Tiered royalty, percent" } } }, "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment", "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment", "terseLabel": "Upfront payment" } } }, "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator.", "label": "Denominator [Abstract]", "verboseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_EquityAndDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity and Debt [Abstract]", "label": "Equity and Debt [Abstract]" } } }, "localname": "EquityAndDebtAbstract", "nsuri": "http://www.cumberlandpharma.com/20220331", "xbrltype": "stringItemType" }, "cpix_FifthAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifth Amendment", "label": "Fifth Amendment [Member]", "terseLabel": "Fifth Amendment" } } }, "localname": "FifthAmendmentMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "cpix_FinancialConsiderationNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Consideration, Number of Installments", "label": "Financial Consideration, Number of Installments", "terseLabel": "Financial consideration, number of installments" } } }, "localname": "FinancialConsiderationNumberOfInstallments", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "integerItemType" }, "cpix_FinancialConsiderationPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Consideration, Payment Period", "label": "Financial Consideration, Payment Period", "terseLabel": "Financial consideration, payment period" } } }, "localname": "FinancialConsiderationPaymentPeriod", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cpix_IfetrobanClinicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ifetroban Clinical", "label": "Ifetroban Clinical [Member]", "terseLabel": "Ifetroban Clinical" } } }, "localname": "IfetrobanClinicalMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Stock Options", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy", "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy", "negatedTerseLabel": "Decrease (increase) in cash surrender value of life insurance policies over premiums paid" } } }, "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInCurrentOperatingLiabilities", "verboseLabel": "Accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInCurrentOperatingLiabilities", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_KristaloseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kristalose", "label": "Kristalose [Member]", "terseLabel": "Kristalose" } } }, "localname": "KristaloseMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_KyowaKirinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kyowa Kirin", "label": "Kyowa Kirin [Member]", "terseLabel": "Kyowa Kirin" } } }, "localname": "KyowaKirinMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_LeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "terseLabel": "Total" } } }, "localname": "LeaseLiability", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LesseeOperatingLeaseLeasedArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Leased Area", "label": "Lessee, Operating Lease, Leased Area", "terseLabel": "Leased area" } } }, "localname": "LesseeOperatingLeaseLeasedArea", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Terms", "label": "Lessee, Operating Lease, Number Of Renewal Terms", "terseLabel": "Number of renewal terms" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalTerms", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Additional Borrowing Capacity", "label": "Line Of Credit Facility, Additional Borrowing Capacity", "terseLabel": "Additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "cpix_MethotrexateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Methotrexate [Member]", "label": "Methotrexate [Member]", "terseLabel": "Methotrexate" } } }, "localname": "MethotrexateMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cpix_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator.", "label": "Numerator [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_OmeclamoxPakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omeclamox-Pak", "label": "Omeclamox-Pak [Member]", "terseLabel": "Omeclamox-Pak" } } }, "localname": "OmeclamoxPakMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_OtherLongTermObligationsExcludingCurrentPortion": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Long Term Obligations, Excluding Current Portion", "label": "Other Long Term Obligations, Excluding Current Portion", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLongTermObligationsExcludingCurrentPortion", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cpix_OtherProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Products", "label": "Other Products [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_PinnacleBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pinnacle Bank", "label": "Pinnacle Bank [Member]", "terseLabel": "Pinnacle Bank" } } }, "localname": "PinnacleBankMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment", "label": "Proceeds from Sale of Intangible Assets, Installment Payment", "terseLabel": "Financial consideration received in exchange for product license rights, installment payments" } } }, "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_ProductsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Products.", "label": "Products [Abstract]", "verboseLabel": "Products:" } } }, "localname": "ProductsAbstract", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "cpix_RediTrexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RediTrex", "label": "RediTrex [Member]", "terseLabel": "RediTrex" } } }, "localname": "RediTrexMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_SancusoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sancuso", "label": "Sancuso [Member]", "terseLabel": "Sancuso" } } }, "localname": "SancusoMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]", "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]", "terseLabel": "Schedule of Rent Expense and Sublease Income" } } }, "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cpix_ShareholdersEquityTextualAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders Equity.", "label": "Shareholders Equity (Textual) [Abstract]", "verboseLabel": "Shareholders' Equity (Textual) [Abstract]" } } }, "localname": "ShareholdersEquityTextualAbstract", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "terseLabel": "Shelf Registration, sale of corporate securities (up to)" } } }, "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cpix_TieredRoyaltyPaymentsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tiered Royalty Payments, Percentage", "label": "Tiered Royalty Payments, Percentage", "terseLabel": "Percentage of tiered royalty payments (up to)" } } }, "localname": "TieredRoyaltyPaymentsPercentage", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cpix_TieredRoyaltyPaymentsThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tiered Royalty Payments, Threshold", "label": "Tiered Royalty Payments, Threshold", "terseLabel": "Tiered royalty payment, threshold" } } }, "localname": "TieredRoyaltyPaymentsThreshold", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cpix_VIBATIVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VIBATIV", "label": "VIBATIV [Member]", "terseLabel": "Vibativ" } } }, "localname": "VIBATIVMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_VaprisolMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaprisol", "label": "Vaprisol [Member]", "terseLabel": "Vaprisol" } } }, "localname": "VaprisolMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_WinHealthInvestmentSingaporeLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WinHealth Investment (Singapore) Ltd", "label": "WinHealth Investment (Singapore) Ltd [Member]", "terseLabel": "WinHealth" } } }, "localname": "WinHealthInvestmentSingaporeLtdMember", "nsuri": "http://www.cumberlandpharma.com/20220331", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cumberlandpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r66", "r68", "r106", "r107", "r217", "r236" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r216", "r235", "r256", "r258", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r400", "r402", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r216", "r235", "r256", "r258", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r400", "r402", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_OfficeBuildingMember": { "auth_ref": [ "r408", "r409" ], "lang": { "en-us": { "role": { "label": "Office Building [Member]", "terseLabel": "Wet Laboratory and Office Space" } } }, "localname": "OfficeBuildingMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r174", "r252", "r253", "r367", "r399", "r401" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r174", "r252", "r253", "r367", "r399", "r401" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r216", "r235", "r254", "r256", "r258", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r400", "r402", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r216", "r235", "r254", "r256", "r258", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r400", "r402", "r410", "r411" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r67", "r68", "r106", "r107", "r217", "r236" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r179", "r355" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r51", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r24", "r37", "r180", "r181" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r80", "r97", "r229", "r340" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Decrease (increase) in noncash interest expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r190", "r192" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Square feet of office space" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r154", "r164", "r170", "r183", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r315", "r320", "r330", "r356", "r358", "r371", "r386" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r25", "r26", "r65", "r103", "r183", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r315", "r320", "r330", "r356", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Office Space" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r255", "r257", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]", "verboseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r297", "r299", "r300", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Liability recorded" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r96", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration included in operating expenses" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r298", "r301", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Additional liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r298", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of the contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r298", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Noncurrent portion of the contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r295", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Net intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r295", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r22", "r47", "r99" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r99", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r331" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r15", "r93" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r308", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "COLLABORATIVE AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CollaborativeAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r58", "r197", "r376", "r391" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r109", "r110", "r327" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r36", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, End of Period (in shares)", "periodStartLabel": "Balance, Beginning of Period (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r36", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r212", "r213", "r214", "r216", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r82", "r367" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "verboseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r81" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r32", "r33", "r34", "r102", "r108", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r341", "r372", "r373", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r213", "r230", "r231", "r339", "r341", "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Convertible note" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r56", "r214" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate spread" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r57", "r102", "r108", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r341" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r152" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r14", "r77", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Discontinued operations income" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings (loss) per share attributable to common shareholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r114", "r115", "r116", "r117", "r118", "r122", "r124", "r127", "r128", "r129", "r133", "r134", "r328", "r329", "r381", "r396" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r114", "r115", "r116", "r117", "r118", "r124", "r127", "r128", "r129", "r133", "r134", "r328", "r329", "r381", "r396" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r130", "r131", "r132", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r71", "r72", "r73", "r109", "r110", "r111", "r113", "r119", "r121", "r136", "r184", "r248", "r249", "r267", "r268", "r269", "r283", "r284", "r327", "r332", "r333", "r334", "r335", "r336", "r337", "r403", "r404", "r405", "r419" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r271" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedLabel": "Increase (decrease) in non-cash contingent consideration" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r191", "r368" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r188", "r189", "r358", "r370" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r76", "r154", "r163", "r166", "r169", "r172", "r369", "r378", "r383", "r397" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r103", "r112", "r154", "r163", "r166", "r169", "r172", "r183", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r314", "r329", "r330" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss) from continuing operations", "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r74", "r79", "r112", "r114", "r115", "r116", "r117", "r124", "r127", "r128", "r329", "r377", "r379", "r381", "r392" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r74", "r79", "r112", "r114", "r115", "r116", "r117", "r124", "r127", "r128", "r129", "r329", "r381", "r392", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r17", "r20", "r289", "r393" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r14", "r17", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r77", "r79", "r125", "r127", "r128", "r381", "r393", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r125", "r127", "r128", "r325" ], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r276", "r277", "r279", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r104", "r274", "r278", "r280", "r285", "r287", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r120", "r121", "r153", "r273", "r286", "r288", "r398" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in assets and liabilities affecting operating activities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other current assets and other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r151", "r338", "r340", "r382" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r42", "r186" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r62" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total inventories" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r23", "r62", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Total inventories classified as current", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]", "verboseLabel": "Inventory" } } }, "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "negatedLabel": "less non-current inventories", "terseLabel": "Non-current inventories" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails", "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r43", "r186" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials and work in process" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r62", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Obsolescence and discontinuance losses" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r84", "r150" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Initial investment in joint ventures" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturity of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r351" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r351" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r351" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r351" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "verboseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "terseLabel": "Future minimum sublease income under noncancelable operating subleases" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r53", "r103", "r165", "r183", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r316", "r320", "r321", "r330", "r356", "r357" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r103", "r183", "r330", "r358", "r375", "r389" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r55", "r103", "r183", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r316", "r320", "r321", "r330", "r356", "r357", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r52", "r102" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r52", "r102" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r52", "r102" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r57", "r198", "r199" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "verboseLabel": "Revolving line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r57", "r200" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Loss Contingency Accrual [Roll Forward]", "terseLabel": "Loss Contingency Accrual [Roll Forward]" } } }, "localname": "LossContingencyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r60", "r103", "r183", "r201", "r205", "r206", "r207", "r210", "r211", "r330", "r374", "r388" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by (used in) operating activities from continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r69", "r70", "r73", "r78", "r98", "r103", "r112", "r114", "r115", "r116", "r117", "r120", "r121", "r126", "r154", "r163", "r166", "r169", "r172", "r183", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r329", "r330", "r380", "r394" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss) attributable to common shareholders", "totalLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r70", "r73", "r120", "r121", "r318", "r323" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Guidance" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r109", "r110", "r111", "r249", "r312" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "verboseLabel": "Noncontrolling interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r154", "r163", "r166", "r169", "r172" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Maturity of Lease Liabilities at March 31, 2022" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r344" ], "calculation": { "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r344" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r344" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease noncurrent liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r343" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Present value of remaining lease payments, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r349", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r21", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r64", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Prepaid and other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": { "auth_ref": [ "r44" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.", "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross", "terseLabel": "Consigned inventory" } } }, "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r27", "r28", "r54", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPaymentsToAcquireBusinesses": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.", "label": "Other Payments to Acquire Businesses", "terseLabel": "Other Payments to Acquire Businesses" } } }, "localname": "OtherPaymentsToAcquireBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Cash payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r89" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "negatedLabel": "Cash payment of royalty during the period" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r86", "r303" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedTerseLabel": "Cash paid for acquisitions", "terseLabel": "Payment to acquire business upon closing" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Additions to intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Note receivable investment funding" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Borrowings on line of credit" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Financial consideration received in exchange for product license rights" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r20", "r69", "r70", "r73", "r92", "r103", "r112", "r120", "r121", "r154", "r163", "r166", "r169", "r172", "r183", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r314", "r317", "r319", "r323", "r324", "r329", "r330", "r383" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r49", "r194" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r30", "r31", "r194", "r358", "r384", "r390" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r30", "r193" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r90" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Repayments on line of credit" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r272", "r366", "r412" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r38", "r249", "r270", "r358", "r387", "r406", "r407" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings (deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r109", "r110", "r111", "r113", "r119", "r121", "r184", "r267", "r268", "r269", "r283", "r284", "r327", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r148", "r149", "r162", "r167", "r168", "r174", "r175", "r177", "r251", "r252", "r367" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Net Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails", "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r8", "r9", "r10", "r11", "r12", "r13", "r16", "r18", "r19", "r20", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Dissolution Payments" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of numerator and denominator" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Summary of net revenue" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r29", "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r261", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r144", "r146", "r147", "r154", "r155", "r166", "r170", "r171", "r172", "r173", "r174", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "REVENUES" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "verboseLabel": "Operating Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "verboseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Restricted stock awards, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock granted in period, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r259", "r263" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r59", "r71", "r72", "r73", "r109", "r110", "r111", "r113", "r119", "r121", "r136", "r184", "r248", "r249", "r267", "r268", "r269", "r283", "r284", "r327", "r332", "r333", "r334", "r335", "r336", "r337", "r403", "r404", "r405", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r109", "r110", "r111", "r136", "r367" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r35", "r36", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Unvested restricted shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r35", "r36", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r59", "r248", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Vested common stock, value" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r35", "r36", "r249", "r260", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Repurchase outstanding common shares" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Common shares left to repurchase" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r35", "r36", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of shares (in shares)", "terseLabel": "Repurchase of shares (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r35", "r36", "r248", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of common shares", "negatedTerseLabel": "Repurchase of shares, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r36", "r39", "r40", "r103", "r182", "r183", "r330", "r358" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r72", "r103", "r109", "r110", "r111", "r113", "r119", "r183", "r184", "r249", "r267", "r268", "r269", "r283", "r284", "r312", "r313", "r322", "r327", "r330", "r332", "r333", "r337", "r404", "r405", "r419" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r234", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r348", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r137", "r138", "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r129" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of other securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r123", "r129" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)", "verboseLabel": "- diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r122", "r129" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)", "verboseLabel": "- basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11374-113907" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r416": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r417": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r418": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 66 0001628280-22-014372-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-014372-xbrl.zip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�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

JSY-5RJF.5"ANI"M\WQ=?Y'(7RA?RI;:7QQI"C MP8\A V$L;T?<.KHRXL5FZR0WS!-,A Q\/-( MHM+0['UX#4VIQU"F:E(, ,W6O7%AS)+2)8"4&E/(T M$G2*%J4\-Y7A@0)42>ND92$:8*:"R]&@ \@P >6H]HV M49&KO.A%L+".'Q?=2NKOLWO;N+J\NU%F/>%G%'F98I/#=!%QE3HER[53?X<@6'XSR. M;?"EP-6_,-9FI ZW!\NMB@0$#ZDAV:6&(Q&A@_58G*.3N>=8C<;X 2BU40@G MH'+FOMED_VHD+W$CHZX6/*5(T&%J"<%&;'/FB_?JCY_!.)C9YM-[RZ$ETH_F M>">C>3')._XZ9O%*E=D\\."_D7JS_+I"7_T4C!:_:W0J[69]Z=?5BK'TNU7# M&LV*4>OL-.SJ[YKUY2]]-9.M;SPA(#4DR+^_J;]1SRFBGXE]%S5F_6V M;C2[)3V7]%Q\>FX!,7U6GBF-\R>5:GH-#,=.9T>C,4=Z].@/JF&T]7IM1VNH/*B7 M.JB36K6I-QJ-=_DYHF-6X[?"MB,\/X4"N($0+R!E-?26T= ;:T3 \Y'1%@Q= MP-VMZ^T."-A&M=S=9]C=3JVM5SN'HMQ7:=[>"%]0WHIJSN*:_5=FX1IZN]'4 MC?J.GG=I.+W<0=6:((!;[?*@\GU0#="3[5;N')%CMG)_X=IF>7=LBLU\Z ;O MP_*4:*'-A9I>K\)_C=+4?::@3[VJ-ZOE[C['[K8-O7,P+^)56KJ]*78Z80#M M5V?=-KMUO;9KTK\TFE[NH(Q61^\:C?*@\GU0C5I#K]>-O!W3,5NW=RZCZ,\G M9#>1Y3]4'9$_ZC-J>J/5UJN--7+B,/4 VXB$8SN8JMYI&7IC73E2>3 OKEA; MU:;>7)?!+DP!3?'-\:NH$:OE#-VIT$YLU_<7\J';V!''1K0GAE[K&GJWV]TZ M35R4NL97?;QU-"*KU?)PC_%PNV"@M8K#NJ0T:97EC@X,8RN MWFPWP;(..SK,U]#I0=+->WYRBM]V*YQ9(<[2[DT ZUN.M-^H8 M=BP/]Q@/U]"KS9I>:]2*%3X/?<-L97\/IB]#[J%E""W!<,-[Y0D]T0Y+Z$KB^AZTOH^I?= MN1*Z?@OH^J-/B>YIY@M.\7=/)/J[Y[E!R;V ME=_6-WP%[G^!G/RZWFTT]6IW6_BH%82;TX!427=Y6EM-[W8;>KV];2JNI+N2 M[GYD;5V,R1O;HK#MD>KV9,06P$2X-9UAZ+NOK#ZGKM>[;;VV!B6L+ ,Y^$%A MOWNC]G-Y3/D^IASPT^OQZOZP!@B/^2/5_04DL9K>K!IZH[XMR%C^;-$C/ZBF M+-:NEP>5[X,Z 98"0[M3W;[XI;2QMVK&9-HC?-4K,[*[S:[>VEI>E[;;"Q^3 MH3?K7;W1+9L(Y/R@3IKMKMYI;7$)JC2O=S&OS9EG^:[]RNSK$\-HZ]5M+BV5 M!MN+2VJCWM!KK=(%ROE!(01BT\"3*BWK9]WHWE $YL@-7AO"C6$8>K6[NA%# M:;'EX)C:NM'-'=YZ>4P+M[6-ZA;0$:59O0MR\E0,;7/J?C^]-K^],MNZ5M/; M]>(7[QSY*9TTFE6PV;:_REH>T4L=4:-=1Q^U+ QYB1:K(^O.$]]?F67=[.JU M-;"YI<5V\%,ZJ=? PSY,)+0\H8V2/X;>V+INM#2L=S&L@XGPU)W6UV98=YMZ MRRA^>?*1'Y/1J8&'72N/*>?'9-3UIK&M\9,_ZSJ_LIJ[ 28Q"'9LM"*1!.8 M'W#RKQ/29<^[DW<^U8UV4Z_NVAEW3[MT8 /Z^599,LNV&Y1S?JGJS7I;-];U MMWS^C2I9)E>$4;+,LIUI ;]T.CO&P0[/+QLA5]'K:VD2_3/T VO\]'R[3B.^ MM\ ,M(:KSZ&FX%>5J5A1Y_#"!$$3T9(SB="R@A6@/!IBSNC:H_"$]M8P*C4- MIF5;K@.B;#HS/7@V<.&;:J49?;/IN$9%TWJ^-A*!:=GPI>7PSPBARQRX#T)/ M6MF(8.L)TX*@VNCT"-$,7C/ M7Z'I!<+3-=.']=DV_B]^CI2+2+@XNKQ8"1.-V&<%'79>F Q7GG5B!Q8W!4?R)$Q/8J_!CB&& MFWJC]F@B&IN% &[V$_W$$WYH!_@>$#^/P02/WY]8LZEP A\_YG$9V U>@P?] M.'%MX9M 'G J("F$%_-380XF*G=*GHL=CB2N'2[/5Y0=/SOPD([Q/_SU)M6*\6Y!KF8P"8B3>/OCLK5&I9\I*',$WIPJD M4+--& SWK@(<8_FI0>+3G1\A:PZ&9B69; 2K@*?A< -W^ U(QO4"\UZPN-/, M1],*8 X.JFGMXWE/,V=PW ^FK<&$37CU(\A5)QR;PR#T!,QNZ9G*C6P@(N+, M]4EXOO>$C?<;10R$B.AWB5])PZ(:_\0

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


$ B+4LH'M _%)X5:=7,CH& 1A'CRK>,I5G[;2S395G[81[+9'6:L?ER\! MQ_CW/_U_4$L#!!0 ( ,Z(K50@*"O2BHX !/;!0 5 8W!I>"TR,#(R M,#,S,5]L86(N>&ULU+UY<^0XEB?X?W\*;K;9=J:9D$F0 '6=O>8XJK63E1$ MK*3,FMFT-3=#\2/#\ [_OV_ M?7]:>"\J7<]7R__X ?[L_^"II5C)^?+A/W[X]?X3H#_\M__\EW_Y]_\#@/_Q M[O:S]V$E-D]JF7GO4\4R);T_Y]FC]W>IUG]X2;IZ\OZ^2O^8OS _C._Z?WJ M^36=/SQF7N 'P?&_IG\A,/%CE@1 \1@"A(@/:(A]D&""F8S\D$?LZN$O"190 M44P DTH %- 0<&9NP"1.*(4(43]_Z&*^_.,OY@_.ULK3QBW7^7_^QP^/6?;\ MEU]^^?///W_^SM/%SZOTX9? ]\-?JJM_*"__?G+]GV%^-8SC^)?\7[>7KN?G M+M2/A;_\C[]]OA./ZHF!^7*=L:4P M;SOZSS7WY>"9;EF%_4RZN]POP7J"X# MYE< !B"$/W]?RQ_^\U\\KX C72W4K4H\\_>OMS>U(N-?S!6_+-6#&=EO*IVO MY%W&TNPSXVJAM<^?EKT^J__X83U_>EZHZG>/J4K./W:1I@=/-5K&1DL8&2W_ MM4[8+QW4[TG?[%37'I3+S?W2EXY-F'[I3=U[S0]J>(7WQ'16N7BA/B[E6._N M5E1GU8?7N*_78I6QQ0BOQ4[,GLH+\XO/^J=2C'E0 YGF[?97;82?]RJYTTJ'C7=?DM7#RE[NMYDCZMT_D\E MKY]6FV4&9S2!+(+Z4^5CY0-$$P1B%6&@!,$^IA%!G,_T%Y>ORI=]II;@U[M* MKUQX*\D_.""Q+_\0D52M5UK0[FOXM#CWB=-?-_,]I+\LV9-:/[/R!JV^<1P* MB_YSI[.WVF3F(VC\"D^LGIY62V_]R+2P?_]E9W9_@[!X*V 7PR*::^SMX5KJ M?.7MM/8*M6N!78D#]1;&$UFEQS"M1%N8=A-^K2W,,4K8FN=&EH_4@ 7P%[7( MUM5O@/D-\&'IO?RKJ^Q?3MZ=Z[2RDZ7BPM"55_PB5MI->\[ P2@:M[83(-FJ MTVM7#)-6\0=OE4J5:C?]C+G;J2*>Y]]G-XG*TA5GR_?ZBKE@B[^I)Z[2&8DQ M]I. :'_!,A7$: HQB"!(O832B*.@EFV_0[7SJ F(2[3):OQ+/J<,ULUO4I/ M.\YI!+*98/J"9V V.47&^[U0\O_K 2)9+A7S=<[@4!U(F\3+9,VS-A 4I&JN M-$P9^&')DXWWCD**-MI7#&AUK1O=5:3Z]5FE>NR7#Y^5YM3/<\;GBWGV^D4K MOTE3_6+,$.$XI"0$./(U][$X LSG". @3(A2@A+);;C/6N+4B'"KL+HM1^[NJ078;=SA7K%UV6IH_I< MUB <>UOV-[8CG@^*9S?+=9;FGY]/^I4I_+>9PI0S%%"@?T4 $@@!RD0",(?< MIW$ ,94N?%,G:&HT\WZUU,O+;,X7AF(RY48HM7#:\4@?( U,'T9%;Z?CE6>T M['W1=@F(7KFB5MBH%'')Y&-FN'A].T+8>_^-A-(;5@B2.(X,&T &4(@#P"6A M@'"%$X9HC)5R88.S4J9,!49+-RHX#Z0=#W2&9V 2.$;F\L++F0$:(>AU^I^7 M-.K<;S3V>.(W7]QNUM\L]812Z^SC]V>U7*N9SV4D @&!@! #I/1"@T9Z^A,_ M((KYE* 8S?;WXR^^TD<2K%[FBR<+O:Z-2P4]56CH-MN/ ;2;YVU &6ESI4+C MXP4TG"=VC(X)"08$B MYA1'Q@QP%"6 "X5HB(3D L^R[:Q $&I7 MB,00,Q*[.$/MT1W!"1H=73OF;(W9P+QIX+HIX?JF73 M0PFCKNU06ZXUH RXW7HL\0VW6FN,;]YFK;O)C5+6:3:[U>^ *I?^,4>* M04J!KW@$$)((,.1+D$0^B32L.%38ACR.GCLUFLA5\W[_L'IB\Z7E2>PQ5,US MOP, \_R.W. N\[RL^B_Z3=IDZH\W/@B&M93O,;VILFL;]F;R/J_CB?Q\3-' MF:XUAE03L^Z?VT23+$5J9O4'5?Q]LWS/UH]W^?&)?L1O;+%17Y//\T3_BQXQ M$^O\;;68B]<9Y]JAEU@"%,($("$0X H10)&,H HPPLJ?G81_7@@6:*M-BQV3 MNLC7?L\#"CN\'^>E93_I]8(GM%'>NK+*>S%F>:O$6VC#]+^7EGG/QK2Y6GNK M%WW5LYXN\\W3VGMF<^D2P]%ZA)N)9H0!&VLWIQJDRHJ?]"K%,X9X6TN\W!3O M:^(98[RM-5YASBCCX1)U,\:XC!67,^3X.$;R=(6U.=:G]=-'C ;JBL!AO%#G MI[5;R-ZJ3'L<2GYDZ5+[M>MKH=_DS<)\%CZH1)-N-F,Q"T(28R!P[)M]+ D8 M8P0$012I@,S_*0M>?W):S%HC;K6G[17'@ M3\L6OH];^/;T]3Y<@M)Y<6N/3J\K7 NQHRYS[6$X7NLZW-F.>CXKO6I6ATMJ M[8H^?4W>KY99RD0V"P(J8.B'(";41#/J53%+ @4"Z2L9*4REL(KDMA7P'1F&WM\>F4;"[&CLHT] M#,=LXW!G2[;17*8?EBHY-U%0>7CDK\O-6LGW3+]'^K_>KYZ>YED>):74-Z5? M1NW0/ZA9A!F.]5H>L AS@.(@ G% !, "$1PB1!BTVI#KK,G4N,D8DG-3;LJ5 MM\F-T&OZPHJK_,BOL,-+E%[%;RUQ9+'60V=);F,,R-"<5XY%8857F7'E%89X M[[>#LK/%T\9XWRX/BCL;=@6T7Y)LKRO29X$ M6![V?_S'1HN\YFL7O\/J61.:AEM]S5SK$#4*@P MB$-( 8&!CUFH?*:0C7]1\_RI>0V%BEZNHU<0U"'8S"4]X#(P:[A!8DT/ M%PP_0P1K)7Y^6+W\HN_,.> ?R/P(BA_SB5_WS%&F^ 6#JLE\Z;*6GS7U8(CA M5CVO4K-$*;9?BS_OU??LG=;PCQF& LDP\?7L#1% "D> )WX,?(&Q+U0<8(H< M"V/8R)W>?NEN\5T:X%H$PPIN2R^B;PB']B(*?;VMPE?EX8WW>_FWT=K+U>[3 MC7"!J5\WPDKRN&Z$"Q@G;H33S2V"%:Z%RIA<954DC.(4BD0DP%>, N0C#F*" M) A"'*J0-Q8UGU\?WC' B@@#)*B?*"D3)IW2\/M">HSO MP9@XV_F;?:$W\'>D/7#.KJ4-(KUZE(T"1W4D;4P_]A^M[G'??;I38I/J9?'' M[^+1!,U^T2_'C-,@P%@0X/. 113">)(0$ CGS,NA JAL-U^.B=@:G11Z>A5 M2GI&2_L-J+,@7MZ!Z@K-X$M.)U2<]J":3&^]"77VH:/M0C69M+\-U7A=BW7? M%^U%IP;J[3E*'(8^Q $",)G9=U7L#T_*JMBG]Q M6/:< F>Q!.P$QL 3=JN;S8F2#1X."\%.N(RT%-SJ^'-/:\%:HQM7@Z=WC;<> MK-7X8$58?U7;XRV399L^K])\A/,3M?>FXE#Z^GXEUJF"K;VIV?YDNV%/J*:Y'-7_*JM;-0! 2:ZYL*D*FR^,,C_NK'+;$NPV:':L-/Q C,-= MI1U>DG^#M^@?F+)?2WAKC;AY(Z1>WLB;(1<-/]T0N7Q+R\]Z]JC2O(;>>J^GC@@B M&'!*@221_G;#* #,#R$@@4@$# *!H72+'SLK9WH'G+F:[4IEG@72\H/;%9RA MOZHY*H6" [4@:D*@WX_C64GC?@&;C#WYS#5>W#*?1CPJN5FHK\F=*0G]CIG$ MU-63J7*>[P-$G0>P[.?F]:38U[[\R+$].-6H#TU-=>OO&>?O6>?SUX,)JCM3<9S(&I<.1Q=$\DZAOS?I.->M-NW(2DOD$]25KJ74#+ MUE)L_6C^;Y*N7]C"B+M5VL^&6>.^'G9?F>D.^L"?(F/*55&!=,^B*V]G;/&/ M9MR/?W=P0P&"=Z;$Z96WA6(7G6S \ HT>FPF]B:CV&^7LG%-&+?]V9L,STE? MM;?1HD6P^.:A_ MHH@S1/R$<*M")&V$3VVIM%/5XY6NV\IF#G'6KF/0_+D9&MF!/Q9&*B.\9?;?H^9;P-<;6NSYSO,C[EM8>Q.6W?4:7 MHE1?-GE- !'0D 52 BYCI)=$*@8TDAP0'+$$<2D4L4X)/'[XU(A^K_:25VC8 MIA95"9QM*$P[.,8)@[%!HF4)JD.3>Z@_53[P#8I/'9IROO+4T35=8MWOV?>R M >@[M53)/)OYE$$L Q\H' 1 .V@0Q F60&"EHA!!JMTUU]:[9R59O:$CM^#- MP^,S]MW[L>S"^Y/'"VU=V_&>!]?V++T]8*,F$F@5JP:]WH^EECV6VK^ PP"9 M!*>RWB"3H-;@\YD$]9>W+;-Z7)]RNXS\9JI.K9;[+47O5^;@SI327BWT0Q^J MML(S&&**H<2 0--N3DD?L87I MDG/EO5,/\V4>;+=*RFW&-QG"6'^2@R0*0#Z."#$">%Y,'D,4)C%! :;E$'Y< M6GZSWVH *P5'&#XMZHT'SO*@>?2A&/J4^4SYZOV]^-*JD\[5AX9YE65]EKON M$^F>ZV'WHMK(!;/[A/.THG:O3V_G*UT+89*/U[=*J/F+$?1%9>_+\#B(8A'X MT(080O-I52&@ <. "BP%P5'$<.P69]@D;GKAAI6V7KI5]\I;-C2:=H?8CD'[ M@FU@7MSB=;N'%TLR$YVX6*S^S)LMYNF/Q4:K:3=_Y;WO.UK1!JU>N:U1X*B, M96/Z,0]9W>.^=WK]I)8R3VAWL=TP/X;J\7=H:A*$YP,Y^IWW2L[:VWB0]?-IH.Z1G MC=C?'CU_0<=.,X5C88+55DMSS'[]?;Z>X5@*9 *[9*CTQSWB/HA]#D&$0D@C M)D7LUK>K4=K4)FC9;6:GI/>[4=,U6+<18-MU44^P#7W\X8I8^S8]34@,TY[G MK,2W:>-ZS[S=2/VV>S$5^]EZ>XG$!J0Q\ 2(I\RHK%# < M< "Y+T*, NI3QZH -9(F1QK%": Y+CA4M^7):!W ML>D/< VSIFI.V(M3E O MH-'Q.+7NZ2.?K5XP\O2@]=(-+>+FOJ4KN1&:9*K46FS.5&,B0,*8]NU1R$ L M.0>,8DZA0CX/N$.-U>/G3V]+H-+0I<+J"6K-L[PS$@//[$JU=N553\!PB#3K M LI(H625BGW55JTSN3'\Z^2F\>*[ZO0]"."JOH6F5>Y KJN] MCU(/ZF7_I!>H!F:P5B@Y^24746CMD]0_>31_Y*)Q^[[(Y8M;'ESD.=?5-GK@ MQPK%T <2(F$J(F# 8FFV%PGUXRBD# 4NL1H'3Y]FR$69:]ZJ&L(A>)9G$&TA M&7K#L:Q[T/\QPCF#^STW.) P[D'!.>-.3@;.7M1NOGY6^F'JL"K0MJ!AF2B[ M_K!1LRA40D)&-5[*!XCI2ZRLV^HXRZTA MMR. (8 V56LY7'E?>-S>M#:)RIPQ6J7EG%6OBHA.,*R3$7 M.=_?L8[8%Y7-5)"P)%81X!AK*D(\ I3@&)#0%S2$(2-(N<4_[#]^>IL;E79- MA88M4 N#@)B.60I*[8L1X@/*]$^1GR0HHG$01('+Z5);S,98;Q4D/=_AYHF% M=LCFR=Q4DEQ[ERHQ74;3CIO;8C0P_V[5NO*^-(3-M"].MV?N,-7HC("W*3^W M9UIMO;G]:[JX99^+G.NU2.?/AVT=F8Q5 CD#'"8A0#C1WEBDYS9,9,@I"W$8 M6YWX6,J;VORN'(C2;=A3N4,?S4N8N[ACO2 YDA?6%L26[M=%: ;PNNIEOH&S M=1& \S[6Y=M:UK),']AR_L]\ ][4M5\MYK(HG[24W_3[5FW.?TW*^O9LL3WE MMCT[Z576A*;0OCU7WH%%>0&9?9M,3L#6JEVK'*OS&O?*D'T"W6\ER5XT&[?R M9)]@GE2J[/7A+3=MGTQ@^S]+.3=:XO)ASA>JV&B:B9BI@.H%5NQKCP.1( ), MR0CX,8(!)#)1A#C&FS<*G-X*;%]?QRW=9F@M]WA[@VOH3=\]10W?[50MZ^#V MN ULA4F_^\+-(L?=*+8R_V3GV.ZN=BQ2]0!_OWKBFJJ,C%LE5@^:W92L0E[8 M5EK>*CQ54O-/;/G7U4K^.5\L9C2*A%X%$/&US;C7NR-MQYF3':9A\"H<^J/W-QF^7K\6 MXUHPZL?G30;G^%OV-DIT*'UQJY[U)'\T%8@_;%*33II'7?S&%ALUBR,L@@1Q M$,0L,GV?)* $14!(%L%0TE @Q^HX%V5:D=:H=7)VVA:M,)^>M!NY-G6;'3]( ME_'V@X K'X8 (ZKTF@8QP(C/0,#]0 GH,Q(&%=[W+BDW_8-^/X(#<(A\ ?F5 M]V(T[AMYN\]W/T".6'? VU/6*[0M ]BNO-\:<6Q73L &F_XK!31*';\(@ T( M9_/[K6[LF..WMV/S;;7.RR Z;I?:/&I2\Z!J_WVPU5EI/,A&IPM$PV2J-0E^ MFX0U"RAJ\]9L[NW%!_J6KAY2]K1M.7>]R1Y7J?'==M=#@+0ZD_T*:+ MN!]S@% 4 AJ) 0BCH7 ?D3L\MNZJS*UA?O[?1_)6Z@D,X%3Z5;M3A]OER%J M]54?"/B1/_=>:<;57I?,G27[%Q:V#.8(M(!S2 _!19VW=!U:P';!IVCSQ!9I M?_=SI1>TMZM7MMC%VMWK(5V;\D4S9(HA1DD,6$QB@"+3-5P("*0O(AY#XDMB MM4-J(6MJM%AHZZ6%NE6<[I6750H[9,9=0+F9^'K&;F!F*V$K-:V:;NF%X'W_ MN#GD%_:'WTC9AAUP=$M#M$.F,2GQPB/&2U&TL^4@8='REMZ.L]ZOEB;(64LQ M)_5SF0<]FTB<,MYYKX5I0)F @5! 814 E# ,&%80*!%&'#&&6< Z'D_9:S,U M>MYIYCV7-1GUBC%[5)[8VF1^W!GE+2JK.I],.0QBZY.F88;F34Z.=J9X![8< M)&L,T=RV%UB'/M%QT.BM3VC#GKN M1APKJC@",*02($8IH$1B(&.!DQ#'00"=]@Q<%9@:YY:Q9,6>OJ';=+M8/4QF MN_*>"PL<.WF[#I =N0X)^\!\>I+=5FGOE>I[E?YY<\"\HV C[NY1H"W!ZS?@ MTU6)<6,[6T)T$L;9]CE=>Y%ODT[*?."\H>V]^IZ]TV;^,8,\#A$,%9 A#0$* M8@4H%@%07,'8CQ@/$B<_U%;PU.AOJVW;YM\7<+;<_QP O:%W._=:=^_EC95J MEZVX/:.YEZL^2%=N.[0&:KI]0?@;]=2V@Z2^9;;E_2T#RK57*.>+339_47=* M>X!YL,W'[Z:.NI*?M%FF,N*FBFS_R%+CB)AFHWF7[F)O=(8QQ8C+" 0Q) "% MON:NA'! H6"ADF$H$^H8=]Z'7BZ3;AT4MW/8W+ZTT;]'4>^;?*$XO6WH_SZDBIONG2@.-NQZ6CC^7 1+MOC['LV&4:NK#*^HY?;==7[*5.O0/<;D-^+9N/&[?<)YDEX?Z\/=Z/^ M=9I5!>2^IG,<_5_'?%/[\%&H MXY)I%0MVV>LW/9;9]5*:RM;/9J?H7C_OP\IL(LTPB>)$QA @ M'F-SVI$8)XT#'"*.1,")2)PVVRQD3FW:?UXM'\!G3;S2NS_(E/!^+Q1VK$9@ M [N=H]0SF .31 <QSN-S:(L;EMYMWU_&IW\-N?:2WMQB+:N52Q/L3 (<2D-18C1924^O44-G+6VL8HD<,[Q@L* M.:OI00S(^2O:%=$72LFU62;=L6*+[# K[&:YSMAB88:[##:914($A$4*J)@B M@%@B &/2>#^(LR@*%/.MJEFWUF!JO+4+^S^,WRA:]>F/^GSIJ>_B4=]3;E"5 MBX*%]E9-N^_4G)RLK_1U6U,=ZVRV'TT+TAQZC(9?@N7J%YM)QH"S91I,ON\. M_M*,H=%WZS@PZ"B,UY6@_]%P;F30&LE+S0[<'SQJ0X36=A\W36C_H+:1B?.% M:4=;NCEZ<4U"@3@@*N( T4"!F#(%,)4T# A7D%OU<#S_^*E]8+XFB=DWNC/_ M[!H+> ";W>*Y/1@#,WFEV&4WN47DW3F;>PZE.Q Q?@LW#4.D(R\.S=TZY=OZ9SJ#@X4!W1&1GR) Q(R M*W>C5L+4/(Y<1V^KI,,D/8N?!7=U165@\CH"I,U&W5ED'/BK*T(C$9CMJ^/& M84W&-Y+8V1O'8[$FO0]HK/'";ME<>1FHLJZ!.51GC/HAB6.@4$@ (@G2;,8% M2+#VT/PHH+A=&<$C.5/CM&VNSYZ>K1INU^%JN[KJC-;@RRQWH%JG.M7 ,$@2 MT[&L-TE/JC&X+O&H[O(6KLU[_0_S![7\+\46V:-@J?H\?YIG2I;?HD10R3B* M0:B(YH4H42!.5 *H2!B#")$P(-9>S@5A4R.'2EV'[_DE."VJ6L;7^@2=@YN48\8CN0A-6#9D[=DB4FCXW3I&>/Y4);6'+A3MO>T\ZP^ MYEW-_SZ7ZF:9K-*GLA+GBUINE-D4__A=<]:2+=YOUMGJ2:6?MPU5!%=$A @! M%9D<>0Y]$%.BUY2^5"B"042X[^)[M=9D:@1Y7:'5K1]22Q+KB M-#!!N4/D3D=-$/1+-64$3CQ>XI,_?SK(@9D/.7N=RPQ=_GV>.M M6N34LWZ942YHN3TM =E/ M^VG[B Z5?&_6Z\UA\>P\AW"=__G.%-8V)*F6ZV+;@DK"!,EW^70Y &9GG7:>I"4TNRH6R1+\'WJ=5FJAYMDG[+N'?#L_^2_8ZZC%^ MK=YV0)TMTMOR42V)4BT6IOSO4OZ-I7\H4Q[HXW?S<#4C2/A!J * L1 A1P" M&OL)\&.8\$@QRJEC;8MZ82XS<9Q0L%+7/!/XJ=+6D>OJL;6DM%[P&IJY]H#: MJNF5>O9(1Q>QZ)=UZL6-2RX7S3[AD,MW=&GX?EA%;%M%L2IM^V&COJCOV?V? M:O&B_K9:9H_K&80L\ 7V01"+4#M6/@.]&W^%Y_;?0*URXF2 *"1P(X/M2^U0D4B!F8:R'3^+$ M#V(>!DE_/?0*H5:S\PV;Z)6=8;HM*9MA#T2@H4XB (4P6Y)^"$QU71 A% 64 M)Q0CIR]03Z"/NA,Y,N0.B_;>@!S:T[W41.^NN0]DKUWT#M$9K8U>*78R??0. M87!II'=T9TO*/[LFW]NA6;][W5U3?GJN33G#_ ]3@$0[ZJ8PR1?]XI6;]SS MB"8F\RK!L5YX0P*8=A6!1!S[,E"2V&7L#ZGDU/BM/'',%6YY(#O(6%K2X!N/ MT,#$68R*T7* @^ AL>N75H=0=%PB'A#J$^H>4I8;V4LUGWW6[^'BV^-JJ;YL M\I!7'PL M9X%K9L2N< R]O6"/A#61-9E\AH#62OS\L'KY1=^6<\\_D/D1%#_FA'/V@:,0 M19,IU01OO*95!FA9SN>@O4M)"(6K-T.41S"& 5 $(X B&0(J)0842I,ID0@9 MV]= LA XM0E<4_+HJBI;9/JI:+6=LB,OH]X\TX? X5SM!34;K"ZIJ9:8W0A4_7R<\9,7+6VZBB/U?Z^KGU@SN3(:2=N[[]J M6G7M6ICX <*"XP0@Q@/-XQ$#/.(1B'#H(^YC@CAJURJFLVY3H_S]IBCG,D37 M'G_=_^_Z-GIMV]%T'V[+Q?/;#.+0FXV]C=](#7!Z W^@'CG=]7NC-CJ] 5O? M::<_$>V^$>]3)>?9)R;R$[IRZTS$ 6:<:'9'Q#?M$2&(H<\ AI!&,59Q$DH7 MLC\G9&JL7>CH54JVW,D\"Z<=F78%:6!6=,;'F=": .B5F.[:L.0;.;U.V!&/I@(%?,IKR<>TNHLS;WV]OI4,2X39K.FG?2 M;>G\56W#6UB6[[Q_WJ9(JCD5, M[0.]U;!#BOL9("U7.IW@&7K!XH9,BV"(.N-[#GXX$3-RL$.=F:?!#;57M@SP M72T?[E7Z9)[W-2F^^#-,*(P$I$#Z- &(,P085:8J;*AD'/F18K';9_F-V^S7H6+7%/'@-USD-I-]JXP#7X2MGP FG&?O,\E/H6*5]X7 M_:(7#5M[#*IM */?@-ES@L8-AFTP]230M>G: 3(G]_<'9A 2AF(4@""2#""? MQ"#FH01$$AA1BBB4[D&5-I*GYA/\NGQ1:U-9:[]Q;1\1EE;#8.LZ# #NX!Z% MB;I:0F*(DD"# 46R.E(AF,<1!$K-8OZ%(^4JXL)B+ M\*D16:ZIM]A^V1<[5=W8RVD$[ AL*%P'YK!*;>_'2O&?3'^I NF=\MYG"ZB= M::P-9KTRF9,"HY)9&VB.^:S5,P:*,Z\+ABSBHDU_GS0/Y5CG*MX_LN77YYQK M_ZH?81H E<$FV ]8B&(%8F%ZY5*) 6,( AQ$*$[T&I#[5JVPQU9\:E1ZN^<* MYF[,@U&W:"[W7/HPZ^9TD;=]$2S=R@D.[]!>Z5Y)CGVC]^MRF+/YLZ4[C.E7 M7IFLL&=]^4'(M/U>"<"55T!@WIB^ J#>:MC&C:/O2_EIQ=;W/"3.\?9]RV_9 MZKW,WKU?Y0N&5']TS>([_]V,F11:F$A << !DC(&3'$?8$R93R07.$95=NV] M0ZOW!IE6Q'287'L_PN?GRRI394/3//9GOM782S9+Z5S*I!%VNT]%9Q1':C]: MJFFJ!)2*>GN:]MC9W0*/?ENZ-PD[A>DG3=QM[NEUR_,WMMBHFI)D1,4R MB+GF%V::*I/0!]S4BI.841(HAGWE%)ODKL+4'-ZZ4G&];'LV#46G_<^> ![# MY=P5A\N5GF)M. LTQ]@H;5)C"CNF%C!9;IW:/*E-YYG50O^\,C&>+VKOE;K- M&Y]?+^57OI@_%)4[[^''S+%'3T\8-S?QZ2IDQ"X_/>%Q MV :HKX>V6PA\6.D7,IN+]ZO-,DM?R^96RO=)1!(!"),0H$1AP$*& E)S!5G M1!+FXNN?E3*UC]0G97(\%F[>^WG\[!STSJ@,_!&I]//NV7?O>I,]KM(\ :'W MUO:-0/3J/I^7-*J'W&CLL1/9_,PB]$D"-J%$9H-G<8PJX<+5[K4W()]+3VC9HM>-O:0-[/& M8$ .OAQUQM"I>XTS)IW[UMA+'*UCC3,(^[UJW&]NN=Y0/-L=G.9-R9$O$\%B M7[.,I #I%0;@6"B@UQ@)53S!V ^<%ALG(J9&*4;#O5"(5BW>SP!IN>KH!,_0 M2PXW9-Q7&K7&][O,.!4S[AJCULR3!4;]E2UVT0_+CL\(D8G20PXB%NJ9'9A< M2>1SP!"&28)PZ%.KMGAGGCVU*7V_RFRW#LXA9;$[W=[^@>?L<;>!]B@X[/^V M1V.DW5QK5-SV9,_;W;C#>G3+>/NEYW4]V/VLN:1E=854L:_)K6*+CVN3*/HM M73TK[;S,( U5H)2OV2UH GA ?2!#*&,<\X!@IS9W=8*F1DIW_]BP5'F) M4IG)5EPER5PH+[_:L01#';)V+D U,8D9%@Y%1TBNT]"HU>ZS0< &(?FLU MU D;MVK#!9-/ZC=S\/P]0=#;D16'<,$C 91$NCE)_/U'Z&2@"8* =^G3+M]0FA: MMV;T,P*FQMU%5DVJ7M1R8^GEU6)GP<0=$1F8L#/FNZKG4*_^I)?5ZMUY^T2D7UTK@Q^_>:^D#)0 M% ,N? Y03!+ F." ,!_I_V.?"C'+S!:6W0)X0%V=^'2K\7!SHS#!^W&AC?W) M,V^+:2A0VNNMM@9[/+?8FQ?79\9FYPH"@[T =NOTB0SKP!^%:D0_[T9T9ZKW M]61$R^MSLC# W\F7(*@XMLF71:;KN8 M;E+9]3)/>7TN0725F>Z-J#;,7G/4 Y]@M061?<,5'M<^DU$ MM9 [;CZJ/1 G::D.M[98Q/_&GM/Y>K4H%UM^E*A(Q#&( M,^6D4!8'X2 3^2 M<8!]Q:AO%8I^YME3(Y-*.X?EZ1%8%@OV]A ,3 *58FU6Z4/>29-^IYE9K6'XXEY^MNG] < M*U7TMCH.4H?^$A#])D37"1LW[?F"R2?)S9>N[]IX[*->2F2O?Y]+O7;0*XBG MG*5NBUUAL];0RPB5+MGB_6:=Z:5%NG[W6NUFZ4_ZG4I?YD*M\RY*,T5$+!*& M02 U_BCF## .&> 8)3X+8RF04S;8(%I.[6->6E'L+U1V>%M#3+FL[;ZTR>NL MC"E;5[G6UQ]DX"UY[ZV'&P#I@7J0]:GI&W4C&P#L^KYD0PAK ML0K+*VP\KA;Z\G51[LPT/MNPQ=8I2H( )S3P 8>" $1\#!BB!/@T"K'D(F+" MM\L7M!/HP@CCY WNJ_QO587#'TNU?[)QK=K@;K'&ZQ7+H5W2/5U'P]!A@=@K MEB.M&<]@^G-/ZT=K.!J7E)>?,MXJT]JB@X6G_5UM3X,UX^MQ>'U?U%4N'+(H MQI(([@.!> 201!%@T \ #^* (*E\&3DU SXK96J>]%;)*Z]4LYV/?!Y2VY/1 MCD -?J;IC%&+@\D&#'H^4CPG:>3#P 9C3X_QFB[NJZ/#M1 F(W-]NZUQ.HN5 MTFR ! @I"@'R,0&QDA@@P?4"/0@"0<.J^JLM(UP6:_7>'Q: '9@B*AWWZK]V M[=YP!FU;JN@)P3?MUK!%]/8RHCTT::B':.#F#&<$OW%3AGHH+C=C:+BW'0M5 M7;+?KY[X?%FN1<7J83G_IY(W4G/=/)D;.67;S:).K=0KT;U&$/K?M-V^&K^NS4;F.IL_:=]O/8.44 Y1#.(HX0 %D@(*:: 7L9!#$7#$ M ^966>Q0P/1V!K5^)IETJZ$;91_!9\>U[2$9F"2/L;CROJT6<_'J_5[^;39. MO'=Z OW1XV+U/!R],M61B%$IYKQYQ]Q0\&^>]W[KV*7&OD1BJ3VGB+HQT#[3^Y-X MNPK;-^'*A&7L_:)K6(WE.+F2:/_HC\B>_0#?@3+=T!N(*RV5>".2=(.HGAT= MG^-&BU+-9W=*;$QY<1CP^WFFIQ*+F:]$3$&0$ D0"/6Y)LP-S3@J8'?YKB]C+FZ5I[#)_47D+M+*E;)G:A )) M(/4QB )F%@)(@IA2_5.2^#A,L!#$J@OC)4%3^T)N5?5R7:N.T0Y1@4VH-L_3 M/K$:_C3_'$QM:JYHMR1XOWIZ M6BWSR5UT[2U;A?U3R1E)H(SC( 1,B0@@)7P0"YJ & 6AE##A<1"Y'?TV2)O> M.7"AK+''*QR;6]I1R9>-X:.O25G_:/E0YDFO9YS'H?)% M &).!4"$2L C"@&-,49G>7T'(FBXM(]$H5]=)&)8J+1A_3Q.4;>HM)+BJG/>1-JY;K MN2RKIVT;2Y1Y&3.N*&,P20!%<0@0BP) ,>> THC'-(9$JJACX+&E*E.CF2IK M**]'4<2C9(^J+'5IK#$_[LSQ%F[=7GH8.SN2&F=$!F:Q\W'%.SN\ T/VFLQL ML[\&C1QV!'3H\&!;==XZ!M@1-HM 7]FV,6-E26#]=2O6+9:M-&,6J[_] M;&S@\3R^S*S\I&G]KG^W?8+C(O#\P-CQ9&>P!Z; VLB\_IBM$8)>2>N\I%'Y MJ-'88ZIIOK@=BVR]P+P!Q,?OSVJY5K,8PS 2>AT'H8P!"N($,!S[($Y@%(1< M_QNRVK9ME#(U7^O6?,)5H9O;C#\/HMV,[PS-P#-^MV K.[9\O("0\X1O1*#7 M"7]>TJ@3OM'8XPG??+'[X4P>:?(UN5G*^8 Y16#((X MEU* (/8%YPD*]'-LSVC.2IC:1-_&,>W4=*H+70_EY3.CG?-/'^V$I]&X_8.>Y@O;?_$VYCE5;<895XN9)>J65_G_U+./3ZY:\5-NK'_Y+)Q]__ MB]>[QW-_* -V3$GXF0HD(Y1SP*)0 22H AQR'S#(*(^H\?*MVFH>/WAJ'_Q* M-\\H9Q^]?8!5\^3N@L# D]G.>*=8[7.6MH[3/GC8:#':YTS8C\\^^^\ML\HV M>LKF=6!,MYB93S$/S50+6* GG8ST? N)!(3'+-8?9A0RJTEW_O%3FWJ5=F4# M+L<\KT/D[+ZO[?$8>")NH;AIAL(]\^JLQ?WF51V*&#=KZJQY)SE1YZ]JTZ[T M28D%>UI]_\;^*&/S*-,?0Z@=9X63$" 4!(#36( 0)SP0,9&462V1:YX_M4F[ MU1!H%5VZ\!CZ.VO?2A:=2H]Q<2E46DG;,;J4VKUNCBV*:TUO+E+ MZ>EM(S8IK=7YL$=I_67N6WIGBHQ_6#VQ^7(F)4<,AAP(J)T-1* $E,$ A)PG M$2,^IS*QW=:KE3(UYBH5W2_X[_U>J.JPN5U&*5-XVL#K$%#2@E<0"(4'KE$\<$,.U9 M )1$<0 32B!RS!1IE#<]"JG4+:M_;15V/3-H MGVX* GX 8_/=A#;$_3_B,' MK!#I^1RA2>+(APD6QI^>*-CW2S769JO.2N.NF69NLO,*=\WE9J, M4_:@9@1!JO_' R0J5,A*8CUCX!Q@@F,%(F3V&4/U%[TU!8LVT]LJO7TUL^I M8O7I4UUAM^.98< <^I1#*^WMM+[:^2Y&\2NO4-W;Z=X?"[GCU2LE.8@?E9_< M83DFJQ9/:,=)>I4^S$ <,QV$,_$"8+AX* 8Y09$I@ M$28QD81!%[JZ(&]J'%6JYFE93V[<= E8.T+J$:Z!6:C0],H["9JL(+QO@M"9 M>2R!Z95N+LDU MA:_?/21G+<;=6&H+TLEN4^L'C98Z/(MAE B.8Q 1R@'R*3%U2$W/Q3!0FB\) M3)RZG[?086I^VK64>,EP<\\WD<0XI-$*'/3<-A 7@4A0"SD(C$AU$, MQ4Q_:N6#L4HXU%I,]QH: FC#H6=A-II[6,U.02'^/%*!4^PI(0@98"*FF1A/(1V40(JN@F/Y4 MFIH3D:NK5YY:7V_?)F_/*--+8/^ZTC OM\S[W=CFY<:Y]G7H/L!VA#ONL W, MOR.-F'M8X/Q)&2ZOR>W#3UX62U>]!?C?9Z&]XF)_#-1 M1M8H+J#D/#)EH+0;J_3J(D;Z)YHDH4)2Q(GOE"C1*&UJ-+Q5UBNT]2IU7>,. MFA"VC3OH";?!XPYJ(!L@?,D*DYXC#YHDCAQY8&'\:>2!S4TMS^]6Q@TM?4_Q M>BU$NF&+V]5B\6F5&L*:"9^2Q/3H@B$/ 0H@ 9P2I7%F$$K( RJ0TPG>)8E3 MXQ.CL+>GL5>J[/UNE/9*K1W]M2HS_K&WK:N._1YSO2;-M<7ZX4JX"&$L&8A[$*B"Q MPDJYQ5T.I*G+U!PIZ%MEYO2O5+!5GZ"A1K7U=N#8(_4F6X8[([U]*[W"3*^R M,X\KW;/4*TV]\C[-E_-,@<_S%_.(G>6#;C3V.31#;T;VHNM;;UCV";C%IF:O MXEI'E+QGZ\=OZ>IE+I5\]_KKVCQ^&\!R+;+Y2RYZIOU8CE0< R28!,@D_/&0 M)R .$420\%#*P*4#G+UH)X]WA"YQYC,@M.K> @DQDR: MOGH(.24)U(N:W&(]+Q.RIVH>-^J8R&R!L.7JO!?M M%3=RI.TELT^#;"_>T8XR_J[F#X^9=KKTL$+[JO?8:J>W]W_^*PT@ M_+_&'26[+\%@V _\<:CT]DK%O5T_HK)WV9[RO1>T;X5:KQ\1-PU&_:ZT N?X M4]/N(?VTW?@P7VRTZ!F4-$R21(#8QQ@@C"!@H1\ 0GP>(!]RQF2WQANEI.E] M4;JVWI"%88,TWZB&QX[@>H!\8"H[UX"CU'*X%AQ', S:A*.2]:9M.(X,OM2( MX_CR'OW:\M$G5'8M_]=FG9F(G)D42O.+4D")T "./JS3B MC-OE[>P8V/6R!W)X)\Q"E[=WQ^P!LW+,'![7HGKKK9+S^U1]+T/<($T()H(! M*OP(($@PB$,5 ![%/,F;'"7$NG+KX;.G1GB5=@[%28_ :F:GCA ,S#B58FUJ MM![!X%"?M3T<(]5FO?A2N)5E/6]O8TG6HUO&*\=Z7M>#4JPUE[3SWVZ6+ZK@ MK_7-\CI)YHLYR]3ZKDI9+TZ&5R+_[?52_M^K^3+[35^^T0,^"Q16$@JDO3AL M]BFEJ3&BO3A*HB0A-*(J"5R\N$[:3(W:;I;:7V,:\JU1^D?O?QF5O9=29S<' MKMM@V;EQHPW!P-2Z9X>!W83?7,L7DT!IUO0[PZZ\?=.NO)UQ5_E-N7W>;Y?& MR]G+ZP7G7GV];AJ-ZO'U MZQW]?/0UMX?^K4:'6W#9[NE7BR9%(WO"U M4XGLU^2@\M,@R#IXJT,@/)(?VQO2;OZN*V*-GK#UP\;SD5WM._">G6]NZU=7 MI6@^:>6+8/Z-EE<*7BW-/NS^IL(L\GED>IT#GR%3KT_ZFN:1"8*,>!AC3J5O MU:ZEM093(_JN)S0[DZNX26USSR][[5;?,W-T?BIT%5_EQ MT,'F:I_N=4L >W:I7;48V8UN"=*IZ]SV0;W&EA<>_$&DYS5?Y[%<,T8BK (H M //U."$:1( )1$"4P(2K"$OL$\>N$LY*3.\4/ ^"3A:K/]?%1)U7RN\%F/^E MEPCSIK&QX\1A\1Z8%"]$G&^-V(LX]WZO[.BSA45K$,<(0F]28PK!Z!8P60:E MVSRI5V[\-%^RI3C,\(",,!)R!42$ H 2* &C$ (<8R2YD!ACOX>\FS.BG7S- MM\^[22H+^LZ[.3,*$IDFY@M)J>CL]!W$'+/ 88$%T7MX;+'T:#3^_ MR&F^9=CDD.W+3EA,HR3@I@0@!4B%IAVW3P&,?/T788AQQ[A=5Q6FMY2Q2%,8 M)AG!D8*&1'I@7G),2:BV=H8@KK8HODF*PMM07%N(VB8J="1#J>:SC\MLGKW> M/;'%HBIJ,(L8"I7 "D1QS $*90AH[',@$J97+0&6D6^5BU7S_,GM>NKF. M7J6D'7'5(=C,2SW@,C#MN$%B3247##_#%&LE?GY8O?RB[\Q)XA_(_ B*'W-F MJ'OF*!/_@D'5O+YT68L(AONY2I6\7;VR1?9:%MU<[_5P4UQB3I($0*G_0)0C MP%0D@1]$+)34]QGWK0,7+@B;VH3>:6:^DUFNO)<6VGO/I?K>CYMG+UM9GCY9 M86X1O- CD@-30*&I5ZI:50(NCI N]<9SA\XA.J%'"$<*2N@"I5L<@B4VC>$' MEYXQ7M2!I34'P0:V][1;-AX&,>S52O@$%YYYHUT6S8Z MC8K=DG$HK JT]2G0@LOU4M^D=/)%$.J*(%^^L67-S[U2R4MY M9_R@,M3\HY:2O"*])%88)0P%0'()34M-A(0BQAIJI$A8MJ[$TP>3FAB]0J"2.WE?5/8UN6??9P*R6*\0*4B". (H8H&I6:(TET8" M4TD0PTX%?EV$3XU#][7=8\$N-')"?2]\O1] MBTU>5.[;*BWV[XX^85_T[#6ER?47R5QVL]1OAUKW6'FN#>(#LN(%!=Z0$NV@ M:>9#RV<,3X;'&GNK 7@SXIY0RGLK MX+K0>K]I\"; 8I4>'L%7Y^[WJW?J5@EEV@K.(LFPH)K2<>)S@$0H >>! #R M4$4D$B1TZR1L*7AJ_/UI8XIU>4_SY?QI\^2M-YJM3?C/O&""S5)C[RWUFV3J MQ"UR+M^U7*NN=O2,K0?)3*Z]2O<^^1VY@]=P% MR5+XR#V1W" Y[9#D>'^+^0ZRT MPU@T$]B " _,7SMPWQ^"NTM_NQD<7(>8]&% 'BD\O2^PW4+5W2%KC%IW>-QX M >SN-A[$LK>XO9U7>RW$:F/BY-FK\<#>;]+4=*%(.)$(1PHDD?(!"@($F P1 M@!$-PY"'2<286\[S>4$NC59:P1-:J#V&SNL3MXX>IV#/!!/:?*U%G6!*-_7J@\FFIV)ZZ MGOIN(C8=*<,*?SL"Z1O3@>ED7]TK;ZMP43Y^3^7^V,4%H%ZYQDKPJ,SC L4Q M#SG=VXZ5JE7NIU5:9/298ETLB9/(]S$0"0D!BC$"U!13(TJ:?F82\\2?+=4# MRY2T8Z%S8JQF2%S,D'UAPTV4O(I7F;V:3*_5]XX*VA4GF@R]9@7&J]MO^NN5+[Q]4&M13I_ M-N1R;]R?&?1)I B-@8B2&" H**!A$ J6<1DE/ $.F79-LB:VA94E>U9[NWN MJ>O]GBOLF'/0!+/]5GD/X(VP.]X2MU;[X1<0Z7T+O$[>Z+O>%PP_M]%]Z986 M>]O?YLLE$POUCBW_*%NWB2".0RXP4(3$)F<)@9@S#!CE, HX#1"BUGO8I\^? M&E%4&GI&18?-TC/(6>PX=\-C:*=@'XHV30#/8.*P4=P-FY$VA.U>%[?MWGK# M&[=US]PVWO9MO6_L86&S63(8EHX O B<^T MHP/UNH>;\+P.[C)Y7>@64>B]&T5X"M\Y#;>?L M=(9O8*HK<;LK^S,-%_0..CYMGV!W51@^RP^/'\S2[8W#@D?;P MN&%2]K=5V)3R&4+Z0Y]P" %BRB2",0%(#!F2/O:IBMR<65O1T_-O/]]RIH=[,4:;&]6/Q==(5:ZN$VIUX!Y9AC'P$6FWBG4$C (AH"))BO M$ \3S(C;R6*CO.D=,>XIYYS_U("K'>=TQVJT'*9/]?!:$TAWT(8GCS9XM>\R58?% M,#VF3J2]38>I.J-K^TO5WM!Y _^D9\N,4QB3*-$.!N,4(!P%@.,P!"*DD(O0 MCP1%K??Q3\1-;[ESN)U_VC(JW]%#Z) \+)8'),$Z#_9. MZ_O'#$,(:40X@$H(_?F, \ "[ /S^UB%88RI<'&U:R5-S=7^>'W[Y>;+7^^\ M'S]_O;O[R?OV\=:[^Z_KVX]NQ%&/K!UK](+7P)2Q+1ICZH'D6FH/6^OIY8KV MZ&9?!*-7MJB7-BI57#3ZF"OKJ/0S#%#(SLP[120&M4]H_OAX>E6_2I=LBHZ-R#:#F?; Z(^TH%V MS^B['6*WA*_QY-KUF>,=5[>T]N",NNTSVK:XS6LW,F%.Q#^PC%5)V8H*04W! M/4DC") ,(> )CP&5 2>_JZSK\E?5RN9 MQ[*I]&4NU/INM9 S0@(1,"1!@ (,D(]"P$(_!M!/M)/!_2B!@>O9;YVPZ3D; M1E=S]O6PF_BE.S?.\D_4#3^M2K\M^BO4\KK6V:=KJ MF_:FK/ZOX^EZ^M119F>M,=5DK+_ ?5/P0^F ?:OB/SZP3,T@YC1*N )1)#E MF"> XL"<,$O!(/>ICWW;W<"S$J8V%RLEJW@4$YUB]+3?_SL/Y.6-O\[P##Q9 MG9%QVNIKM+[U'M_YIXZVN==HU/ZN7O.%[;SNK^D#6Y9EYTR]W-5B+EE9DNZ; M?C&JQ=;79%M6]T[_)L^+6YL6$MK_WQP$FJB0A"PA &L7'2!BXC0AUO^I?71! M Q\+MZ8\?2LX-2KY>OO7ZR\W_^_U_V[OKNYL[[^LG[]OMQ[N/7^[S M?W%S]WL?5+M%PEL.U<"TMF_:E7=@7+[0V#?/+$%VQ<%W%GH[$P>*JQEJ 'I= MS?2NY*AKH*$@/EXY#2:G6TG1^U79J_Q&RU\^S/E"7:_7*EO/0E^%L8P4")0) M%)TX MY]UF/5^J]?K]ZHEKCBN9L$@XR@YZ.^S5:EB_?S0_WBROGTRY]Z])S2U5YO0K MG"41#X@?,4"PC/3JE4: J@@!AK%>U/I"2>GDL8ZD]]0UO[_OP,CCU>O79"S=1_TFC3P@QU^VL<6W M+>_-ULH(,=$@&[8P$:'7W^?KF0A90F6@0.P' 4!(OS0LD!(H'PF!?*42*-UJ M>Y\7-+4O4*ZGMZ=H$='\N]'5N:9W#;9V'X ^$!N8L=N!U:*0=S,2/5?QKA$V M<@GO9I-/ZW=?N+YM[/9[99ZYN%E*]?V_J]<9Y7II#DV\-E$A0 F%@!*#HE!Q M1!0F86(5Y%4K86J$4(8?EUIZN9J>UM,U3/L8R,O'-)WA&7CV.R/3(B*[QOJ. MH=C'3QTY!KO&J-/@Z[H+VU8(7"KM4:1*SK-/3.3^PV=END!_6#VQ^7+F1X3' M9A&KYS8'** AX)3HN4T0"IF*8Z'<&F=?$#BUJ6[TS=<-N<9>I;+I5I'WROZ] M4-O5#;@$NZ4[T".80[L%77%L41;0#IR>RP%>$#IR&4 ["$[+_UG>UW+3?\,7 M<_%K5N:W5A7!7N_UX\KW/Y22AW6_^RV''W]:UA.-G8M[^S;47 M\HE?5':3J:>U_OMK8J28I#8=8L(8"!.5*$E /N:Q=' M(A:Q""+!,70+ '=5P67NC!,6OK7 M5R@(_9V[#,DGF-QT96GE;[R ,S6*%R'HBVI[19LQFURS*IGDW(60=H'5( AX!XI-3 9JA[2A=T MQ:.E%[K:=Y!VZ'QSQZK5UYOL<97JE76Y&I,R\6444T!]R0"B2 *: MZ,^II(G"4&@6%TY+WCI!4R/GO1K,6TU;KGEKL;7U-;LC-KA/V0:L]O6J:Y 8 MIESUL;"WJ59=8W)ML>JZZ]O1PVFOC9ME68&I++UTG67IG&^RG)167[1UYHAO MM= /?<@KLZAUMEUD"8Q)3&4(_! A@+!I-1=A" B-$I\2%,0P<5O@]JO@]):_ MA4U_<2.>GD?-CJ[>;B0&)KE]P_ZM[!RDE\^5<56M.&_?/!/9>VB@5UDXR+IZ M&/![Y=6>51R5C8>!]YC#!Y+2.JZBJ8BXB!$B**( 8U\ I(1V% E5 +)0GL(TW+]GN M9NZ9@([^R[;O'GXMI7[B.D_A^II^2U 12($% %*8 ( M";W8#*/8#]W(Y+R@B=)(J>Q5D42I(?4JA5T)I 9?6^KHCMHXI-$"L!9TT8Q& M1Z*H>?C(%-%LXBDY7+B^9?Q%:M)BLM=O>JBSZZ4TKL^SV>/\HK(9Y1@I'S/ M?"$!"C$%3(4 M7\@-3!*5FE=>KNBVWVN)W)<&Y-R#,"P@Z3?\HDG@N($7%J:?A%S8W--AI^IF MO=XH^6&3FB537C[D-Y.?ER=N%J=MZUF$"8-<1B! /@%(0K,'Q370>D$#D7M:][SKH\#5OWOY]@('W^GQ@&2LWLP+O>W#73?'NJ5]V/3\G:H!QU[#&@,50#^V-Q;]6ROL;LAB;U=7>TB*SZ^WSY7XHMLD<3SK7. MC*]TIUF)/:]2]3F39=5+$HJ("QD#A$0(D!]!$(>0@2C!#$L5;E,OW0Y0APBJWH$=*7S* M!N">@JB<(&J,H+)[TGCA4TZ6'<1.N=W9SH/[JUJJE"WT(O9:/LV7),"7L>9EO>;4;IP,@$PX(5' 4!19=A2TE#@]7ZY4.-^ 80M['[5!7KU2V/_?.$I5>?;Q+,D=U]"P!./;V;&_K+P\Z MK\NAUWZ4Q7X"6 E0$%H,H0(T:S"" SU@I%QMYHG-8*FYMZ5:;E?]"7M"IW4 M 6J[).P.T] +0GN$>LE='JZZ29VP-\]5;JQN[UR>^6LS" M!&(2QA (B:EI12D 9[$$L0^#$ HII6]=?/[@R5.;ZJ5R7J&=_0GX(5S-\[H3 M" -/9$O[G0ZTS]K:^@3[\&FC'5F?-6+_C/K\!>V^P,==R7=]()DB48Q-<(K0 M\Y!)#%@D$-"^/O*E'R44$3>_OD[4]!SZ2E/OQ\5JO?[)>]8?G+51V6-'L:_5 MJ9+YQS*BT>V#78N_W0>[#TP'GN=;,+6.1>#;(/NWEY#H]=M=*VS4;_O[^[$EUM?4+.#KQUX "'2Y,&A IQ 12)4<(1%1&G;=WW:>[+?CXHM-/> M:;?:C.T'EL%/;@Y*#_77[NFR]8/YZ6/N#5XVL\DW[V7O;YM:?ZZ)"(DIX4)" M$. P!"A*$* 198 E@10^YS)&3O$E3<*F-MMOOOSV\9D$:!?&"6Y:[^5 M(^P<'5%G1,9R/:^\7+4!/,T#DX?Q+0L1;^--'IA7ZS\>7M6Z+D]J".&#*OZ^ M67[-'E7ZM6H@5+6C0QA!J&* !?(!\KD"#"," BIIWO!)*>36CLY.L-5;/6I/ MNEQ+3Y21L&Q7OVJ5_T.;UG268V#+"KWA.EIMGUQ1[\=*Y9],[Z("YZW:O3>K M<\.I[\H_-J+'K@/D ,>9JD N=_<7K%)&0+];I>GJ3RWH/=-OF?[]#'/%F$ 2 MQ*$2 &F"TNM:O;@-DX"KP)<,2ZMU;1OA4UO25F'[O%+4$Z6FW8-;:@? ?0>] M3UC'W5O?E?6OH-XJ[[V_!'4O43*7,!L\/IKD$C4V$S<5G],=H^9IL M1F-&(F0J='/" )*4 (X) 202"6)"BI"PKO252YH:5]7,K'*KH8=HO +?]NSD MC-K;4-%%P'JAG0,P!N>80MJ;$\J!T3;L<7A#Q]V53R8(^%')OZY6EU&_!@CRJF?M#H$/! S-9*HE/,>C'8MMUH.@73<O;D.V;H ;2!J6&WE9*K.$CGYPLH],H*=;)&I84+!A_SPJ7+6YSZ%[7:CQYL M_I#7J6(S)*5@,0L C;EV$##'@$8A!S'D :6!),2W;X31+&MJ!%%HYC&MFL,Y M\04\F]F@9Y2&7CKDBEYYI\Q0('?=*W(.9^G](3C2J7DG)-V.QNVP:3P$O_"( M\8Z[[6PY.-BVO*5E;:_RU/QK4I0A_/M;];9ZDF3V;O7;^E*;D3>2N-.I2]SH=:[0!*!9,2A7J?IP=">&0Q"[:-A M I(88QA'(N0".A4#&TK3J9'XW>;IB:6OQK];JLQ+"\,<*X<--JQVON$D!FO@ M;TEIA&=FN%>9X6WM\/BK5UE2A!*5M@P20S0:\/T6.AM,VW$KHPT-^DDIM<$% M=FEY]'FU7AO9)MAWI?73JLCR\[5:%KWR[MGW;RI]Q]9SD><%S9(X)()$ @C& M.4")4(#3B(! AF' &981CMW7=D\F^^LO*R1D=!(U* M2=UY%%H![3:#H6 :V,+U0,B+:>$2!+U)%UH;'HU_X9)J=2J&B\_V<]UJQ4D* M1MXYA KF,3)3FZ0VFAU*P%3&0,YYAG!..>;"CXWAM N?;W__#.! M"?SK[AQ ME+!\6,^>L6QG(^SF?%TS:@-;G.,*1Q4?>,DP'<[_:=,_J%MSULFHWDJ;BJ=. M2.MS?4W.IMB%5KDZFST1">0"$4D20'2. $*8VI\82(5.&6&8Y%KZFI[FKJ9H M@C;5>9&J9/4DZ6Y%U76Z7X_4X--^!]%.R$'H72XA$=@ M'0VLB'H5OG<(%QX MOK\OLBBX96WC]\5.Y[-:BH7:S)5.<4Q)"A)!%4"Y((!K@@&%E$"%N232BZ:Q MHZ^I;4%JHA9?OZ@+Z^\+M"'L[A8$P&T$#Z$.V;T39+U\A M@!'<7VOH;W7.X MH'B3$W'IE7YFXZ?7S6*I-AO3 U\LBS,1T_QF(:L#DF+'I-5ZK62MHL#;99'9 M)N>QD%Q"E0)$S:X'Y1("QC,.,%*)C%62)\JI[FH8<:9F?/:1.V8'(NRHM+O8 M0PR.FU$:#_*![=9.D:BFR2PZTB6J*7.(;#/J1#M]PMFW,+@&-8%7BC2JE0P# MWZDA#=1JSSR>AJ"46I2 )ESR3*: 2ELZ)58:$"C,(%*%$&[3[XT71< =;-_X6 :V+ZU1(]M!J+K7]>K;]HLQ8B]L^7W.F<2(0 U2I(SA2/(,\"P7(-5QFO(D1C!U MVMY=Z&=J%J.JOKR3-2J%C2II?6M5-T-[^9(I$& #VXZ>6/4H4]V)Q)55JIO; M'KE(=:>"YS6JNQ_O:PBJ3./R%LN2C&_9]G4S3S6"2(L8< '-=BQ!&%"L&,CB MC!("D8P3S\KUS1U-U!3LTNKWTD:EN+ZVH 5=5V-P/6;C6 -ON'J8@VXLKK0' M+8V/;!"Z53RW"!>>#[>WV!\_?&#?B[.CC^HK6]BZ+(_ZY\5&L.?_4FP]QT0D M24P1$%G" $(2 :IX B12*&,$&>?"*S&PORA3,RLV)^+Z'8GC,/3?K80']S8[ MF5JNX3?.F<953H%26H/:;34@./KU] M?/\INGO_)OKX\/3;Q_?1X\_1AX^/;WZ[?XH^OOWEWY\\#W,=B; M#J^'IV3W@VGHL^B;T[3[P>%PMAR:NITMQ>MF514?H7G"8TPT(#'- 4JAK=ZB M,I 0FF?,&"*<.]V]G3<]-7-3">=#XWV$5+?-N$[_@>U")5>?\M?'&/APE/?% M8BSR\0N?@R>)>).VW>S@1V^,2/O=).DQGW?C$_T$04PBDN:=1/9!.94\=CNZ'^\WZ#^N57FQMSM0\C9ED"F&0 MY0P#E!G 2&JKP\5(BEQ(KGGN0\U_:-IK?H] RV]S A=5KF&1,>HWP6N8F;VA MQ%EF/+%$QP!1S #-C6/&!(]3*&.BD6<4=C_4QHF[#H<;44S06!) "%:VC"D# M+),8))PF&4P40;GR659Z?FLCK"7A,'-;0?HA,?"R84$X2NZ=V;\^OQ:)/1_L ML;C9_=Z=Y&J_-R9TM=P:^9[M8V^79KB,!0RWTIQ#%71YJ34_ZIIRKM;I0M+P M1+_5X^ZK';O_+OQ_>S:W-/ZHY4&V(>]SC;5*<09!HE((D,QB0"2"@!.,):,4 M"^29'-?5W?2LY8[UWM('U"H8+,THLLT7\V/Y/>]R6/SL0B?R;I8B%)H#VXZZ MF$6FO^+;(H'-B*NB0MIP)L$%DZ!&HK/#4K5SLY M7MAZ^_V]^33N_EQLYDF:"HUS#5*6V_AS;=W3- 5YFE!-:"9AXI10W];!U!R' MNHR1%3+ZW8KI>"+4"F.W;0@!SL#VP!L79R-P2?FNB6_>K4UZ\[?3"=_:^"B3 M_))JNXE]\;DK:7>WH31O5;N5UKS]#?^XQ_N5\=(=\[+/GI_0MUK( M%33WNE7;WM%UQZV-%D[7J$0]?J[Y@9[YTF;/9?_W\/]>%W^PYS*L9'>>:G]Q MMY3'_U![JS^[A2)L^4[*L&49G1RJ'@ M0-E;=#.0"! A(1 \4V8[(0CEJ!K$AZ5COIVD_:BGA0^5;J8[/C4%A MD_>4)EO[XR&7V<\>7S>(;O9X^($9*7^FT,-RR$:5)B4Y;:$+X$4MA[HV]4CW M@T+AS'$07(.:X^LD&M4N$*O]6\'BPD3)#.]S2]:-N9L!N!K) MP:W L^EA91>=/]09E/6_/VZ_J'6T_<*6T?%+H2[8G" +:D&:>QK5C'0J>VI+ MNA_N&:2SV:CMILI"WI^HIY!F6DL)5$X00!0*0"AA0,5)K&,:8X*09W1.4S_3 M"\O99<&S0EQ/XMAF+-T,Q=7X#&PH2OEF>YJ (?AB.S$(&UC3V-.X$35=RIZ% MTG0^/ !)P&_+XK[9WO7+4RIR$BD )=P'(\/ MH%62Z5 !7 ++BP7@8F/]+X0_K%=_+*22/WW_;:/DVZ;#F>8R0O-,*"2Y4 !F M,@,HE@F@.-, )5*@C&F1$N9%L7V--%/;M[744_._,.P_/NX7AJ.@/L*%8;13 MQ!;5_,'J$BV6/S:>1,_:RJ6%O3&\&MG@-X;])1K]QO!J\)IN#*]O])J:ET_L MSP.5^?=WBZ5ZNU5?-W-$4Z181@%44@"4B@QPR)#Y*\22(\(4IOYU+5MZFYJM MK-*B[-U23=SH=RMP5$CL>9;5C;6;70R&X,!V[QKP>A9YO #* (4KK";E>-I5N]\@]'XU)6K MV5U9UF[[O;@NH#'AB4HDR&.:F&4,$T S% -.$I9+HC1*O:YHFKN9\/JUE[/7 M'4P+JIX+5F^LQENIG&'JOT(UHC#,TG3CYJ=[KD*KI5PMBR-! MSI;_>-1:K97\R+;JW=N?'C]6W"]YG&1:9"G C!D'%V(&",H$R#+(!$^,]\N] MZG$Y]3HU0U&(YGEHZH2NX](?&K.A/8)"WF@O<%1)'%F1HQ\*H7\<@'['"Z>P M7H13S^,Z%SY@G/D<7B]?XXJXE3RO\VL\K?9TU"5)]3R%RFS#H27Z2E* >)X MJH0V?\UYFD,2IVY%)8)+-C4[5JWD10"H#''0&6X,?7RED4=F'/>J))OH3VR@%@/X,2%D.X&?E] 4)M=Q9 =]*W[<2>E MF2:;#ZO-ECW_G\7+_4JJN8(X8TP2@'.1 X2-J68DIV9TN4 Q0L:W=#HO[>YF M:G:W*F)1B3J+2F$C(VUDQ?6M^=&(;+N M]=&EWGFEC\ZGKV3.L&QH97#0/)4P26-%@$PM)RMDRLQ_*(TYR*6DL+YU?+HFL3M#:/KUMCKI>6 MBG+.LDSD" H@8,XMVS4$3$IC7A51.48YQH3XA3YZ2N S <8)>@1FDUO(:FD, MHTTAL">'J>\HZ#2&6!$!8)H:FYPQ JA,8I **"F1,>&F<8_\M0''8(STMIWX M@)7R5X,0K0XB1__RSP0FR5_''RLW4S_@" R\#.PDCRK1HU)V>X!0BAW5Y+9Q M585&X=:)GL@%74-\91AU?>D)T.G:T[>9'E5=_N/[ZAO[C\5ZL:PN, A+2!SG M*>#"VKN$(D RC8$D(DX@83$D3LR6C:U/S9,OY(L* 3UJFYQAUFUWKD9B8*M2 M Z%/I9%7]I?:AO_1?C M?;\J>^)IP[5LG,S?%]LO]Z^;[>JK6C_\6?&UVT0E\__RB?TY)R03.L4QT!A# M@#"- <4Z UFF:!9#A$GLZ2_WD&)Z/K.]85B7BGCNIOL, LPE4UQ3LUZHU Z" M\13-L ";H2!SEB0Y]HH[&G@(QBG@,Q;X;O[OP) .O%I5TI?7:COYHV\+6U"^ MTF 6[76(=DK8&[:098%Z0QBX:)"_'".7%.H-U'G!H?Y-71E:V50*%,N8X2Q& M@%-H5AN=I("23()<M5B[>IL:A;M[?O[QU\?HJ>[__W@66>U$U+7 MD]HP0 U^9+N/L1R\DJH+),,$7-Z\:JJ+ZJW!E^$JI-;"K#Z;&?C5U@6Q]!E% MU+!0FN:QPD 0)0!"0@">QM@XI@SB)(]1$GNE9S9U,C43864$5LBB1,HL*MAS M^D1B-R+J9BFNQ6E@"]$'HCX1E*T8A Z8/.]H[/C(5E4;PB';G^UQC-90?GF? M9K2]KQ-C/K#U4LF[I;P38OUZE/>X)WM#"$JF!05Q1FR(MD* 2F,U6,HA5%!2 M+9P*TH47;6IFYJ#),?UHI I="E8I5FIC:4M7^_QC/UJ^ <;8X:2;V?-QG2DX]+1Q];O['40^#L/ M;L/V.-ZI[R!('1T9#]/#E9%M/R^6B\T7)7]9K6095KNO691317.8,[//YQP@ MKG- I& @AQE+P7*Q_UAC\5QO/1. &0 MZ,22W.2 QD2"3/(LAX@2EB=^Q_N!!V"3C M\F]LO;!Y%#9'+IFGDB90P@SDF3'YB*8I("G6(!5$(2Q(EE#N8_Q=.Y[:"K 3 M+C++KV>58&>LW4S0$ @.;(?*:L%[F6=1(754BAV97>L>W8]=Z'K;(E^H@AHD MY\Y'M4J^D)R:)N_W>QPJ_:JV7U;;M?K3-%3%UM TSU6>0Y#35%DSA "+XQQP MG"99G"")M9,9:FE_:M:F+J''[KX!.(?CENO@&-ATU(7K$Z75 (G'J<5UT(QT M]. 'D=^Y03L G9O_AM?&V\&WRWRT#>]XK)]/]6F[$O_XLGHV;VQLG:_M]_>K MK6JZ\,V10BA--2!,Q ALWYP3##@@D.=QP))Y)7F[]SSU.S5GNZ+NY68-@.K"QK,O\KU$I=63% M'OXJWANNH+Z6>^^C.EO>H)QZ6_X-]#1=PFPR7Y^5C;7?O*PV[/F7]>KU9?-V M6047-:??EP$%G\P"ITIO\-G63/_T1:FM/;24'::B$@50FS(QI M:HQ@&F[C6[%V/QB=SV,Y;_=8(1=0VZ@Q[BKT>T& MZFQ=NZ$H_BPP;ZI]W'^^LK4QX\_?2X*9N88D2164P+QA#R48!C2/)4B5%@12 MBC5/72E@6OJ8V@JS$S/:RQF5@KHSO[2AV6WZ V$TM&GVAL>+[>4" +VI7MK: M'8WGY8)B=9*72X_VW;M7-N516XK^GY]7WWQIK;N:F- GNA?3.HE%R8I"TD%8 MKUT@";P/[.APY*W?9=7/=WL.[_2LL[-69G'\F8FBF$\12PPA)H)*#O(4(8!$ MS@$Q*QJ0"4P$5"@EB=OJV5Q7E1=<\084@8Y!ECEMEAQG!KO M5.8@P520G&<8*N87-W36Q_2BA$H1HXV5T;?R^"F CO/Z&E"&GM8E&H5P [!4 MMZH>N/[X:2\C%R!O4?*\ GG;@_U#,S=;ZPZ4V]Y=RBQ?E\I- 7R=SU])15S]Y]UBJ9(Y%D1*R!*@5)( E' " M2)(P0(766/&,XSCIQ41<[V5JOOPINV[U0V2%C1Z7?9F(CX"]?"(5!*Z!;4)O MI/H3$37E>6NLJDRF/,0*:M@Q]S!#AC MW,S[5$&>4"$SKPW\:0=3F_)'0:*]-N]G$+HM_-< ,_#D]L+$>Z5O4SSH"G_6 MR:@K>YN*IRMZZW/])O-[M6TJ!5OZ#4>E8.O5>^%KUZG!&QA^QH.;'H_M1#9,_+*A9(J?,%URVU)%U)! MMB6PPY9^%C&6.F-9*%&OO@?4[-$_KX\+>'][_Y\F2Z@.MFF@)#-K!- MJJ2-]N*.D+'C#E#8&"V'?L<-U7('XBQBR^/5?M9F;\0.Y3#GDLA,(3>U:;7Q?FC^UJJ7;)79813&R5G!,:YU!G'*2: M2$L89798.$8 (R148O9?W(VR);!<4W-0"FFCKSMQHY=*WEG!D2FZ"D@-.GS= M%NF&@S*P%3M2*JII-8M*O8J]<4VS650.X5ZY?9[C+'JXZ1!Z,$S<9BA'8J88 M=TC]F"W" ]_)B!&PN_&8-,)C=,3 ,4#S?8.GFP5Y,C]M[&G;:FE+;GQ@Z^WW MIU7;TU78<()BC*3.@#+^.$ ,8L!SP@'2619G&M+O@'? 0?=;1MQJZ&\W HX<'A\>VO/( M^@'Z"!JWL]\,'N[4]S_D), M[_:K"#?11>9I4=$LP.U6C[%Q,]O#XCVP<;X0VW,X.SIH,V^%6QHX6(426C;V3M$7S=Z];U MH R\_GCAT2-^MDGM*P-GCYH<.6*V29WS4-G&IZX,XGAG(]/>5>&=W^]?UVMC M$>:4)Y*GG "4HQP@@13@"-JX6&T4S"1A"OF<&'=W-[7)?-B!/A=1F:(4LQX% MVS/,HQEMMSU_. P'GOL'^ I)9]%>UEE423M ($@G*L/$A#1W>9OPD$[U6R-% MNM\*>W75%#C);'28$@3 -#5V1L8QH()H@!,BI42*$#\[X]'WU(S._>.[=W<_ M/7Z\>WK[MX?H[I>/#P^_/KQ_\HQ6]0'_NANB:4>OMM_E#![%V@.P46YN;A[5 MV@,8UWN7 +;GPR5 M)GA>V^*CL3<_K];?V%K.$\HD%!*#A%K6 RY20..4@H3E*"6"TT0YE8+OV?_4 M_)66G+7&@B^_6SVB2A%/AA3?87*S+ ."/[#9&0#W "F#3N@-G#?8+<.-DP>= M +J<0>C63/^" C\;1XH]_Y=BZY_-OVSF' N12)(!Q@0&B$D..$EBH#+"DEQ" M#F/O@@(G?4S-L.T9\TLY(RMH5$CJ7U'@%,[+I[H!0!K8 /7 IU=)@18$KBXI M<-KNZ"4%6A1K*BG0]F@_CV=WW_.TNA/&=JS53Z^;Q5)M-FKSR[I(XV.F#/!$9R!62I(DB147:+Y4G]E6R2=W3^=2OTX?-RT_[K/>!PX(>V$+ M&>G5.F)6]$U1SL5S^W,1]IR*/(FE/6U7$J!4&2.;)1"D$ LN\IA0O[IC0? > MT>)6\MH87%8*'/%*XNCU9;6,[-Y^L?P<&'8W3S$DF -;YIVH%LA*V.@@[2PJ MY WG!;HB$]3MN]CIJ'Z>*P2GCIWS>ST)(;XPTZ1Q&*6]+53+31D]H],<*H8$ M8%0:.Y-E E"&$5 DPSE!V/P.^\7]-G?D,R7&B>TMY 3<"AJ)FJ2>5!#-L+K9 MD>NA&MAZU#':6>2C0*/W9D[8)=&F."TW 5AZW: )2_70W-6X[ Z=ZIX1.G0_ M?3US[YO55[98SM,\48HP#A3-S$Z/:@X89,8!-&9"2FWV@]BZFY'2=, MM:605_#W5D"ZF8/KX!G8%'@B*LD8%D3$@"H= R0IM_R],1#"_(AP;+X/[;7?Z.AL M:I-^+UPONNY.6!WW$X' &OR8V1$G_VV# P!AMPQ='8Z[77!0_6RKX/).ST@= MX\W=+:7]CSU+_H,]VSW)W?:>K=??S7[[;^SY5,L_L;KY9ZAR=LO:MUQ0#*G M*J<*:@WR/$XMB84]K^8<2)JA1,=*<^)%9W&IPZFY,(6\4?=AGV=\\B7(W:Q1 M2" '-D178>@?I.P(3-@PY4N=CANH[ C!6:BRZWL]P_Q6R\]FSGY]H_CVR311 M[>$)@@1*A@ 7,@=(&9^'89(!F*=QD0&1,*\;F>9NIF98K)3 BAE9.6>1E;3G MN4@+KFYVY'JT!K8>_8#RCP'LQ"%L'&!S5^/& G:J>Q8/V/UT#\* ,I[&N#>V M24="CO87)_2Y5M%@UN^V$KJ0:;BBXY&>?35*(Z5:]T#++V&Z$XC.Y.?F-\=+ M9.Z4_"@IN?M)O\FY66_GCUHOA%GV%\_2;#,JBC.>JXRF*@8X4Q"@3 JS7C-[ M1D$H%#PUNP2G[*&V#J:V/O]=;:-W9?J#/9@K,OX+L:-/]@VWR=R*9K>A"X'1 MT#Y]B<5.OH"L;9>4[UJ*S;NU9=C\[70);FU\E'E]2;7=K+[XG'_,:17&?XAQ M>S#F@FW5W!87S-)$ I(F%""(8D!E;';Y4B*F=)[$VNE^HJN3JL:>70.@=?-K:\&C1IY=4JX>?7GQV:*K" M^]72_,.K^;?JEZOE9FZVY"E#F0(:*QN+'L>6D(L#K80D7!"H$YMAR7,H]LKM'O*.<+UR8-U.!<8;KH'-6 _^PUETT"EZ MO#Q* W(A=H%[(U[$1I$FRI'8!5]_OL3.5OL9ZUKHGR61>K]:LD:>VTVU?4@Q M420Q^[ TA68+EJ@$$*P+NO&,:*8HS9G/D:EG_U/SY^KB%SLUHP"H:5#GH=[T M/&3U'2(W.SL@\$/[AZVD#W8 ZG\OKW^V7]CRA/4[_"%N3SB#FE)?&4:UG3T! M.C66?9OI2P^Q5(_Z?JWD8OLS$P5]COVWMUOU=3/GN_*$3VO4SJ!-OQ3BD4A$-? M+5V#7@^6"0=4 A-.=/4X,O>$@_+G-!0N+_4S*O:L_.URLUT7UQSOS5>RB\VW MV=8D@4"@V'A4,4? .%0QD-IL?%F*A4QC'WO2UM'43$EQ_W(0=!9947LZ2ZW@ MNMF/$) -;#IZHN5M-"Y!$=1>M'8VJJFXI/*IE;CX?(_KZ7,RB.J8[L#F=Z#( MF:<"8A93:S(8!$C9=!XE, M)+;8#<&JV 3T9K?J,2C=IF98H F/R,!6P1T,_Z3A1IW#)@L?=S%NDG"C>F?)PII%D9O*J- ,)MO1/<8X!X;$&"L92,0YSH9%?[L]Y)]/S%CZL54'[ MKKH!IX9I/D;^N)OQH^(;U6R,@V]^ MLN]E_+?**S9K_X?U:FE^%.7QZ8?5\T)\+_\\T$5#I97 + $JA12@G&A 5:Z! M%FF&5*Q2HKQBXGT%F-I"_U&)@B)CKT/TR^M"LJ5K(%[O@7"]+A\.WL$OR+_5 M83T6?A:5@D>_5_\=A,2[+WJ!;\ ]A1CYSKL?1.>WW#W;"42"9[HT6Z#M]P_F M&]S>+:4-77ZQC\RA3%*2H100$N< )0D'-)4,\!PQ)3FDL,R)-_09BI0E^YW-EGNIY"Y\)+43^DJ"MO:1<#-Y@=&]'6G;3FYCZZSDLP+E MAXLH7\_@=A&P8;GM87[VIB0M_P3LRH+N<@M<)= GZ.7=V M..HW[:+ZZ8?M](Y_%F!5J+0*9T1"29RF&' I(4 \MF2%@@+,&4N5@@(SIRBK MLY:G=M+@57_Y'*?N*7^5]@//[TJNP)E\C=I>G<)WW.IHN7N-RM23]IH?\)][ M'VTL9<%S!Q$F.N<29-)REK,4F0VRDB"EC"0B1GF"N>N\V[[K%IOMPJ;7_:J8+:A6WMX%X@!LU/OJJ7=H<;1I=Z9$?Q:?\YIZHU6="U%MSK_,W(3F M8M!XF0Y5AZHG=[-"]Z\5]M'_5%MU/H/\^5I M#D4&90Q2G9A)2Q4"S')3P)1CQ;3".1=^!S"7.YW>68P1-?JZD[4XQ?RV6O_# MUBM[6:^$ZJA&T1=WMQD?%LN!#<%>V%ED\=S+.XML)NE*1SN90Q9X<\4G<$VW MB]V.7,;-%8;SRFW.;_;,%5ALJL1M)?V8B!!HZ-U-W@P$9V!X>C<5>WEE4RAK]8-7ZL>0V:'N4%\KMWC#J!Y1D.$;.S2;VQF-@R^8.A7\:>I/*89/,CWH8 M-X6\2;FS!/'&AX(R&?V\6+*E.&+FV%^\*:9$%A,("-4)0$BG@%-+;Q83%<<\ MBW5,_#:$_D),;X-8\.#HY]6WBHQ([X2OT13])0@94=?8N%F-8?$>V+1<(!W: M*U$C'1KD(K4_B&.0"W6),05"(0>8'$F$7%KJ9QM_6:WDM\7S\QQG3&=$Y("G M!3UK1@&)8V)&@YD=)T=:2:^MY:[AJ3DP.[G\S-0>)C?CTT?Y@4W*1;V]C<.I MDD&G_+[Q42?RJ4JGT_/L]_TFG9G.BZUZM_C#SNVM&:4%?U9ENH@Q /,<0C.& MN2WG;:^01$)L[3<&,H1)2K#&<:;]G(_N#J?G:!R$K)*X9M%2>08L7P#9;2*' M V[@Z5T*"@I)HQI\NYRO]QWP><]\-U2"VH,+78YJ)=S4/[4=CF_UO'RVY574 M(3O<)HWO;M"^_\JVKVOSWR+M])"9%#.%*18IH)HC@)(T 321"&22"D@30A+J MQ0'80X:I.0>?Q!=Q/;G0I?(Y8XWV.@X7H8/B_G0E^:%]+,:B6JA MP&R/]/?981C*G/1A$LBN@#'LA7P/.<:]N.\/U-D%_Q5-]3.2ORZ6*]NH,;_* M?,;;>9+$&*>* \828?8\4 >HQRD2 JB$"<4.96D:.M@:N;-UH1?+;>FOV<[ MV1:5F)[6[ Q&-U-U#3@#VZ%/6_-Q?5D]FT]I\Z]155+F;KM=+_CKMK ZVU5T M MY.C7!&J V@H!;FK)-1S4>;BJ>VH?6YOA0WA_$M1W>.>8*XS"6 @F%;51L! M@E4*XECRHG)%1I%/A-YY%UZ3?[1 O\^2T/MDS[W+O9*PVFZ+ZK5ZM M[0739BZ4BA.-8I!B939!*H6 XIP"(82"RK@%N9\+T-[5Y)P!&XZV=[R?C;B1 MJ,OKF8#9#K&;70@#W,#VH;91L7C=.^'EGXAY$8JPN9CMW8V;CGE1[;.,S,MO M]#,8]ZNO7U?+P@Y]L@OFYNUF\ZKD/($)S%!,08YB8RTX2X#Y9#1 $!*18,$3 MZIFHW=+3](YD2T&CC95T5KH1FVA1"!O]L%A6__*CG]5HP]G-9 3 ;F![48'V MJ02M%'(6E6*&LQ<7< AJ+-KZ&M527%#XU$Q<>KQO6D$]ZJRIIHMYXOG5%M_[ ML%K;?Z@[DD^KX_WD?C/-$R8AH3& 4 B !$T!-58'$(@2RA**F?3:F PCYM0V M-PW1I(TUF/91^$_LSR(&M=0\JE1WW?3/HF(WY9L/,<@'0W"LH,0Q$#K);.Z* M!CPU[ 0^F)&\WT7UT3P?/IH Y=4&&F:W)?'V@S?PBCKR M1 ^9I#/DR 1.[!E$U)&3@8:$^SR!:-#>>M0?N&?/L$C++=9PQLV>) M!04H01QP3!40A.>)0 2*W*DF24/;4[/L.^D\Z@*<@-5M:J^$8.@=1R7891:. MR]_,2A0%,8H/>"@XCCJYX4?A5\N@6=_.8@4GKXQ7C:!9UJ-R RV/]"@2OMA^ MOULK=K^2:JXQHR+-,R"R& *42PE(PB&@@J4\H3+7.70N#%YK>'(&I[@D,,)% M5CJ/\M]UL+IMSC40#&UPW+3W*^S=H&K_8M[UQL8KX-V@PE'1[J;?!V.0^ZC$ MZO-R\=]*OI7&N"[T@NV#S2J.2WFWE+6 )O,[8X=EQ6E7/EDQZS_\^:*6&V6> MK]&:STDB(<&* )JG9MN9Q[;*64H 3B 2E/)4)JG/MO,F6DS-E.QJ&:A26,^= MYVT^!+>-Z>2'=V SV41^.(L.$$1U#*JHW1W#<%G;HH9#5 &Q)P'=A_GN/J * MCN+%>O&'03D6QQO0HZ989TI2D*=I#A"F9J^:2?,'YSE7,%%0>-[N#R'F]$(#:EK:H_3U M3D^;L^5\R6+?M,\+F_;\4DM[/L0H]4XR'^1K<3-NM_X"!K:2)T._5["X?3F^ MJS&_[DAI/T16#9S2/N2 A&7H&$+0<8D^!H3ZC"]DR+[\#T(?C(7;?K^3E;8!>/C<- -/ 1K070EX'JAL%Q2KG[A> M>K1G@3++C*ID<>_[B3VK1WV:W#O7"'*$: 9PG*< $9X!KD@&W_?3Z\O)LO9VE_%6M[>23BXWZ;6D:OK>S]/.R M*.:7:RU5G*: $6JL%]?06*], I6B!.(LU4AYW?-<)4]1HU?N\:MO5.FN/"HJ1.]6GVBFD*SZ)?UJH/*O%_9M&OA M#5]O4[->/ZT6J]7W\S.>Q,97]!T4K@JHI"U MOZO7#KJ_MQ<$RE$=OA\.(ALP?XP*J2VL]]VP7N7V781I,,^OO>>;.7\7P>CR M_RZ_?&4)%-OHVZWZNIG'QL20C'' E"UY0G(!",LT2!2."18JY]S+!)UW,35[ MLYO)7-P#I9E:N@V=@&^*)3/\")6?*#U.0Y-#-;0J0G*G96G#D M_,F>;D=E-GY>K8T->;7>S<;L)&N9CW,&59)+S &/;<9RSB@@Q.*8BBSG3$HA MU;Q>G-ZY@GM[IT[?."V_\7K7PWWJ!T$+9Z-*:BZR0CU]CLN(.SH<85 W-RER?QF&MN+V#F_V2#,J&BC3J=^\KFUZ MD]EKK>2G+^I9?U2?%_8BS1[UGAYRK8P ZY>5^:7ZI(2E>K,% !,9YP*E#%"( MBFT1-SY)C(%6*5$,J91JIXR!\*)-S9@1*8!L&Z,_\I;(_CI4\-@M11]M4P/81BRMO' M.^%8T#PG$LB88^,_VHN )"8 933G@LL.3EL(&1,HX23$4']!6U^N__^EL MO?[TKS_^^,Y]_['S4^O M/KJ:[OH@/9;_^#_^^NI=.L./ :;SU3K,4WW!:OJOJ\TW7RU26&]D_DVZ?GCP M$_5OOKSU2M)FQ.4L MS/.GL[#\&/Z<%A]_K!_\\<6"8/$F?*AD;QZS_OH)__U/J^G'3[.K[YTML?S[ MG]*GZ1>H^F7RXN7_[?J7?[RFX],25P2=#=^OZ!O;9]2W'4<3?EGC/.,%SY=O MFRW2K0_-JL07R\O?G(6(L\UW)QFGD\V3G\75>AG2>H*2I6A00'0E@+)6@%?1 M@DE9!Z4#XT+=%D$E?T7T;Q2TPO3G#XO//]*#25&"_T/5+^'BRXU\[KWR0DZ' MT7ZY)M_39R=>%L5S#L L,E#>>8B)%<@N::]3*,7)HTF_^<;;E-_4\;-E^F&Q MS+@DPW+YRK!,]_1]&]3;3_SX*2SI09#.IK-\^=O5P@RAL_5B .E=J(;(_=,/ MQ'7!Y1+SJPO-/,C M%<2!4'#[S7LAP?2. MA".DV04:7E+XOR13MA'\.Y(_OEBOEFN?@\ MG2>3-8K4. ML_\U_;1QM!6WEJ(Q@KB/Q 6SM#M&%B%RHW1$@=P-O+O<>O]^$.GXC'0@T8X, MD&K]GBTQ7- =E7&5T*Q,!)45B2(9"N"-D-%X7J([/LZ]^<;]0-#QB>C!XAM9 M[?4F?O;F;#&_/+\3JGCG= %FK"6*DP5G2!0%72H8I-+7&_K!JK_[UOW4W_$Q MZ%%B'!D"[S"=+PF^7,3WT_4,)U$EKKC8W.Q0S,2<(N\')=!^1DZ1$U:DXR_1 M[[YU/PAT?/YYE!A'AL#[9:@Y3^^^?HR+V02YH<#(6,B9Q*!2#N SN37&AR12 MSBGQ#P<=GU0>+* M 84D'H?!0(I!%')U#$M#G5'NIF _>'1_3CF >+N R!1,+(D3#E0F#79+MHF"_/*SN#RP'$&\7,*G) F2B*B[V5%!LEJXU@06N%U@Y-T9SF:7U">G)0NQ *I$#I+Q'"+C 8K6 MC@GTQ@H.]^B.CX;/)(478!!"+\8TT26J2_OSLCN:U>GZ]K75&-NB?% M65:\BT1^O>1GJE[C*@TI:&NX-Z98-A P'J-C/Z!T?(HYL*@[2?W^9;I*8?8_ M,2Q_H>^L)B9;1W0FL)$1]C?IB$9G8#80]I-%J>W1:'G@Y?M!I.-3SB&$VA4N M+BH;+I@0+FM!GA-D+RB@*J& ]ZX +]QX4:R*8KCBH7NOWP\;'1^"#B/8D='Q MC#C(&RYFX<,D*^0NT1:94R;"7='@$W/ LQ0A<2V5.1X1MUZY'PHZ/@(]7(!] M.!I$^3+,7LXS?OE/_#J)*))*20-%59$\)8L0(X^TZR&ZY!RWX?C=8N>K]T-" M_Z>=1PAT[)R(BR.WZ[WNL@!.J2"",Q&DTR01#!XBQ=F00\E6>^U$.3X2>>CM M^]44=GR\.8A8!X/&O_UX3XZOZ!O'-Q @P,]7F.F+U6(VS;5?Q/,PJZT0*!3# M]>HV)_MV%OCF4P=N.? T+H[L17"^@@\A?)IL$NWJ'O*Z_#*=T\NFY$\L+BH- MK^"7= C"*@[S M(('Q;4^)__84Z@XU.Y?O>+9:D7"OEQKGMC#D$- (H&62P3EG0,OH,D_.VD>O MY _G]38=XW0[:(:*2Z,T@- /-D=D4./BR+WJ-OU;\WK%AC6"T[8JP>9-SYC, MP9$?#L(@_<_IE%ALB)T[Y(P+H6,TO!,LQPB["\R\"*NS9_-<__/S/\ZGG\., MV%D]6[\(R^77Z?S#;V%VCI/H=6%:.9 E(.W,4M)6'P1(R7C0$KW.CWG!AV-H M+_)ZP-110%BTUDD74'N64JWO7+W%A,14G.&ON+Z\UK;!.\V5!!3.@4I,@?=& M@5'96A=3SOA8RO$15NH1JL;IZ-(.6(-IH L\O9Q_)KH7RZ_$Q$3;&)@Q%GP6 M!I1T9,JEI6 D,R6+M1(?35D_'#\WJ1BGW4L[O!PLX2[P\7I]1M'J3:%,C!#1 M9T1PAOY0F@5P/A5R%LEMS"J&$!_+.#@<)?=I&:<'3#NL'"GM+A!SFWRE@U0N M.^!6>E",(WB#'BPR7BR6PM5CUXH#.<[C=(AIN <=+./#CWP6ZS ;>,M9S-.6 MA9!4S#$Z<-%1$.$C[9LR,M HBE,A2\<>JY@98N>Y(J8'AV60Z.I808]XGQ1-].B12S5Q8H\\9JO1[*)M*VBC[%(09+1 MI@EH'J.J!_=E$/0,)OHN=J5?IO/I&E]-/V-^2?J8?YB2XWXAKS2;"",V<\ MZ$SR4")+"%ZE6J66HR\B,-7F8/"2@AYNO5Z(I112">(#D=03%HP!G M-8<2OK:G9 BA5 21"V(GZ!CL<6J5-I<4SQ.U[C;82-(#:B*7H*V^Y*: M,.\2;KI5V4"V6_D(T2H*+(2U(5EAC6T4^.\F:-QSZ590&D#X79BG'3RD&**E M^ ,LMZ+&(!&\IA5AA38Z*W(U0YMTU0.QT^P8NA%VCA1Y#V'?8O[A/2X_OIK. M\75Y001,UQ.!.6DK"B0;J\_("H0@-7"M8E$4UB)OY&WOH*:;_:NAGWVL$KJP M/P_LR3=.QIASN7"90$4LH$HM0D-BJ1B-G D1)&MS0_9-TKK9V=J!;%CUC.@U MU6J<[:Z]73>OXVSZ8:.MU<]?TNR\5LAO[?&;VMIK,9\P9IB6DN(,6D2@K%+@ M=$%PRB15*/B(_DXSK/M%/X>\N)MM;WA@-==#%U;MA@@G)AN1G9*@(U>U,YPD M*=6CX2)TRBB3#6UR6V\0,>Y=[:F/G9XD\@[3N/YNIZSO5_4O9WX)2KHB1\V?0QQ=1WY",^2$]R#B8I" M%0&9;C'41%6]S]CDL'^->)Y\$PR,JOHM-^!&QLLR]=-:#$+4:0I0" MOK@ SO%DE=!,-ZHW.?("LF%U[GA8^29L#U);%Q"\T8WKHNRO.!E,8.3$)@J4 ME*$@/:"S$(4-J(U,SK4YG+U+26]P.TS'.W;M@\7=!6#>XCI,YYA_#LLY+:S5 MLY3./Y[/:N.&G[!,TW0]0<$L2YF!"3F#4D76E-4,*6'V:&S.HLWQ[+=I&SN) MH@FH!E9)%S"[+ZI)X=[EK!DY&8:6"J^#.)V*8+G.2.+C5K-(',74IZ MLSNC^4Y'J>B?)E:="">0A)4(/W4"I+ *@I >M$4=G*>?/#H#:>P8M3?[UU$H MT!P.'=C9;QT.3")C3GMI(:B00$GK:J*HM53&)"S3(LI M%16X9$4UQ21Q"T13 2<&Y%<1.;'>1]@!18\KH$ULO5ZMS8B19$1C%ZB"Q M5FRY+&E]A A([JYWDI@T;:HD'R!H[.#AU)@Z0 U]XNGFH ZMBT9.]E8[F4&A MD.!SO6QVN=A@-%G@$QFKITY(:9:5='ID':J0 >%U2K_^2L"K1=FF_=%/!_/I M'WA\>W]^'[X&\N5?SHD4O'KA]1F(4DD+6P@]FT@PU(;YG#8[JZ-WBEF?6S69 MVDG0\;=4GW%^CK_0(JVI,?61OT_79R_.5VMZW?(JC:\6-=._^7WX,DDI"AZ* M %G;4JK(!)!I9L"23(8YA\4]-ECTF&NK)Q,[KK<_!(KN7V*UU5@G6^IJDZ[U M\Y=/U0I<%^8K$[R4R1$TA*M5.1:")&=32)ER]6\SRQ!?%)04HH'R]36%*D9-9.^U*X34W!E-JU$C[ M09K&-57#:'T'E 900!=@>H>;JPCBXZ]A^7>L6:1;64UX$C)J+L"70B+*.D#( M6I)+Z7E(3AJ>VU3^/DS3N&:I"9@&4D 78'I+^B 2:G?YGV@_GRTV71$OV?$I M8#2>@=YX'J=KW&JI)L@:4!%= .NND"99*>:%"&!$O:N2M2B'!P.:E@H*E7@I;:J$ M[U(R;G%4,X?\8&%WD%!S5<1\$?B^6JQ6$\-B0B4L1-Q$$EE#2"R!Q83%,6E< M:=3<\CXQX]8B-8',L2+O #6UB?UJ4P)XP<-5.EF4V90@'7A5TX=8#.!8CL"\ MUJFF[CILDXSQ$$7C^M@M3I,&D7T7&]4EY9VZ#F<,E_72H^ NHS/%#O6,:""J7IO+RF'XZ/R<3>GUI M]1S+8HD7GWL?ON#JYR\D-U+6=!Z67U^2,%3%/3G8V0#G6F:>77:R54BS/Y7C5I>T1^J .NJ@E._-Q&,YK:-\WE-PU[8\=\3=@Z4;P>6B1!]#?R] M3*\J1H=2& 1O;!W,Y,!Y,L(A)L]]=H+9-OES3R9UOW0,]CT!K:VZNO 4;[$X M\9*'G%2&Q#B1[WT"+VEA6>="2D$RJ=MD*MXB8S\D?5=)B(>+N0.K==G^XPTN M-^GAUSGGB%SDDNN$KT!^(1<0+#= ?S.>N]J>LLV)WD,4[8><[RJ[ M_*W@A'A\'E;3M&%T4BUI2#*!4'5OUUQ#U+F E^3<)'3E44-Y&0B)'16,E=Z&DPG1;M R!RP;1S&/=T">I01FD3OCLQ"R30^,G>2,>P/; M!%_'B_W[V6]_FL[.:Z789GEPK;1#%R'Y3$*S:&O@(D$44^@?B=Z,=;Y[A]1Q M[W#'VW,/5E<'UNR)9OL6J](8EX11U5S3XD/N(3*/($7.4L081=8][+M/QFBS M2]H>=MZ#5=@!6N_*;\O+1"KTWI*K*XN2]2RZ@-/D0MB8;:0M@#%WFMUW2]"X MM[ GV7\/$7T7._#O6(>C8WY&#PT?\-=-]?;K98E*.:A(#D6)%<#C@5: MT"HB1A:9;=1J[TEDCGOXTA8S!P+TZ>KK&9TW?8C;?4ER5+Q>M<202)0,"P29 M'<@4%$_&*U1M#I^?2.BX!S ]('00%?X3M)9Y$59GO\P6?[3I+'/]]-,VEGF MJ^%[1%Z]Z JK%%"0';/5QC':[F4J$ 5FD#Z0=>/5U6SC+CU&U0 WLO69;Y:+ MSU.2W_.O?R/AOYQ?E94\2^OIYXLNK%C9(FW^RH9U2XCP*)#A;&L_R_SR^*4%?O%V^1.$K3&=Y*8GN_>*I:K!G:8;)=/7 M,]QH>YYO-AB9*)/ZS..C:-%8 MH5W ]#)EI9[8?*QEC!=\"&0A9BTN6G(I[BP$M))"W,AKE82TILUQZ6YZQO6A MNX/B $KK GP_?TE(L@M?MJ6SU8G:S=L.24ZRCMD[R8&653T/)B_)6V1@=&$Q M%Y8":W.>=Q39X_K'W4'Y=! 8M8"FGM#7:&&)Q-9/>/'?E_,JZ7?G1,FO[X>*[6SWQMD,EYA\V_; F(2:KZ=W DZ9-Q],? MQ*$#1+0Y:5>0M3F#>XRJ<9/IND'KX KLPFNXO_RNY/8B?)JNP^PZPR<0/]Y' M,-$'4 +)&7).@K6)TY*S*=HV?IY_K MF>!$<59D% %L4K&F+4KP(43RZ;,WQD@3V^4N?Y.ZT>=]-,'&-R%XI)JZ*-V^ MSU7M'3BG7ZJ.-,K">76D0ZK#A\DI 7)(!"1:K47[P*TK)T+=#;)&G_XQ#MP. M54RG.'N]/L/E]7YQT4A99ULD"0>8L774M*+(C1<-*65D4M36+6UR O:C;_1. MH>,@[VA5=1ED;P*S]15;-R933ZRQP65"28[UR"S4W@J)Q[J\*':.Z&VY4S6^ M?V#]\&M'[RG:$EV-M="I)[=9.?4Z]X+-F]P%(;R+OK:'5K7,H!!W007(.2 % M6ER8NQAK:^IV4CEZC] 1#=[Q:NO@$G[_2]Y=:0H3CN3-&JX@%%% ::QS65@$ M+H,IADN9&O7J/H[N<6%[XHOU$ZJX@SY">[*Z.\=LHI7QREH#PECRFXNU=8 V MV0J,5C#.?!%MPNBCR![W,.C$<#Z=@K\K\US[IQ([B<1I X)*V4!04D! C\%Y M]$RV20K9G\9Q>^%V:W:?I+H.3.P#G%T,E=@M2).$%_44(D1/RXZ1J^ZR9\0F MTS86Y(RW&;C^=%K'/3TZ=?'(4$KK(KYZ$[YN[R2>I7^<3Y=(W-)R6W]],POS M=9W!0]_=3!.@6N+>\9EPY-'99?#(87NX6 MG[1171=GF_=XNQZ_LYHX\JV+MQ&R0T>V/W+PLE@P.FFODA 4-IX&B#>HZK+X MY&30.U0]_:1>W&/I^?EJ.J^3YU=_6=8"KVRY]2YGT'ES#Y4#Q.(S%%[[6<>< MG&T3MW^+LB[K0$Z&O&/4U#'Z[L_#-$84[C1H2SZ,$J9>3SE:6C&Q4+(,S#?J M6/\MTKHLN3BAY3M"45WLM?M+<**%]4:Z )FB+U#%(0E-)$ O&)84A-1MIN/N M3V.7YY2MT-A(=?T&S%<9=3L$R8JR*6* X&LG64T+KW;VAR PN33 M:1UWRSYUP#R4TOH(F)>+A)@W9:AO\=-V.ZA)R.2%D$")ICJ9S.2859'DA3#R M0E2@1>VS@9)B,B*Z'$H;0[D7>5V&R8.AY'Z/AH$5UL$A]TU&?EVL<45^R29; M+M6:9<,*)(L2E",+'[DND&5&ER,O!=NXB0]1U&598W63;0:4G,3K4?#29I#$MVGK,LYNC,RA5-4%_/87X43K6BID$I@8 JBH M.#@K&$3'E4L^^=QNO-R>-'89:+>"8R/5=1!H5[;J_^MET>4M+Z&=R<6K_<1MMPCJ,J+8) M5UH@Q)00BE61H64#D*VA,4Z/#IVN >,.^O[^\+T$Q1\)*9_GM_TS4?I(+XHE??UU]L<#=$] M_.K))^P=#.TRZOE 47:$%S)FRM MTI16M[$/>Y%W=!^PRY>\WYP,LASKE; EJR]KOBR+X*V58'C0Q:0@/;;)JKM- M1S?]OP?"Q;U&7H=+O8/C_BOJ+R12FS4MYM74/OLR74U0NVBBTI"S4G6$IB:' M.)/. UH*1+UOE0_W*%F=(.H ?3\$G:.%WP&2[O#PT^)CF,XII+),\F2 52]! M>4%. Y*@BM&6_@V%I3;7E3O)Z00YQZO[;@>VHV7? 8!NG,#^%:N+,5%%BVQ] M!HVU?--(!,>L!2:R)$]0::O;[&#W2!EYXO?QZKWKA1\EZR[2)=[BFJ2 ^7)V MX)8/'Z6TB52:?.4C)0DQ& -""G2N-M].;:Y9=M,S\C#NP8$S@-2[0,_NKNU; M;K26G!5F008D4RR*@*B%!LUC\$D%F;%1]=XC5(T\=GMP) VF@2[P=+6W4^2, M+^G+U40R[5F]KLDZD7!4;:'FI )9F2A!1\R-G>;;JYT[LOJH($Z,4OA+2>.:WVI0E9[^>A"0$),AL2+HDT? MV&'H[ZT/8CL$CZ#OOK#^^NIV!C%#379@1OP (N;WO&C2>'*I#Z;$7I%YGZ^Y8D1-6BM Y(YC :.VY M>H7G&?G\+"9!SA&7OJ%[\"AMO?5E;(S$X?3416[U8SQMEMB$:Q-,[:M+*RB" MRN2:NR3)234HH'2CW#K;)1\\.5%0N>HF0>&*5EP(QQ]H^ MCX3"-!>%M:G?//IU\L/8;X=RT4_IDAKNEJ4-S?>_.UURG#%R-Y;[[\:MY9F%U=]-P85<5+RIEE$!P]*&L*^&P2 MF=&DLR_),=4FQ6P0\H^UPT<14?LRSQ:K\R6^)Y4^G]7B5YY$2%EDH*V(]B(A M'<3@%!1GN3&&*:W;=(<=FI-Q[XQ.C^V[%GM49 SF#8]FMS?C/FLU&PTH6)08 AK>YCBE"WO^*_ZQ'557/:OE M8DY?IHM77 R@O?CS>E4RQ@(3Q@&FY$ Y)(]*TE\EXY@4)U'&-@>?3Z7TG\$> M/P6;]RO]&VJV@].'O]4V&C^OUM./)+;51&D3M+89HBX"E(^*?'YG@"G%#;T^ MNM@F$?/>NX^/NB.TTD=B)7ZHPGB+GVJ468/-74N%UH:PQ3# D.H0>6,I MQI449=HB4LS&\-CH"'X?\L:]-1\?@\/K<$!HCN9@WOS$3S6M?M;(U]SUHA.[ MG=_DM2L/-!?KN(D&LJD=;1D6<"%Z2!DQ".6TDFTR81!L\=[K-EOX@2?\,/N53T';/IQQ$5[T'ZY?% M1O5.[@TN-_6]! MR)@4_9-\HQ8'#U%T=%WQG>=>.PQ"B9B]M5!LR:!,S8O&A)"8Y-(9&61H)UN'!482A&#@;)2@-&/."BU2:%3R=QC!G=JKI^#I7JQY M5]C];LB CS ML<HI 4BC"RY*Y_"8J=C^Z4XOR%(5>6I0!9-?%">K+ M.2TPK&NJ#JK8-5;\H$R>8EG(D<+*Y+0 )3."RYP!#SH*"F@IK&T3:+3A9QS@ M#H&Q^[7+8ZN[@\NHVU+8/7_\5UR_+N_#EXF4*>I=2@Q]"O#0:HC$,K-2BY(+% M\C;#;9Y,ZC@5E@W@U59)7103W6)Q@HHI31$V%$UR4KPPB)EY$%PXP[FO[;S: M8VRT4!LY_(3SQKEL;HXL9()V$(45 M9>[<\CT0'.YX^,CM\ 8/#X^57Q*^)Y$Y8CAW-"86IU)/!_[13N:V)[3W M.'R6__?Y:EWOMR>6):V<%,!B34?B9*F#5;1LG3 \QY"LB*=#X;<)'C%Z.PD> M!U99K\A\71YB=%)$)#*8A61R'8-=YVXGBE-B3$87F9A7;>;I/)'0$8/"$UG& M050TV'RGT]_QU$NM\S ;^*KG\JFGNO'9R47KBY^D@^/2.F I&% L$!I##" % MES$4GT1NLZVTNLE^-E]/U;KLI&FKBT9VD^BM9 ZR>+"F1O"12? 4TY.;J9W/QA:73\-T=X7( M@^#D6Q4=QZJD]XR:RY5\>$[@G21!'F()R3";+2_J)%4F!"0JR= M1@1S)F&;=M'-K,UU AEMLNNOOT\SOIR7!4F\:F@KZ[K%_DRB7<[#[ 5%N(N/ M!,3G7]\L%_D\K5?/YOD=+C]/$ZZN%X1";SCCM9M41A*5XR0J9H";@E88(X-I MTZBB&4N=6K:G8/*1_,$1U?^]V,,CL@KO/J*)16R9/?@@_!P&&3$K2$R16UVR M@8!9 G/DTDL;G$JG*4;MUB1NYH HR4WRBH%7@M7X!R$(KT!8$UV(5BO?IIJL M"3N=FL*G8+&Y*7RRVD<\!EXMUY,M#Z^76PXV<_J48UPS], 92Z"<<. ]KV?9 M'-$:%6,N^\"67G #LO2WNW!]B(*1D38^*!8#:J@/A-T4R':TEI;2F""):N\D M,4%QE"LZ0JV,*-KJ$O8;P_(4F-TG8QRL#:/9^S Y4LQC)VO\YW*Z6@<*LW$[ M)2TK2YRS #HZ"THH"Z%X"25(QST7+MVMQWX@4^/NDT=7^[&:6@PEMK%U_B[, MT_EJL:5_;2EG3EM7&P$[%HERD2SX7'?$Q*+WT2BIW%ZJOO78<2Y_&ZGZ M<(&-K>H78987L\5R2[HC;SP%C:"S-Z"0K%(D2P3:<.:]RRF:_? XLST:Z?L8H8VM\-VYM]BGKY?XI<&1F--'Z$R,;6]NOU&2XO1;*E'X/!XNLL5LMH8W*.$?W6 M :DS9RF]99SOM]#O/WRU4D:1D'D M*0)G)J$JED?6ID'$#2+V.Z1A_0/D6 %W@(VGGH6_NAI3SEBR.FL#B7%;2X\< M4+!J:V=](X(-(OLVI7@'DSQN#5<_]P^GU7T'(+^\5+_.LTB^2"YI]ZX51HJ) MVCU)<<# +"]:!A/:]$VX2\G(&;ZG X<0BNEN)5#:9E+/(BP>:: MDX@4[7FM"T@;F32:*RG+7J[4W2>/"X[CU+082F)=%)K>6!.U+TUEXO?I^NQR M75RDK]?LA=4*Z=]<&X PKM%*0T;9&8H',=5R'8H,1?0Z%(_$2YO2@P.(';'H M]#AP[#8MS?34>W;;RSGQ3U ^X^^3M>D]6%=2ARB#;2 8I00 M?0K@I9/<85 >V_3O>8RJRH?!QOR/40'KXC@S+X94$]Q_2RL@TK"=X#$KD M(0E>1]UQ5ANHY-J]P+ (J<3@LU;,I#9%F U-S778>O62%^?+NNCN]*$E_K20 M%J%86DQ*$N8)X@&@IN'LYU'5 _WY$Y^C4L:^N] MS\?T"7[L<:U,U.-TG\(O$I;)8@0M)U&:C]<>!UX&&_.XVR:_K:>SC9MDZX\LD^_?[G,G"!7RPG@-I"H(B<' MC%D!.MD8AR7 XV!-@!RIE[+WJ(3>+8<(<=: U&'B=P8C@ M/9E@'K@6/B6W,#O?)JJM(X3?4\@JM-1+M;6)/&DHM<: MD)/C3QLW!0-(S/"41#9>D6ENG!]R34PGWO+ L#E0V#WAY1?::E=GF/^R6.35 MA#/ABW$!C*X-<#T)Q 4OP<1(NZT01J4V\[MWT]/)9C4P:@X7>;? V0R'N[*= MO+I_WHKH"U$RB"QD"JRX+!N[.P\3-TX%_DDA=;@ROJ/LB,OLD$6Y M\?72KK(G]^3E!!@77+.>2R0-GME9X,TOH*;;6 B:7F);8Z%KX%!D4 M=31877DWE\FSV:8>I&:M7"<-\&"3* Q8=A25""\@)A,@2PQ<)6VB;KP7[DEI M)R[YD3AZV,EJH*\N:B^N.'P;_OAK((:F87;'>#M;?+(F AEK$J 4%APO"ER2 MUBNG5&G40_W;M'6"NB;H> B*PRBJ"_!MJK^O&+OBZMWYIT\SVGF>S?-?<9G. MZIB>%?Z-]IOEB\5\-?TPOQ@2J*)4H.A8)0>O T# > [.G4^YW$))BTXMQJB%&3F^US!&="!G3.^I**U7=K&3N+2=J'N2L747Y9UVFRFM[@@'Y) M4?5T!0PV5&[8LUOR(+R.14,P(H'"0-+ %$!P)KTK'E7K(Y0GGMT.WL9N7" = MJ(HN!HO?E-C$!E&KV"5$D6KSKD!;N:L6E4E9'+K";>,K)*)BG,9X(R/HB<+O M_>SM%8;58=61V]\<].1L%S4#'8Q=//H*#()9*7U48#BCS8212Q*,1I#61122 MD0EHDWQVFXYCC<*KVA8 7W_"6ILU_W#Q\.L:.L<-=YYG2$[Z>@6OP6>N($0> MC$I6&-GFL.MQNL8]9#@""7?-PH#B_SX,Q>'%U+=^OX'1:%A"?0K:8C;K*\+,-^IPA4E^Z)B M!.9L3>*I$[YJ68L)L7##@N8A?$OU3WIC5[;A*:J^W6:WA7P[.)/99? N6:SG M474^[M>[A=R@;Q(Y[EC@ ^DZE MJ+'S=*\O5M^28'_^\@GG*Z3-X=TYL42\OIS3_G!WL46KK8ZTS@3CM6=FI*T^ M*PZ%.:FL\$;'!Y[4P#^&.PC+ M10AI:X?ID@L9D\C "P(X7? =.TYOE@O;A]=J)=B# MN+$Q-1 0[A8N#:R5GH%VHXZG9*M45/4:KB;O1$=.'J. X4S/*IB6Z6/[T'< MR$500P-B7\ =J)T. /?\G"1*X<6VI*N(Y&-U\5SV%E1Q ;QQ$@1Z85.H?F4; M;-VFHU,8':KF>WU"#I;YR#-87YS[E[V1S\/L/2X_;BRQC9[Y0GP(YQDH M)0PX$0CWW* .F7L53+OX8@=%8Q\=M?&2!I%_ISC:+B]BWW.E.03!$W&2L8JG M%B([+X-01M\="MD023TX0L/H? \@':" L<\=GR\7(?^!J_6&GU^FG_%_8EB^ MQ3G^$6:O-XONWXPA5XAZBYC\'(O^/TP]D:\[//]-T/6&O#%N?S]=O*("Y3 MS:L4N:@@O &4]1)1,%\;G4FP4EAGG$[*MO'+GTIIC_[Z,-AKJK/>,?D6J\MQ M^45\Q$,QMHL,27:&SR'[*UTRHJ(NG1(OVZR1*I3NDF?*[Q$&=%F!P"4F >]DN) MVO>-XQ:-G-1*'2WP3NW5#7XFN88Q+@:P6(\$BZC%\\',?D\P:Z&13@"V6-YFYTWX6J_ 5N\7SXFUA-//F"?D#CI,04)DJCJ$+-9! M+PCH J\EQ:A"NS3B?2C<"W+N>X72ZMCZR&3/N\8UQJKOBY_6^&FJF/B MN&-180!:2!)4K(?,/%D@+Q!U#C%GVX;)1\D:^RCU8!P\?E)PC/ [V-T>*,#8 M]DF>1&NY862*>8EDE%,A$>F4P,?"R5RR.GCU!%"Z2]?81Z.-L'24^/L%TXVF M!LQ$94JMX,%,JX/(A.!4 #1"218T!MZF-/&;I(U]LMD:4@:61'X9?_YT?MWA)06OM18,;/(>E"P% MG$X9I"3^4U&:YS8\/X7*KASUIZ!DOYUP -5TX&H]6CY]R=_%M66N1[R_3%5Q(ML/14VKBAU/J]P)? M$NNOM/>\_P-GG_&OB_GZ;#41Z&,*T8+AT8"R4=8,2@721,:4-\KP$<&[@^)Q M0]6^H'NL0K\CX$Z*+28EXVHC 0:*U:Y*$B,4XS+W+(J$XP)UW("W.V ^26$= M=.]\E*^_U?[*FRPZS#]_277PZ\?ZMXECS!-_"I0*A9@LK/:X#!T0'4647[8H?8'#BK>%9^ S>^D2,& 4N*F)$99:*Q^1CFZ3O M!P@:-X?H9*@;0AW_AQT;3?AMQD:.KT]&'>3N> MU4"TWZ*XT4VW<]YEYP%5[=N7>"2_VGC@27'E*5B41C;:Z=L=KVW%."G2<*7( MVJ7:)%E%7VV49)!-KG/F1<1\BBUC2TY7!V9/T?OC6\(APNX@0KO=Z&WB#-KL M+*/]BT)+I0-"4+*Z24&69)4QJDT/K-MT]'5C?01&CA!O[]["._H[GBUFI(M5 M;7.QV?-^PK@^9(=Y^&&#;C%[TGSD'K.Y7KQX_+.+QU^W4&.H444*ED6H VB- MABAH06B3&8]*UP2&O6YD=S[^:&.P7J2_WQ+/KXLU7H^,NVX!62]$BTR:O&B+ M-:;RX#WWP*Q@/'M:$;E-DX6]21QGFQE(]??,2!/%?+<6YOX/CG!N#WC+:6S2 MGERV,U:$5RE-"81858?>\@"."4E;EHT4V#+)^3>EV]!8;6.PUV4CJ.>UA(P" MK.J%;9?Y,LP_X";:>O[U^C/;DX%G?X1EON@U8"7*$%T!G^JN7-LG>;06:'=/ MF7G#O6Y3XSP8"]T9NZ= YYZQ&T6Q/?CBM;- 9>%"II7GQ;QRN>G6PU2*GL0) MOIAZ>L5H)S'90(C:)Y$C=ZI-:*S;9DZ6 MT%9Y^GN;S,-NL(*&SDHD+L,X2"US65A$.:1FI'-#H9-)>L>5>+41WDC#N M\=.XF]HP>AFY->T]!GZ?KL_>XFPCO]79]-/[Q<_S=8VH+M:@DMP%5AS0_VD- MRAJELU! !L5TD3$QMU>AQ6&0>YRX<6S60#!X#%0#ZF1DN/TT76*B'U_V<+9& MZ^ 5F7!M0#FY*6KCD*10G+$8PWYI(WNAZ?:[.P++D.I=#"+K#IRC"^-\V7X^ M)V]C"HP,]B"FW']_B/ =?>D M86Q-=X#VM[A:+Z=IC?EFW).9"8E"*8B9DU>21;U9%0FT1U:D9T&+-C'F3G)& M/J 8'26+H54V=F'MRWGMK#G]C!L&+EI5K[9\Q.(#HW ;L&0'2J,$$E: P@+Y M.#RFYO \G<1!M=8JZ5_4.>;E= MFCD9:62P('TARVPYV6AM:)%FF^KWR3@WZ@+W#>UDS(*!$;5_G?8)G#,:#";-"_JH]LQXNO_L_M!PN.(6PTFQ M POS32O]D)%^==7@3K&0LDLU FQGF+G\Z7Z:PV@5PN/BS#QV?GZ[/%AVT#;.@)B4992U&5(Z\#%(L6@G%(CDC6S)3L:)\X.CS%^@;(X?PAKS^U9@VYKKJXDUUW;[^C.7%MP7ET0M'V<8/,5SC-QA MC>2E!*<+*R$DURA-_&":QSFU&VW7'5R-HX<5E_D [>A5J7_F*Q_+2@'^([3+4@?5KW!2FD-UK6Y(B:E*\L.,$2%!E\ MS<60\6Z=PT,AR)!DC1,M-\3HR)KK84<_- :\4,++.4GG?'- \7I]ALOW9V&^ MO>;Y"SUBO7HYOY#F1)%JHB5I6*YI+0?MP!M#>U JJ69;9R_;M(TZ%8?CC-C&.F->19LA>*: "QU8-$681B>; M#Y+47;7M4U2[S_WSTP7?P<[YX.T\O,8X0QM#\AWF MTISTWOH A>^;&_,4Z7>*HENW^N1&*@RJ3IFH300]]4)T/3 M=Y ;\R3]/S4WYBG*&/LL9T=6A^<%!4\(2E>[S9R&J(0!*TM@J00A[LZ+^F?) MC7F2XKZ1&_,4*79@8>K.?1V^;M9(9"PC)\,;7!U%7+^JP0,XFV7(O.A[&<0# MV93[M(S<>:W)WG2DQ+O#S(TD:A4"D! MWJ.E)\@QO?'")X(2H15F9@V.V0.)9A20"L]BF M__0N:L;=;8[5\*. .4#<'4#F+7Y>S#Y/YQ]N,[.UF4XG8329W%!+ILD*,W#* M&"C1%B:D*DZTPEP^79 PBVV-5:26MC(F_+*"); M)(C)(Z",A15;)+-[A3G[PV#L/CP'JNRNT@^0W\AJWPY:N0RW,&1MG 063)WW M%!+X5 +)HC86DBDROM>ESUZ*O_7JD55_B.(60TAQ;/6'+S<(3TS)G&S-[T0B M7-#NY0KW((I.42GFS=VJTV/4?_/5XT2R@ZG_8"EVX$G^%I;3NMV]#>L+"UB\ M=DI'=3GPRWD(.A@@R;B@(Z<(O(WS>)>2<2M"VP2K1TF[,[1L?>A$I&HK&$@O M:=5P7[.YL@?&4D&-S O3)E/@/BWC1AC'Z?81H!P@Z Z@\FHQSXOYRSD],8;Y MWU\7H@)SY>?5R^>OWUZV(C18"LD'K'"99&0<.*,H3K)9HG Q*M-H6N@^Y/4# MJ$,PN/$I6.EWB%RMBO,1)2V-B!)+#E0)03P3@LPS&@ON-68&K7QV4G/ MR"DI1^OY&\ Y0.@=0.?%8OX9E^LI+:/*R-9R&L1HF"K@8ZQ'!Y8<_XRU=KV4 MF%(J/+O14A[[(/:Z]O;#$C ?NSRZC_>JJ$17S5D>K XA0I]BA(_

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